Ventricular arrhythmogenesis in the genetically-susceptible heart:time to change concepts of mechanisms and management by ter Bekke, Rachel Mariet Anouk
  
 
Ventricular arrhythmogenesis in the genetically-
susceptible heart
Citation for published version (APA):
ter Bekke, R. M. A. (2018). Ventricular arrhythmogenesis in the genetically-susceptible heart: time to
change concepts of mechanisms and management. https://doi.org/10.26481/dis.20180622rb
Document status and date:
Published: 01/01/2018
DOI:
10.26481/dis.20180622rb
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 07 Jun. 2020
Ventricular Arrhythmogenesis in  
the Genetically-Susceptible Heart:
Time to Change Concepts of  
Mechanisms and Management 
Rachel ter Bekke
 
  
VENTRICULAR ARRHYTHMOGENESIS IN THE 
GENETICALLY-SUSCEPTIBLE HEART: 
TIME TO CHANGE CONCEPTS OF  
MECHANISMS AND MANAGEMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROEFSCHRIFT 
ter verkrijging van de graad van doctor 
aan de Universiteit Maastricht, 
op gezag van de Rector Magnificus, 
Prof. dr. Rianne M. Letschert 
volgens het besluit van het College van Decanen, 
in het openbaar te verdedigen 
op vrijdag 22 juni 2018 om 14.00 uur 
 
door 
 
Rachel Mariet Anouk ter Bekke 
 
 
 
Promotor 
Prof. dr. P.G.A. Volders 
 
Beoordelingscommissie 
Prof. dr. H.J.G.M. Crijns (voorzitter) 
Prof. dr. C.R. Bezzina (Universiteit van Amsterdam) 
Prof. dr. F.W. Prinzen 
Prof. dr. P.J. Schwartz (IRCCS Istituto Auxologico Italiano, Milaan, Italië) 
Prof. dr. H.J.J. Wellens 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research in this thesis was supported by a grant of the Dutch Heart Foundation/ The 
Netherlands CardioVascular Research Initiative (CVON-PREDICT). Additional research 
support by the Health Foundation Limburg is gratefully acknowledged. The Dutch Heart 
Foundation also contributed to the printing costs of this thesis. I also thank the Stichting 
Hartsvrienden RESCAR for a financial contribution the publication of this thesis. 
 
© Rachel M.A. ter Bekke, 2018 
ISBN 978-94-6159-821-9 
 
 
Cover art and design: Claudia Volders and Rachel ter Bekke  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For all families including mine:  
Jade, Myrthe, Inez, Marga, Frans, and Esther 
 
  
  
  | VII 
CONTENTS 
CHAPTER 1 1 
   Introduction.   
CHAPTER 2 21 
Arrhythmogenic Mechano-Electric Heterogeneity in the Long-QT Syndrome. 
Rachel M.A. ter Bekke, Paul G.A. Volders 
   Prog Biophys Mol Biol 2012;110:347-358 
CHAPTER 3 41 
Electromechanical Window Negativity in Genotyped Long-QT Syndrome 
Patients: Relation to Arrhythmia Risk. 
   Rachel M.A. ter Bekke, Kristina H. Haugaa, Arthur van den  
Wijngaard, J. Martijn Bos, Michael J. Ackerman, Thor Edvardsen,  
Paul G.A. Volders 
Eur Heart J 2015;36:179-186 
 
 Editorial 59 
Vox Clamantis in Deserto. We Spoke but Nobody was Listening: 
Echocardiography can help Risk Stratification of the Long-QT Syndrome. 
Gaetano M. De Ferrari, Peter J. Schwartz 
   Eur Heart J 2015;36:148-150 
CHAPTER 4 65 
Proarrhythmic Proclivity of Left-Stellate Ganglion Stimulation in a Canine 
Model of Drug-Induced Long-QT Syndrome Type 1. 
   Manuscript submitted, 2018 
CHAPTER 5 83 
   Heritability in a SCN5A-Mutation Founder Population with Female 
Susceptibility to Non-Nocturnal Ventricular Tachyarrhythmia and Sudden 
Cardiac Death. 
Rachel M.A. ter Bekke, Aaron Isaacs, Andrei Barysenka, Marije B. Hoos, Jan 
D.H. Jongbloed, Jan C.A. Hoorntje, Alfons S.M. Patelski, Apollonia T.J.M. 
Helderman-van den Enden, Arthur van den Wijngaard, Monika Stoll, Paul G.A. 
Volders 
Heart Rhythm 2017;14:1873-1881 
VIII |  
 Editorial 103 
Founder Populations with Channelopathies and Church Records Reveal All 
Sorts of Interesting Secrets: Some are Scientifically Relevant. 
Peter J. Schwartz and Lia Crotti 
Heart Rhythm 2017;14:1882-1883 
CHAPTER 6 107 
   Beauty and the Beat: A Complicated Case of Multifocal Ectopic  
Purkinje-Related Premature Contractions. 
Manuscript accepted for publication in Heart Rhythm Case Reports 
CHAPTER 7 119 
Life-Threatening Ventricular Arrhythmias in the Genetically-Susceptible 
Heart: Time to Change Concepts. 
CHAPTER 8 141 
HeArt Project. 
Rachel M.A. ter Bekke, Claudia A.A. Volders 
Manuscript accepted for publication in Tijdschrift voor 
Gezondheidswetenschappen 
 
SUMMARY/SAMENVATTING 153 
VALORIZATION 157 
REFERENCES  163 
GENEALOGICAL SOURCES 195 
LIST OF ABBREVIATIONS 203 
ACKNOWLEDGEMENTS/DANKWOORD 207 
CURRICULUM VITAE 213 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Le cœur a ses raisons que la raison ne connaît pas” 
  | 1 
 
1 
 
INTRODUCTION 
 
 
 
 
 
 
 
CONTENTS 
GENETIC PREDISPOSITION TO SUDDEN CARDIAC DEATH 2 
Genetic Susceptibility to Sudden Cardiac Death 3 
Infarct-Related Ventricular Fibrillation 4 
Inherited Arrhythmia Syndromes 5 
Drug-Induced Repolarization Prolongation 6 
Genetic Modulators of Disease Variability 6 
ARRHYTHMIA MECHANISMS 7 
LQTS: A Purely Electrical Disease? 7 
Arrhythmogenic Role of Purkinje Fibers 9 
Brugada Syndrome: Depolarization or Repolarization? 10 
VENTRICULAR ARRHYTHMOGENESIS AND THE AUTONOMIC NERVOUS SYSTEM 10 
THERAPEUTIC AVENUES 12 
Antiarrhythmic Drugs 12 
Interventional Modalities 13 
AIMS AND STRUCTURE OF THIS THESIS 14 
  
 2 | CHAPTER 1 
GENETIC PREDISPOSITION TO SUDDEN CARDIAC DEATH 
One early morning in June 2017, in a home nearby Maastricht, The Netherlands, a father 
heard a snoring sound in the corridor while traversing to the bathroom. Startled by this 
peculiar noise, but still somewhat drowsy, he checked on his sleeping daughter, who was 
well. Two hours later his other child, the apparently healthy 29-year-old son, was found 
dead in his bed. A stilling “why” is what remains amongst the relatives, and a deafening call 
to health-care providers concerned with the topic of sudden cardiac death. 
 As exemplified by this case, sudden death is defined as an unexpected, non-traumatic 
fatal event occurring within one hour of the onset of symptoms in an apparently healthy 
subject.1 A cardiac origin is suspected if a potentially fatal cardiac condition was known to 
be present, when autopsy has indicated a cardiac anomaly as the probable cause of the 
event or no obvious extra-cardiac causes have been identified by post-mortem 
examinations with fatal arrhythmia being the likely cause of death.1  
 Sudden cardiac death (SCD) imposes a sizable socioeconomic and psychosocial burden, 
claiming almost a million deaths annually in Western Europe and the United States. It 
accounts for 15-20% of all natural deaths and up to 50% of all cardiovascular deaths.2, 3 Out-
of-hospital SCD occurs with a yearly incidence of 39-100 per 100,000 individuals aged 20-75 
years in the Netherlands.4, 5 In the Dutch province of Limburg SCA affects approximately 15 
individuals per week.6 Once SCA ensues, the victim’s survival rate declines at a rapid pace 
(8-10% per minute),7 prompting urgent attempts to rescue the subject by cardiopulmonary 
resuscitation, preferably with community-available automated external defibrillators (AEDs) 
utilized by trained volunteers. 
 Ventricular fibrillation (VF) mostly underlies SCD and usually occurs in the setting of 
coronary heart disease and myocardial ischemia (~75%).3, 8, 9 However, SCD is the first 
manifestation of heart disease in approximately 45% of cases.4 Inherited arrhythmia 
syndromes predispose to VF, accounting for 5-10% of total VF victims, relatively often in the 
young.10 These primary electrical arrhythmia syndromes comprise of the long-QT syndrome 
(LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), 
short-QT syndrome (SQTS), short-coupled torsades de pointes (TdP), early-repolarization 
syndrome (ERS), and other rare conditions. In <5% of VF cases no cardiac structural or 
electrical abnormalities can be ascertained; this is referred to as “idiopathic VF”.  
 In this thesis, I will focus on life-threatening ventricular tachyarrhythmias, including VF, in 
the structurally-normal, but electrically-compromised heart. I will investigate genotype-
phenotype relations, assess novel SCD risk indicators, evaluate triggers of arrhythmia, and 
discuss antiarrhythmic treatment. Special emphasis will be put on electromechanical 
interrelations and the influence of the autonomic nervous system. These aspects are 
examined mainly in the long-QT syndrome, Brugada syndrome, and multifocal ectopic 
Purkinje-related ectopy. The gained insights into ventricular arrhythmogenesis and 
treatment will ultimately also benefit patients with scar-related ventricular arrhythmia, 
which is typically characterized by a more heterogeneous structural substrate.  
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GENETIC SUSCEPTIBILITY TO SUDDEN CARDIAC DEATH 
SCD has a complex, multifactorial nature and usually depends on a combination of acquired 
(e.g., myocardial ischemia or scar formation) and heritable components, modified by 
external/environmental factors. The segregation of SCD in families11 implicates the 
importance of heritable factors for the development of life-threatening ventricular 
arrhythmia, both in primary arrhythmia syndromes and in the presence of myocardial 
ischemia. Generally, the younger the SCD victim, the higher the contribution of genetic 
components (Figure 1.1). Besides genetic variation, phenotypic expression can be modified 
by DNA phosphorylation, glycosylation, or lipidation. However, such epigenetic or 
posttranslational modifications are rarely addressed clinically. Lifestyle and environmental 
modulators of disease expressivity, e.g., smoking, obesity, sedentary habitus, and dietary 
intake, are of great importance but fall beyond the scope of this dissertation. 
 
 
Figure 1.1 Schematic representation of the relative contribution of genetic and environmental risk factors to 
the vulnerability to VF over a person’s life span. 
 
 Primary electrical arrhythmia syndromes are typically characterized by an autosomal 
dominant inheritance pattern. Rare genetic variants with large effect size can be 
encountered. The annotation “disease-causing genetic variants” applies here. Oligogenic 
modes of inheritance are recognized in Brugada syndrome,12 with causal SCN5A mutations 
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implicated in only a quarter of patients. Even more complex inheritance patterns are 
suggested to contribute to SCD susceptibility in (late onset) coronary-artery disease 
associated VF,13 where common allelic variation only exerts a moderate effect size.14 
Analytical approaches to unmask these different genetic variants should be adapted 
accordingly: linkage analysis and exome/genome sequencing, combined with smart 
bioinformatics, are suitable approaches for common and rare diseases related to rare 
genetic variants. Common genetic variants are currently identified using genome-wide 
association studies (GWAS) on large numbers of patients.15  
 The identification of genetic contributors is important for diagnostic purposes, risk 
stratification of the index patients and their relatives, elucidation of molecular pathways, 
and to find potential therapeutic targets. Unfortunately, limited sample sizes of 
representative populations, heterogeneity of the arrhythmogenic substrate, and the 
difficulty of obtaining phenotypic information after cardiac arrest complicate scientific 
progress in this field. Founder populations with increased SCD susceptibility that share an 
identical-by-descent mutation are gold mines for identification of genetic modifiers16 as 
they are robust to false-positive findings due to the population substructure, they typically 
share a large proportion of environmental factors, and they may be enriched for rare 
variants that are difficult to study in the general population.  
INFARCT-RELATED VENTRICULAR FIBRILLATION 
The strong familial component to SCD risk in the presence of coronary artery disease8, 11, 17, 
18 has sparked several groups to investigate associations between postulated 
electrocardiographic markers of augmented SCD risk (e.g., QTc, QRS width) and common 
genetic variants using GWAS in large populations. As QTc prolongation constitutes a higher 
arrhythmic risk in acute coronary syndromes19, 20 and heritability of QT/QTc approximates 
35%,21-26 it was postulated that genetic variants affecting QT are associated with ischemia-
related SCD.  
 Genome-wide association signals were found between prolonged cardiac repolarization 
and variants in NOS1AP, a gene that encodes the nitric oxide synthase 1 adaptor protein.27, 
28 These variants were associated with SCD in Caucasian US adults,29 findings that were 
confirmed by the Rotterdam study.30 Also, a polymorphism in the KCNH2 gene 
(p.(Lys897Thr), rs1805123), encoding the alpha subunit of the rapidly-activating delayed-
rectifier potassium current (IKr) and affecting QTc duration,31 has been associated with 
polymorphic ventricular tachycardia (VT) in the subacute phase of myocardial infarction.32 
Furthermore, a common genetic variant in the SCN5A gene (p.(Ser1101Tyr), rs7626962) has 
been associated with arrhythmia risk in African-Americans (OR = 8.7; 95% C.I. 3.2–23.9; 
P=0.001), especially if co-occurring with additional arrhythmia risk factors.33 Other rare 
SCN5A mutations were identified exclusively in women with SCD in two large prospective 
cohorts (Nurses’ Health Study and Health Professional Follow-Up Study).34 And finally, a 
genome-wide significant signal was found at 2q24.2 (rs4665058) near the BAZ2B gene, 
which almost doubled the SCD risk (OR = 1.92, 95% C.I. 1.57-2.34, P=1.8x10-10).35  
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 Alternatively, but more tediously, attempts have been made to directly associate genetic 
loci to infarct-related primary VF in well-defined SCD cohorts. The Arrhythmia Genetics in 
the Netherlands Study (AGNES) identified a common genetic variant at 21q21 (rs2824292) 
near the CXADR gene that was associated with primary VF (OR = 1.78, 95% C.I. 1.47-2.13, 
P=3.3x10-10).36 The CXADR gene encodes the coxsackie- and adenovirus receptor and has 
been implicated in reduced cardiac conduction properties and increased arrhythmia 
vulnerability during ischemia in CXADR haploinsufficient mice.37 Clinical replication studies, 
however, failed to confirm the association of rs2824292 with VF in first infarct patients.38, 39 
In the Genetics Causes of Ventricular Arrhythmias in Patients with First ST-elevation 
Myocardial Infarction (GEVAMI) cohort, a single nucleotide polymorphism (SNP) at 
chromosome 3 (rs11720524) in intron 1 of the SCN5A gene was significantly associated with 
arrhythmic events (OR = 1.87, 95% C.I. 1.12-3.12, P=0.017).40 In conclusion, the inherited 
susceptibility to VF in the setting of myocardial ischemia/infarction justifies the quest for 
risk loci, but is not yet ready for clinical implementation. 
INHERITED ARRHYTHMIA SYNDROMES 
Numerous gene variants have been related to the primary arrhythmia syndromes like LQTS, 
Brugada syndrome, ERS, CPVT, short-coupled TdP and idiopathic VF. Inheritance is usually 
Mendelian and genetic approaches mostly rely on family-based studies. Although recently, 
GWAS meta-analysis identified 35 common variant QT-associated SNPs in genetically elusive 
LQTS subjects.28 This provides exciting novel insights into arrhythmogenesis and brings 
forward new candidate genes for ventricular arrhythmias.28 
 The long-QT syndrome constitutes the most paradigmatic example of inherited 
arrhythmia diseases. Prolonged and dispersed ventricular repolarization predisposes to 
torsades-de-pointes arrhythmias. Since the first association of LQTS with the Harvey ras-1 
locus to in 1991,41 allelic variants in at least 15 LQTS-susceptibility genes have been 
described (Table 1.1). Three major causative LQTS-susceptibility genes encoding ion-channel 
alpha subunits explain approximately 75% of clinically-diagnosed LQTS cases:1 KCNQ1, 
encoding the alpha subunit of the slowly-activating delayed-rectifier potassium current (IKs) 
was recognized for LQT1;42 KCNH2 encoding for IKr for LQT2;43 SCN5A encoding for pore-
forming alpha subunit of the cardiac sodium channel (NaV1.5) for LQT3.44 Other minor LQTS-
associated genes encode for 1) the alpha subunit of G protein-activated inward rectifier 
potassium current 4, KCNJ5, which is implicated in LQT13,45 2) for cardiac potassium- or 
sodium-channel interacting proteins: KCNE1 (LQT5),46 KCNE2 (LQT6),47 AKAP9 (LQT11),48 and 
CAV3 (LQT9),49 SCN4B (LQT10),50 and SNTA1 (LQT12),51 respectively. Finally, 3) calmodulin-
associated LQT syndrome allocated to the CALM1 (LQT14) or the CALM2 gene (LQT15).52 
Other multisystem disorders displaying concomitant repolarization prolongation and 
ventricular arrhythmia were linked to ANKB (ankyrin-B syndrome previously LQT4),53, 54 
KCNJ2 (Andersen-Tawil syndrome previously LQT7),55 and CACNA1C (Timothy syndrome 
previously LQT8).56 
 6 | CHAPTER 1 
 Prominent phenotypic heterogeneity including SCD susceptibility has been observed 
among LQTS patients sharing an identical-by-descent mutation. Low disease penetrance 
(~25%), differential expressivity, and non-genetic factors such as age, gender, and the use of 
medication57-60 have been postulated to contribute to this phenotypic variability. 
Furthermore, compound heterozygosity is present in ~8% of LQTS cases, hinting towards a 
more complex genetic architecture.61 
 The SCN5A gene encodes the pore-forming alpha subunit of the cardiac sodium channel. 
Loss-of-function mutations in the SCN5A gene resulting in a reduced sodium current (INa) 
have been causally related to Brugada syndrome in ~20-25% of cases (Table 1.2).62 Although 
the Brugada syndrome is considered to be a monogenic disorder by some, with an 
autosomal dominant mode of inheritance, disease penetrance is considerably low63 and 
sometimes the causative SCN5A mutation does not segregate in affected family members 
with the syndrome,64 indicating a more complex genetic architecture. The unraveling of 
such complex architecture in a familial cohort with a SCN5A founder mutation and excess 
sudden arrhythmic death will be one of my PhD studies. In other conditions, like Purkinje-
related ectopy, atrial fibrillation, sick-sinus syndrome, dilated cardiomyopathy, and cardiac 
conduction disease, SCN5A mutations have also been implicated. 
 Idiopathic VF is a rare SCD entity where fibrillation occurs in the absence of an 
identifiable cause despite extensive cardiac work-up.65 A familial history of sudden cardiac 
death or resuscitated arrest is noted in ~20% of cases, suggesting a genetic substrate in 
some.66 Table 1.3 summarizes genes and risk haplotypes involved in idiopathic VF, as 
currently known. Also mentioned are the reported genes associated with short-coupled 
TdP: CALM1 (c.268T>C, p.(Phe90Leu), rs730882253)67 and RyR2.68 Allelic variants associated 
with the short-QT syndrome, CPVT, and ERS are listed in Table 1.4. 
DRUG-INDUCED REPOLARIZATION PROLONGATION 
Genetic susceptibility to drug-induced LQTS, potentially leading to TdP, can be identified in 
5-19% of patients with acquired QT prolongation.69, 70 Mostly, genetic variants of known 
arrhythmia genes play a role in this.69-72 For example, the variant in KCNE1, p.(Asp85Asn) 
rs1805128, increases the risk of drug-induced TdP nearly 9-fold (95% C.I. 3.26–24.17; P=1.95 
× 10−5).73 The mean allelic frequency of KCNE1-p.(Asp85Asn) is approximately 1-2% in 
healthy Caucasians69, 73 but this variant is enriched in LQTS probands (4%).74 In addition, 
common variants in the NOS1AP gene have been associated with QT prolongation during 
treatment with verapamil, sotalol, amiodarone, and diuretics.75, 76 GWAS analysis of sotalol-, 
amiodarone-, and quinidine-induced TdP, however, failed to identify common variants with 
large enough effect sizes.77  
GENETIC MODULATORS OF DISEASE VARIABILITY 
Phenotypic diversity (including SCD susceptibility) among carriers of identical-by-descent 
mutations is often remarkable.57 Common genetic variants other than the high-impact 
familial mutation, also termed ‘modifier genes’, can modulate disease variability. Multiple 
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LQTS-associated modifier genes have been identified: KCNQ1 (rs8234, rs10798, 
rs199473403),78, 79 3’ untranslated region of KCNQ1 (rs2519184, rs8234, and rs10798),80 
KCNH2 (rs1805123),31 SCN5A (rs1805124),81 KCNE1 (rs1805128),82 NOS1AP (rs12143842, 
rs16847548, rs4657139),78, 83 and adrenergic receptor gene polymorphisms ADRA2C-del322-
325 and ADRB1-R389.84 In contrast to these disease-aggravating variants, the KCNQ1 
modifier polymorphism rs2074238 lowers arrhythmogenic risk in LQTS patients.81 Disease-
modifying SNPs associated with the sick-sinus and Brugada syndrome have been identified 
in the SCN5A,85 SCN10A, and HEY2 genes.86 Thus far, these associations could not be 
replicated in other cohorts.87 
 The mechanisms underlying variable expressivity and phenotypic diversity remain largely 
elusive due to the complexity of the genetic architecture. Here, family cohorts provide 
substantial benefits. 
ARRHYTHMIA MECHANISMS 
Throughout an average person’s life span and generally about 2.5 billion times, tiny 
electrical impulses generated by sinu-atrial myocytes travel down the specialized 
conduction system to coordinate contraction. Ventricular excitation-contraction coupling 
proceeds from endocardium to epicardium and from the apical to basal regions. Ventricular 
depolarization and contraction are followed by repolarization and relaxation. Importantly, 
but often disregarded, cardiac mechanics feed back on electrical properties mostly via 
mechanosensitive ion channels, to maintain electromechanical homeostasis. Cardiac 
arrhythmias can arise if individual elements of these delicately balanced processes are 
deranged.  
LQTS: A PURELY ELECTRICAL DISEASE? 
In the last decades, ample research has been performed to decipher the molecular-
biophysical basis of congenital repolarization defects and the electrophysiological 
mechanisms of TdP in the long-QT syndrome. Cellular experiments, ventricular wedge 
preparations, and Langendorff-perfused heart set-ups have contributed substantially to this 
mechanistic insight. Intact large-animal experiments and human investigations in LQTS, 
however, are scarce, which limits the advancement of the understanding of arrhythmia 
mechanisms and optimal management in patients.  
 Acute repolarization prolongation modulates myocardial contraction88-91 through altered 
myocyte Ca2+ loading. Conditions that promote myocyte Ca2+ overload (e.g., rapid pacing, 
paroxysmal tachycardia, high blood plasma [Ca2+] or low [K+], cardiac glycosides, beta-
adrenergic receptor stimulation92), can evoke [Ca2+]cyt oscillations due to spontaneous Ca2+ 
release from the sarcoplasmic reticulum (SR).93, 94 These [Ca2+]cyt oscillations may also occur 
in the case of inherited SR dysfunction, e.g., in the presence of calsequestrin or ryanodine-
receptor gene mutations.95 Spontaneous SR Ca2+ release, when occurring during late 
repolarization (i.e., early Ca2+ aftertransients), can activate inward Na+/Ca2+ exchanger 
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current (INa-Ca), which delays repolarization, thus contributing to the “conditioning phase” of 
early afterdepolarizations (EADs). EAD upstrokes may then be carried by the reactivation of 
the L-type calcium current (ICaL).92 Diastolic spontaneous SR Ca2+ release during beta-
adrenergic receptor stimulation results in INa-Ca-induced (and ICl-induced96) delayed 
afterdepolarizations (DADs). Such delayed Ca2+ aftertransients (which typically occur late in 
diastole) deplete the SR and cause prolongation of the subsequent action-potential duration 
(APD) through reduced SR Ca2+-release dependent inactivation of the L-type calcium 
current.97 This holds particularly during conditions with reduced IKs, such as in drug-induced 
LQT1. Beta-adrenergic EADs coincide with early aftercontractions based on Ca2+ 
aftertransients. In fact, these aftercontractions often commence earlier than the upstroke 
of their accompanying EAD, often even without frank EADs, but never without a 
concomitant delay in repolarization.98 The resultant spatiotemporal repolarization 
heterogeneities will be further exaggerated by regional heterogeneities in ion-channel99, 100 
and Ca2+-cycling protein expression101-105 or myocardial conduction properties. Ca2+-
dependent inward currents thus facilitate EAD- and DAD-induced abnormal impulse 
formation and reentrant excitation by enhancing regional dispersion of repolarization and 
causing functional conduction block.  
 Short-long-short RR sequences mostly preceed arrhythmias in conditions with inherited 
or acquired IKr defects.106 The presence of a pause allows larger amounts of Ca2+ to 
accumulate in the SR, eliciting a larger Ca2+-induced Ca2+ transient.107 The post-pause Ca2+ 
transient rapidly inactivates ICaL, resulting in a smaller ICaL during the AP plateau. On the 
other hand, it enhances the inward mode of the sodium-calcium exchanger, and IKs is 
reduced (by prolonged IKs deactivation). The net effect is AP prolongation of the post-pause 
beat. This allows for the inactivated ICaL to recover and generate pause-dependent EADs.107 
In ΔKPQ-SCN5A myocytes from mice with LQT3,108 it was found that besides AP effects, the 
altered Na+ channels contributed to pause-dependent spontaneous diastolic activity in the 
setting of increased [Ca2+]SR, spontaneous Ca2+ waves, and transient inward current (Iti) 
induction.109, 110 Combined, pharmacological inhibition and congenital mutations in LQTS-
associated genes will amplify repolarization disparity, facilitate triggered activity and 
provoke functional reentrant excitation under specific conditions.111 
 Intact large animal experiments112, 113 and human investigations in LQT1114 have provided 
crucial novel mechanistic insights into the role of mechanoelectric feedback to prolonged-
repolarization-dependent arrhythmogenesis. In a drug-induced LQT1 canine model, 
Gallacher and colleagues noted a marked electromechanical window (EMW: QLVPend minus 
QT) negativity that preceded TdP onset during beta-adrenergic provocation.112, 113 Within 
this EMW negativity, and before EAD generation, sizeable postsystolic aftercontractions 
occurred. These mechanical eruptions mounted substantially to amplitudes of 
approximately 25 mm Hg (and sometimes much higher) in the final beats before TdP. 
Subsequent reinduction of TdP was prevented by verapamil, esmolol and atenolol, which 
significantly increased the EMW to less negative values and eliminated the 
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aftercontractions. Clinical data obtained within our team reinforce the notion that 
ventricular mechano-electric interactions may conspire to induce ventricular ectopy, 
nonsustained VT and even TdP in the presence of a profoundly negative and very dynamic 
EMW.114 Combined, these data allude to the arrhythmogenic role of mechano-electric 
feedback loops under conditions of non-uniform repolarization prolongation and 
sympathetic stress. Mechano-electric arrhythmogenesis, although new to the field of 
inherited arrhythmia syndromes, is well-recognized in commotio cordis,115 stretch-induced 
arrhythmias in ischemia,116 and volume-overload ventricular tachyarrhythmias in heart 
failure.117 
ARRHYTHMOGENIC ROLE OF PURKINJE FIBERS 
Subendocardial Purkinje fibers are specialized for rapid electrical propagation, and they are 
structurally and functionally different from adjacent ventricular cardiomyocytes. Purkinje 
cell APs have a longer duration, exhibit a prominent phase 1 of repolarization and have a 
faster AP upstroke.118 These unique AP properties are determined by Purkinje-specific ion-
channel compositions. Contrary to what is known for ventricular (working) cardiomyocytes, 
the Purkinje-cell INa contains an important non-inactivating and TTX-sensitive component 
that contributes significantly to APD.119 Purkinje cells contain both L-type and T-type calcium 
channels, have functionally different transient outward currents (Ito),118-120 and have a 
sizeable inward rectifier potassium current (IK1).118 Furthermore, the absence of an intricate 
t-tubular system drives Ca2+-induced Ca2+ release from the corbular and junctional SR. This 
typical intracellular Ca2+ handling of Purkinje cells makes them susceptible to cytosolic Ca2+ 
overload, DADs and EADs121, 122 and triggered APs.123, 124 Combined, these features may 
contribute to the participation of Purkinje fibers in the initiation and maintenance of 
ventricular arrhythmias in inherited arrhythmia syndromes, myocardial infarction and 
congestive heart failure.120  
 In the syndrome of short-coupled TdP, characterized by polymorphic VT,125 triggering 
premature ventricular contractions (PVCs) originate in the Purkinje system in ~86%.126 
Proposed arrhythmia mechanisms include 1) regenerative Ca2+ -release events in Purkinje 
cells or adjacent cardiomyocytes,123 2) phase-2 reentry in electrically coupled Purkinje-
muscle junctions, and 3) substantial conduction slowing of pathological Purkinje fibers.124  
 In 2009, linkage analysis in three genealogically-linked Dutch families with idiopathic VF 
and SCD identified a shared locus at chromosome 7q36.127 This haplotype contains the DPP6 
gene that encodes dipeptidyl peptase-like protein-6, the putative beta-subunit of Ito with a 
predominant expression in Purkinje fibers.120 Overexpression of DPP6, as is found in 
idiopathic VF patients with the 7q36 risk haplotype, accentuates the Purkinje-cell Ito 
resulting in localized repolarization shortening, steep repolarization gradients, and the 
likelihood of phase-2-reentrant excitation. Overall, this electropathological profile 
corresponds with the clinically-observed short-coupled Purkinje-related ectopy that can 
trigger VF in the absence of detectable abnormalities on the 12-lead ECG.128  
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 Mounting evidence has implicated a triggering role for Purkinje-fiber ectopy in LQTS.129 
Likewise, hyperexcitability of the His-Purkinje network (resulting in the syndrome of 
multifocal ectopic Purkinje-related premature contractions) is caused by a SCN5A 
channelopathy.130 Besides multifocal Purkinje-related ectopy, this syndrome can be 
associated with cardiomyopathy and SCD. Typically, no signs of LQTS of Brugada syndrome 
are found here.  
BRUGADA SYNDROME: DEPOLARIZATION OR REPOLARIZATION? 
The pathophysiological underpinnings of Brugada syndrome are still debated but two 
leading hypotheses have been postulated: the depolarization and repolarization 
hypothesis.131 The former argues that delayed and discontinuous right-ventricular 
depolarization is conveyed by a reduced INa 62, 132 and microscopic structural abnormalities in 
the RV outflow tract.133, 134 Shortened APs in the RV outflow tract are believed to result from 
hampered conduction and electrotonic interaction at structural discontinuities leading to 
excitation failure.135 On the other hand, the “repolarization theory” claims that 
repolarization gradients exist secondary to the combination of reduced INa and differential 
Ito expressivity. In the epicardium, this results in an accentuated epicardial notch.136 Both 
wedge preparations137 and human data138 demonstrate the prominent RV epicardial spike-
and-dome AP morphology in relation to a coved-type Brugada ECG phenotype. Dispersion of 
repolarization develops if epicardial AP domes are heterogeneously attenuated, favoring 
(concealed) phase-2-reentrant excitation, and functional reentrant arrhythmias. 
 The majority of Brugada patients experience arrhythmic events between 18h00 and 
06h00, while resting or sleeping.139 Heart-rate spectral analysis showed brisk increases in 
parasympathetic activity prior to VF.140 Edrophonium, a parasympathicomimetic agent, 
aggravates type-1-Brugada ECG whereas beta-adrenoreceptor agonists ameliorate this 
phenotypic feature.141 Besides the influence of vagally-mediated heart-rate slowing, internal 
and external influences impacting on the arrhythmogenic substrate remain largely 
unknown. 
VENTRICULAR ARRHYTHMOGENESIS AND THE AUTONOMIC NERVOUS SYSTEM 
Cardiac autonomic innervation comprises efferent and afferent neural pathways that 
intricately govern cardiac inotropy, chronotropy, dromotropy, and lusitropy on a beat-to-
beat and longer-term basis via feedback loops between the intrinsic cardiac nervous system, 
extracardiac-intrathoracic ganglia, and higher brain centers (Figure 1.2).142  
 Sympathoexcitation impinges on ventricular electrophysiological properties exaggerating 
dispersion of refractoriness,143 facilitating triggered activity,92 and reducing VF threshold.144 
On the other hand, there is mounting evidence of rich parasympathetic postganglionic 
ventricular innervation across species. Functionally, vagal-nerve stimulation operates mostly 
by antagonizing cardiac sympathetic actions and, thus, it prolongs the effective refractory 
period of canine ventricular cardiomyocytes via cholinergic-muscarinic pathways,145, 146 
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increases VF threshold (via neural nitric oxide synthase (nNOS) mediated NO release),145 and 
increases the variability of the dominant VF frequency.147 Intriguingly, vigorous and 
simultaneous excitation of both limbs of the autonomic nervous system is implicated in a 
wide range of arrhythmias, including TdP, in susceptible hearts.148 
 
 
Figure 1.2 Schematic illustration of autonomic innervation of the heart. ICNS indicates intrinsic cardiac nervous 
system. Multiple reflex loops provide feedback: cardiocardiac (level 1), intrathoracic (level 2), spinal and 
brainstem reflexes (level 3). Furthermore, additional control is imposed by higher braincentres like the 
hypothalamic and forebrain region. [Modified from142, 149, 150 with permission]. 
 
 
 In LQT1, it has been shown that arrhythmic events were mainly provoked by exercise or 
emotional stress (~88%) and during swimming.151 The potassium current IKs is normally 
upregulated during beta-adrenoceptor stimulation and at shorter cycle lengths to ensure 
repolarization shortening under circumstances of stress. Deficient IKs fails to do so, which 
can cause AP prolongation, dispersion of repolarization, beta-adrenergic 
afterdepolarizations, triggered activity and functional reentry. Interestingly, a distinctive 
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arrhythmic trigger in LQT1 is cold-water diving and swimming, which strongly drives 
sympathetic and parasympathetic nerve activity.151-153 This hints towards a more complex 
vago-sympathetic interaction, fueling ventricular arrhythmogenesis in LQT1. The potential 
contribution of the parasympathetic limb is further supported by the notion that higher 
vagal reflexes, specifically after a stress test, confer higher arrhythmic risks in KCNQ1-
p.(Ala341Val) patients.154 In these patients, heart-rate variability analysis indicated that a 
higher sympathetic control of the QT interval and a reduced vagal activity of heart rate are 
associated with less arrhythmic events.155 
 In contrast to the circadian arrhythmia patterns observed in congenital LQT1, arrhythmic 
events in LQT3 and Brugada syndrome occur mostly during resting conditions.139, 151 LQT3 
patients exhibit longer QT intervals at slower heart rates,156 and show QT shortening upon 
at rate acceleration. This clinical observation was confirmed experimentally in a drug-
induced LQT3 model.157 Documentation of LQT3-associated arrhythmia initiation is scarce in 
patients, but a predominant non-pause dependency has been described.106 Bradycardia-
related ventricular arrhythmias were prevented by preferential atrial pacing in a subset of 
SCN5A-p.(1795InsAsp) patients.158 Cholinergic stimulation in a mouse model of LQT3 with 
the knock-in SCN5A deletion of three amino acids (ΔKPQ: Lys-1505, Pro-1506, Gln-1507) 
provoked sinus bradycardia, QT prolongation and TdP, underscoring the proarrhythmic 
propensity of parasympathetic hyperactivity during augmented late sodium current (INa,L).159 
It is currently unclear if this effect is exclusively mediated by bradycardia-induced INa,L 
enhancement or whether a direct impact of muscarinic stimulation on ion channels plays a 
significant role here.144, 159, 160 
THERAPEUTIC AVENUES 
ANTIARRHYTHMIC DRUGS 
Beta-blockers are the cornerstone of pharmacological treatment for ventricular tachycardia 
in the setting of inherited arrhythmia syndromes and acquired heart disease. They operate 
mainly by interfering with beta-adrenergic receptors, but also impose sinus-rate slowing and 
possibly affect cellular Ca2+ handling through RyR2 inhibition.161 Carvedilol also suppresses 
spontaneous SR Ca2+ release161 and INa,L.162 According to the ESC Guidelines, beta-blockers 
are recommended in LQTS patients with a prolonged QTc (class I, level of evidence B) and 
should be considered in subjects with a causative LQTS-associated mutation and normal QTc 
(class IIa, level of evidence B).1  
 Metoprolol, nadolol, propranolol, and atenolol were equally effective as preventive 
therapy in asymptomatic LQT1 and LQT2 patients,163, 164 with nadolol conferring a significant 
risk reduction in LQT2.163 Propranolol provoked additional QTc shortening in LQTS by 
concomitant INa,L inhibition.162 Although beta-blockers effectively suppress arrhythmic 
events in LQT1 and LQT2, breakthrough events still occur in 20-30%,165-167 especially in 
patients with a history of cardiac events.168 Retrospective analyses yielded conflicting results 
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on the efficacy of various beta-blockers when comparing the suppression of breakthrough 
events.163, 164 In this high-risk group, propranolol appeared the least effective drug.163 
Nadolol reduced the risk of breakthrough events in symptomatic LQT1 and LQT2 patients, 
whereas metoprolol led to an increased risk with OR = 3.95 (95% C.I. 1.2-13.1; P=0.025).164  
 As LQT3 patients typically have slower basal heart rates and experience lethal events at 
rest, the use of beta-blockers is still somewhat of a debate,151, 165, 169 despite being 
recommended by the ECS Guidelines.1 Based on the results of a large cohort of 406 LQT3 
patients, chronic beta-blocker therapy was associated with an 83%-reduction of cardiac 
events in female patients.170 The type of beta-blocker was not reported. Ranolazine 
preferentially inhibits INa,L109, 171, 172 besides Iti, and it reduces [Ca2+]SR load.110 This compound 
has proven efficacy in LQT3 patients, either as monotherapy173, 174 or combined with a beta-
blocker.175 Ranolazine may be considered in LQT3 patients with a QTc > 500 ms as add-on 
therapy according to the ESC Guidelines (class IIb, level of evidence C).1 Mexiletine156 or 
flecainide176 are useful alternatives in this condition. 
 Amiodarone, with Vaughan-Williams class I, II, III, and IV antiarrhythmic properties, has 
complex electropharmacological actions, targeting multiple ion channels (K+, Na+, and 
Ca2+),177 besides its beta-blocking action, and is highly effective in suppressing ventricular 
arrhythmias through effects on reentrant pathways and abnormal impulse formation. This 
drug induces differential repolarization prolongation leading to reduced transmural 
repolarization dispersion.178, 179 It is considered unsuitable for arrhythmia management in 
LQTS patients. 
INTERVENTIONAL MODALITIES 
Invasive treatment of life-threatening arrhythmias in patients without noticeable structural 
abnormalities has developed considerably in the recent years. In selected cases, 
radiofrequency catheter ablation of VF-triggering Purkinje-related PVCs can (at least 
temporarily) prevent VF to occur.126, 129, 180, 181 In the case of a genetic mechanism for VF, the 
arrhythmogenic propensity of Purkinje fibers is not confined to a particular endocardial 
area, and VF triggers may arise distant from the site of ablation. As such, these patients 
should be treated with an implantable cardioverter defibrillator (ICD) besides 
antiarrhythmic drug therapy, whereas a dominant focal trigger may additional be ablated.  
 Neuraxial modulation through left cardiac sympathetic denervation (LCSD) was first 
successfully employed in a patient with therapy-refractory angina pectoris and ventricular 
arrhythmias by Thomas Jonnesco in 1916.182 Some fifty years later, cardiac sympathetic 
denervation was occasionally performed in sporadic idiopathic VT/VF and LQTS cases,183, 184 
and, by now, has established as adjuvant treatment for large numbers of patients with 
suspected sympathetic-induced VTs.185-187 Currently, LSCD or bilateral sympathetic 
denervation188 entail important treatment modalities in patients with refractory VT in whom 
medicinal is ineffective or contra-indicated, if ICD therapy is unsuited, or if breakthrough 
events occur despite beta-blocker therapy requiring ICD shocks.1   
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AIMS AND STRUCTURE OF THIS THESIS 
The aims of this PhD thesis are captured as follows: 
1. To investigate the modulatory role of mechano-electric heterogeneities besides 
non-uniform repolarization prolongation in the arrhythmogenic deterioration of 
congenital LQTS. 
2. To refine risk stratification in LQTS patients taking electromechanical parameters 
into account. 
3. To unravel potential genotype-specific determinants of electromechanical 
disparity in patients LQT1, LQT2, or LQT3. 
4. To explore the proarrhythmic proclivity of unilateral sympathetic stimulation in an 
in-vivo canine model of drug-induced LQT1. 
5. To investigate ventricular electromechanical heterogeneities provoked by 
increased autonomic tonus in drug-induced LQT1. 
6. To study genotype-phenotype relationships in high-risk patients guiding 
personalized arrhythmia treatment. 
7. To pave the way for the identification of genetic modifiers in a SCN5A founder 
population with phenotypic overlap and excess SCD using unbiased whole-exome 
and targeted genome sequencing. 
 
 This thesis is structured following these aims. A critical appraisal of the contemporary 
knowledge of non-uniform repolarization prolongation, associated altered cellular Ca2+ 
handling, and mechano-electric disparity in the setting of LQTS is described in . Chapter 2
Furthermore, preliminary results are provided on the non-invasive assessment of EMW 
negativity in LQTS patients under basal conditions and EMW dynamicity during instances of 
electrical instability preceding TdP. These pilot data inspired us to investigate the 
discriminatory role of EMW negativity in a multicenter cohort of 244 genotyped symptomatic 
and asymptomatic LQTS patients ( ). Next, we investigated repolarization instability, Chapter 3
electromechanical interplay, and LQT1-associated ventricular arrhythmogenesis during 
unilateral stimulation of the (intact) stellate ganglion in a canine model ( ). With the Chapter 4
intention to improve understanding of individual genotype-phenotype correlations the 
following two chapters,  and , are written.  illustrates the novel Chapter 5 Chapter 6 Chapter 5
insights in arrhythmia patterns and divergent phenotypes obtained after meticulous cardiac 
phenotyping of a large kindred segregating the deletion of phenylalanine at position 1617 of 
the SCN5A gene. This founder population allows complex family-based statistical analyses to 
assess residual heritability besides a shared pathogenic mutation and paves the way for the 
unambiguous identification of additional disease-modifying variants. In , at an Chapter 6
individual patient level, genetic profiling adds to the mechanistic understanding of life-
threatening arrhythmias, unraveling novel arrhythmia mechanisms, and even guiding 
personalized anti-arrhythmic therapy.  discusses these different layers of complexity Chapter 7
important for ventricular arrhythmogenesis and provides prospective for future research. 
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Finally, I take the opportunity to share with the reader the HeArt Project ( ), an art- Chapter 8
based intervention that paralleled this dissertation, aiming to promote the synergy between 
artistic and scientific creativity. Artistic perspectives are provided to translate complex 
scientific content to the general public. 
 
 
Table 1.1 Genetic variants associated with LQTS. 
 
Syndrome Chromosome Gene Protein Functional effect Freq. Ref. 
Long-QT syndrome (major)     
 LQT1 11p15.5 KCNQ1 KV7.1 Reduced IKs 30-35% 
41, 42 
 LQT2 7q35-46 KCNH2 KV11.1 Reduced IKr 25-30% 
43 
 LQT3 3p21-p24 SCN5A NaV1.5 Increased INa 5-10% 
44 
Long-QT syndrome (minor)     
 LQT4 4q25-q27 ANKB Ankyrin B Ab. ion chan./transp. Rare 53, 54 
 LQT5 21q22.1 KCNE1 MinK Reduced IKs Rare 
46, 189 
 LQT6 21q22.1 KCNE2 MiRP1 Reduced IKr Rare 
47, 190 
 LQT7 17q23 KCNJ2 Kir2.1 Reduced IK1 Rare 
55 
 LQT8 12p13.3 CACNA1C CaV1.2 Increased ICaL Rare 
56 
 LQT9 3q25 CAV3 Caveolin 3 Increased INa Rare 
49 
 LQT10 11q23.3 SCN4B NaVβ4 Increased INa Rare 
50 
 LQT11 7q21-q22 AKAP9 Yotiao Reduced IKs Rare 
48 
 LQT12 20q11.2 SNTA1 Syntrophin-α1 Increased INa Rare 
51 
 LQT13 11q24.3 KCNJ5 Kir3.4 Reduced IK,Ach Rare 
45 
 LQT14 14q32.11 CALM1 Calmodulin 1 Dysfunct. Ca2+ sign. Rare 52 
 LQT15 2p21.1-p21.3 CALM2 Calmodulin 2 Dysfunct. Ca2+ sign. Rare 52 
Jervell and Lange-Nielsen syndrome     
 JLNS1 11p15.5 KCNQ1 KV7.1 Reduced IKs Rare 
189 
 JLNS2 21q22.1 KCNE1 MinK Reduced IKs Rare 
191 
 
In chronological order of publication. 
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Table 1.2 Genetic variants associated with Brugada syndrome. 
 
Syndrome Chromosome Gene Protein Function. effect Freq. Ref. 
Brugada syndrome (major)     
 BrS1 3p21-p24 SCN5A NaV1.5 Reduced INa 20-30% 
62 
Brugada syndrome (minor)     
 BrS2 3p22.3 GPD1L GPD1L Reduced INa Rare 
192 
 BrS3 12p13.3 CACNA1C CaV1.2 Reduced ICaL 6.6% 
193 
 BrS4 10p12 CACNB2 CaVβ2b Reduced ICaL 5% 
194 
 BrS5 19q13.1 SCN1B NaVβ1 Reduced INa 1-2% 
195 
 BrS6 11q13.4 KCNE3 MiRP2 Increased Ito <1% 
196 
 BrS7 11q24.1 SCN3B NaVβ3 Reduced INa Rare 
197 
 BrS8 7q35 KCNH2 KV11.1 Increased IKr Rare 
198 
 BrS9 12p12.1 KCNJ8 Kir6.1 Increased IK,ATP Rare 
199 
 BrS10 7q21-q22 CACNA2D1 CaVα2/∂1 Reduced ICaL Rare 
200 
 BrS11 17p13.1 RANGRF MOG1 Reduced INa Rare 
201 
 BrS12 Xq22.3 KCNE5 MiRP4 Increased Ito/IKs Rare 
202 
 BrS13 1p13.2 KCND3 KV4.3 Increased Ito Rare 
203 
 BrS14 15q24.1 HCN4 HCN4 Reduced If Rare 
51, 204 
 BrS15 3q14.3 SLMAP SLMAP Reduced INa Rare 
205 
 BrS16 19q13 TRPM4 NSCCa Reduced INa 8% 
206 
 BrS17 11q23.2 SCN2B NaVβ2 Reduced INa Rare 
207 
 BrS18 12p12.1 ABCC9 SUR2A Increased IK,ATP 4-5% 
208 
 BrS19 3p22.2 SCN10A NaV1.8 Reduced INa 2.5-16% 
209 
 BrS20 12p11.21 PKP2 Plakophilin-2 Reduced INa 2.5% 
210 
 BrS22 7q21.11 SEMA3A Semaphorin 3A Increased Ito ? 
211 
        
 
In chronological order of publication. 
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Table 1.3 Chromosomal loci/genetic variants associated with idiopathic VF and short-
coupled TdP. 
 
Syndrome Chromosome Gene Protein Functional effect Freq. Ref. 
 Short-coupled TdP   
 sc-TdP 14q32.11 CALM1 Calmodulin 1 Dysfunct. Ca2+ sign. ? 67 
 sc-TdP 1q43 RYR2 Ryanodine rec 2 Dysfunct. Ca2+ sign. ? 68 
Idiopathic ventricular fibrillation    
 iVF 7q36 DPP6 Dipeptidyl 
peptase-like 
protein-6 
Increased Ito ? 
127 
 iVF 16q12.2 IRX3 Iroquois 
homeobox 
protein 3 
Enhanced HP 
conduction 
? 212 
 iVF 6p24.3 DSP Desmoplakin ? ? 213 
 iVF 12p13.33 CACNA1C CaV1.2 ? ? 
213 
 iVF 14q11.2 MYH7 Myosin heavy 
chain 7 
? ? 213 
 iVF 2q31.2 TTN Titine ? ? 213 
 iVF 10q22.2 VCL Vinculine ? ? 213 
 iVF 12p11.21 PKP2 Plakophilin ? ? 213 
 iVF 19q13 TRPM4 TRPM4/NSCCa ? ? 214 
 iVF 11q24.1 SCN3B NaVβ3 Reduced INa ? 
215 
 
In chronological order of publication. 
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Table 1.4 Genetic variants associated with SQTS, ERS, and CPVT. 
 
Syndrome Chromosome Gene Protein Functional effect Freq. Ref. 
Short-QT syndrome      
 SQT1 7q36.1 KCNH2 KV11.1 Increased IKr <5% 
216 
 SQT2 11p15.5 KCNQ1 KV7.1 Increased IKs <5% 
217 
 SQT3 17q24.3 KCNJ2 Kir2.1 Increased IK1 <5% 
218 
 SQT4 12p13.3 CACNA1C CaV1.2 Reduced ICaL Rare 
193 
 SQT5 10p12.33 CACNB2b CaVβ2b Reduced ICaL Rare 
193 
 SQT6 7q21.11 CACN2D1 CaVα2/∂1 Reduced ICaL Rare 
219 
 SQT7 2q35 SLC4A3 H,HCO3-exch. High pHi Rare 
220 
Early repolarization syndrome     
 ERS1 12p11.23 KCNJ8 Kir6.1 Increased IK,ATP ? 
221 
 ERS2 12p13.3 CACNA1C CaV1.2 Reduced ICaL 4% 
200 
 ERS3 10p12.33 CACNB2b CaVβ2b Reduced ICaL 8% 
200 
 ERS4 7q21.11 CACNA2D1 CaVα2/∂1 Reduced ICaL 4% 
200 
 ERS5 3p21 SCN5A NaV1.5 Reduced INa ? 
222 
 ERS6 12p12.1 ABCC9 SUR2A Increased IK,ATP ? 
208 
Catecholaminergic polymorphic ventricular tachycardia   
 CPVT1 1q42.1-q43 RYR2 Ryanodine rec 2 Dysfunct. Ca2+ sign. 50-60% 223 
 CPVT2 1q13.3 CASQ2 Calsequestrin 2 Dysfunct. Ca2+ sign. 1-2% 224 
 CPVT3 4q25-q27 ANKB Ankyrin-B Ab. ion chan./transp. Rare 225 
 CPVT4 17q23 KCNJ2 Kir2.1 Increased IK1 Rare 
226, 227 
 CPVT5 14q32.11 CALM1 Calmodulin 1 Dysfunct. Ca2+ sign. Rare 228 
 CPVT6 6q22.31 TRDN Triadin Dysfunct. Ca2+ sign. Rare 229 
 CPVT7 2p21.1-p21.3 CALM2 Calmodulin 2 Dysfunct. Ca2+ sign. Rare 230 
 CPVT8 19q13.2-13.3 CALM3 Calmodulin 3 Dysfunct. Ca2+ sign. Rare 231 
        
        
 
In chronological order of publication. 
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ABSTRACT  
Since the first linkage of the long-QT syndrome to the Harvey ras-1 gene in 1991 ample 
research has been performed to decipher the molecular-biophysical basis of congenital 
repolarization defects and the electrophysiological mechanisms of torsades-de-pointes 
arrhythmias in this condition. Mechanistic knowledge is mostly derived from cellular 
experiments (cardiac myocytes, cultured cells), ventricular tissue (including arterially-
perfused wedge) preparations and Langendorff-perfused hearts, with relatively little 
information from in-vivo animal models, and even more scant intact human-heart 
investigations. Until now, much emphasis has been put on purely membrane-related 
pathways of arrhythmia initiation with a prominent role for spatiotemporal dispersion of 
repolarization, early afterdepolarizations and reentrant excitation. Here, we review 
additional factors that influence the onset of torsades de pointes, notably myocardial Ca2+ 
(over)loading and spontaneous SR Ca2+ release, occurring particularly during intense 
sympathetic nervous stimulation and dynamic cycle-length changes. Recent tissue and in-
vivo data suggest that spontaneous SR Ca2+ release, underlying aftercontractions in the 
isolated myocyte, may organize to local myocardial Ca2+ waves and aftercontractions in the 
intact heart. In the setting of prolonged repolarization and a negative electromechanical 
window, these spontaneous [Ca2+]cyt-based events (which often arise during early diastole) 
may exaggerate repolarization instability via [Ca2+]cyt-activated inward membrane currents 
and, as we postulate, via mechano-sensitive ion currents. Future long-QT research should 
focus on the intact beating heart with preserved autonomic input to examine these 
arrhythmogenic mechanisms.   
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INTRODUCTION 
Intrinsic electromechanical heterogeneity is present in the normal beating heart. 
Differences in action-potential morphology and duration exist between various regions of 
the ventricular myocardium under physiological conditions.100, 232 Likewise, spatial gradients 
of contraction and relaxation exist, e.g., between the endo- and epicardium, apex and base, 
left (LV) and right ventricular, and at the circumferential diameter.233 Differential 
expressions of transmembrane ion currents, and Ca2+-transport and storage mechanisms 
underlie these non-uniformities. 
 In patients with the congenital long-QT syndrome, electromechanical heterogeneity of 
the ventricles is often increased. The various LQTS that have been identified to date are 
caused by genetic mutations in ion-channel subunits or ion-channel-associated proteins. 
Mutation carriers may remain asymptomatic during their entire life, but severe cases are 
susceptible to syncope or sudden death due to torsades de pointes and ventricular 
fibrillation. Although these syndromes are considered “primary electrical 
cardiomyopathies”, LQT patients may exhibit mechanical wall abnormalities under basal 
conditions. One initial echocardiographic study revealed a rapid early contraction and a very 
prolonged phase of wall thickening before rapid relaxation in more than half of referred 
patients, who had an averaged QTc interval of approximately 500 ms.234 In some of these, a 
peculiar double-peak pattern of later thickening was observed. Similar results were 
obtained by other groups using M-mode235 and tissue-Doppler imaging techniques.236 
Mechanical wall abnormalities were normalized by intravenous treatment with the Ca2+-
channel blocker verapamil.237 More recently, strain-imaging studies revealed that 
contraction duration was longer in the subendocardium than midmycardium of 
symptomatic LQT mutation carriers, but not of asymptomatic or healthy individuals, 
indicating transmural mechanical dispersion in the former group.238 Prolonged contraction 
duration and augmented longitudinal mechanical dispersion were superior to QTc for 
arrhythmia-risk assessment. 
 While these clinical data hint to an association between increased mechanical 
heterogeneity and the occurrence of arrhythmias in susceptible LQT patients, a mechanistic 
link remains elusive. This applies particularly to the dynamic beat-to-beat instabilities of the 
heart just prior to the onset of TdP when sympathetic activity is often enhanced. Does 
mechano-electric coupling contribute to arrhythmogenesis at these very instances? And if 
so, how? 
 In the present article, we review the literature on arrhythmia mechanisms in the setting 
of congenitally prolonged and/or dispersed ventricular repolarization, focusing mainly on 
the role of altered myocardial Ca2+ handling, spontaneous sarcoplasmic reticulum Ca2+ 
release and the generation of afterdepolarizations, aftercontractions, and premature 
ectopic beats. The concept of the “electromechanical window” will be discussed. We will 
argue that in the intact beating heart, besides [Ca2+]cyt-dependent pathways, mechano-
sensitive activation of ion channels can participate in torsadogenesis when 
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electromechanical heterogeneity exaggerates and systolic and/or diastolic occur. As much 
as possible, we will seek in-vivo confirmation of cellular mechanisms. 
CELLULAR CA2+ OVERLOAD AND SPONTANEOUS SR CA2+ RELEASE DURING PROLONGED 
REPOLARIZATION 
CA2+ HANDLING AND CA2+ ACCUMULATION IN CARDIAC MYOCYTES 
Thorough insight into myocyte Ca2+ handling is essential for the understanding of 
arrhythmogenesis in a broad variety of cardiac diseases, including the LQTS.92 Under normal 
conditions, Ca2+-induced Ca2+ release from the SR is triggered by sarcolemmal Ca2+ influx 
mainly through L-type Ca2+ channels (Figure 2.1A).239, 240 A rise in subsarcolemmal [Ca2+] by 
L-type Ca2+-channel influx and/or Ca2+ diffusion from nearby ryanodine receptors (RyR) can 
activate these RyRs to release much more Ca2+ from the SR. Both subsarcolemmal [Ca2+] and 
intra-SR [Ca2+] influence RyR-channel gating properties.241 Multiple local Ca2+-release events 
summate into a propagating whole-cell Ca2+ transient that activates the contractile 
apparatus via Ca2+ binding to the myofilament protein troponin C. Changes in the size of the 
Ca2+ transient feed back on transsarcolemmal Ca2+ fluxes, adjusting the SR Ca2+ content such 
that the size of the Ca2+ transient returns to its basal level. 
 It has long been recognized that Ca2+ can also be released from the SR without a 
preceding membrane depolarization. This process, referred to as spontaneous Ca2+ release, 
can occur under conditions of myocyte Ca2+ overload when [Ca2+]SR is abnormally high.242-245 
Protein-kinase-A (PKA)-dependent phosphorylation of ICaL, and PKA- and Ca2+/Calmodulin-
kinase II (CaMKII)-dependent modulation of SR Ca2+ uptake (via SERCA2a and 
phospholamban) have a large impact on SR Ca2+ levels and the incidence of spontaneous 
Ca2+ release.246 The functional consequences of RyR phosphorylation (by PKA and/or 
CaMKII) are still debated.247 Several conditions promote [Ca2+]SR accumulation and 
spontaneous SR Ca2+ release with self-propagating Ca2+ waves, including beta-adrenergic 
receptor stimulation, rapid electrical stimulation, digitalis intoxication, and elevated 
extracellular [Ca2+].245, 248 
 The Na+/Ca2+ exchanger (NCX) is the main Ca2+-extrusion protein for the beat-to-beat 
regulation of contraction and relaxation in cardiac myocytes. Because of a predominant 
stoichiometry of 3 Na+ ions : 1 Ca2+ ion inward INa-Ca is generated when Ca2+ is extruded from 
the cell and outward INa-Ca is generated when Ca2+ enters via this transporter. The direction 
and magnitude of NCX are dependent on the membrane potential and the intra- and 
extracellular [Na+] and [Ca2+] in the direct vicinity of the NCX protein. The dynamics of the 
AP and the resultant local Na+ and Ca2+ signals change the NCX-reversal potential on a 
continuous basis. Under normal conditions, it functions predominantly in the inward mode 
during the decay phase of the Ca2+ transient generating inward current during most of the 
repolarization. This increases the APD. 
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ALTERED MYOCARDIAL CA2+ HANDLING DURING PROLONGED REPOLARIZATION 
It is well established that AP amplitude and/or duration per se are important regulators of 
contraction,88, 89 mainly by changing the amount of Ca2+ released from the SR.93 A prolonged 
AP-plateau phase contributes to incomplete inactivation of voltage-dependent L-type Ca2+ 
current resulting in cellular Ca2+ loading.249 
 In addition, pharmacological modulation of repolarization can profoundly alter 
myocardial Ca2+ handling even in the absence of beta-adrenergic stimulation. Drug-induced 
AP prolongation with the selective IKr blocker almokalant caused a positive inotropic effect 
in isolated human ventricular muscle strips (steady-state pacing cycle length 1000 ms),91 
consistent with earlier data.90 In canine ventricular M-cell preparations pretreated with the 
IKr blocker E-4031, sudden rate acceleration or a single premature beat could induce or 
facilitate transient AP prolongation and the generation of early afterdepolarizations via a 
mechanism linked to Ca2+ loading,250 in line with model data.107 Furthermore, optical-
mapping experiments in dofetilide-treated Langendorff-perfused rabbit hearts revealed 
discernible [Ca2+]cyt oscillations that preceded EAD generation by minutes, indicating that 
they could arise from spontaneous SR Ca2+ release rather than Ca2+-induced Ca2+ release 
through ICaL reactivation.94 Thapsigargin and ryanodine, by suppressing SR Ca2+ uptake and 
release, successfully prevented the occurrence of EADs. In another study on Langendorff-
perfused rabbit hearts treated with sotalol or veratridine, the NCX inhibitor SEA0400 was 
effective in preventing TdP by suppressing EADs.251 Collectively, these data support that 
acute (drug-induced) repolarization prolongation causes myocardial Ca2+ loading, potentially 
leading to overload and [Ca2+]cyt oscillations owing to spontaneous SR release. If occurring 
during systole, these [Ca2+]cyt oscillations can activate inward INa-Ca to delay repolarization 
(together with inactivating ICaL), thus allowing for reactivating ICaL to generate EAD 
upstrokes. Besides these electrogenic effects [Ca2+]cyt increments will also activate the 
mechanical machinery and dictate myocyte contraction. At least on theoretical grounds and 
depending on their timing, local spontaneous contractile events or aftercontractions could 
activate mechano-sensitive non-selective stretch-activated cation (ISAC) channels to 
contribute to the initial repolarization delay and EAD formation (Figure 2.1). 
 Virtually nothing is known about Ca2+ handling in native ventricular myocytes from LQT 
patients. In a transgenic mouse model of the LQTS type 3 (LQT3; gain-of-function mutations 
of SCN5A) sudden accelerations in heart rate or premature beats cause AP prolongation 
with EADs and triggered arrhythmias.108 Mutation-altered Na+ entry contributes to the 
occurrence of pause-dependent spontaneous diastolic activity109 caused by Ca2+-dependent 
transient inward current in the setting of elevated [Ca2+]SR and spontaneous Ca2+ waves. 
Ranolazine, at concentrations that preferentially target late INa during prolonged 
depolarization, inhibits these spontaneous events by decreasing [Ca2+]SR.110 Irregularities of 
Ca2+ handling may also underlie prolonged and unstable repolarization at increasing rates. 
These are corrected with verapamil.252 To the best of our knowledge, detailed studies of 
myocyte Ca2+ handling in mouse and rabbit models of LQT1 and LQT2 are lacking. 
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Figure 2.1 Overview of [Ca2+]cyt-dependent and mechano-dependent pathways underlying membrane 
depolarizations during myocyte Ca2+ overload and spontaneous SR Ca2+ release. (A) Transmembrane ion 
currents, and Ca2+-transport and storage mechanisms. Beta-adrenergic-receptor (β1AR) stimulation initiates 
two intracellular signaling cascades: (1) cAMP- and PKA-dependent phosphorylation of target proteins (e.g., L-
type Ca2+ current and phospholamban (PLB)); (2) Ca2+ / Calmodulin-dependent protein kinase (CaMKII)-
mediated signaling (e.g., ICaL, PLB and ryanodine receptors (RyR)). Elevated [Ca2+]cyt can evoke Ca2+-dependent 
transient inward currents (INa-Ca, ICl(Ca) and INS) and Ca2+-sensitive transient receptor potential current (ITRP). In 
addition, (after)contractions resulting from (spontaneous) SR Ca2+ release can activate mechano-dependent 
inward currents via non-selective stretch-activated cation channels (ISAC), carrying Na+, Ca2+ or K+. For clarity, 
not all PKA- and CaMKII-dependent pathways are depicted. IKs indicates slowly-activating delayed-rectifier K+ 
current; IKr, rapidly-activating delayed-rectifier K+ current; INa, Na+ current; Ito, transient-outward K+ current; IK1, 
inward-rectifier K+ current; INaK, Na+/K+-ATPase; Gsα, Gs alpha subunit; AC, adenylyl cyclase; PKA, protein kinase 
A; CaM, calmodulin; JSR, junctional sarcoplasmic reticulum; NSR, non-junctional sarcoplasmic reticulum; 
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SERCA2a, SR Ca2+ ATPase; CASQ, calsequestrin; SACNS, non-selective stretch-activated cation channels; SACK, 
K+-selective stretch-activated channels. (B) Left, diastolic Ca2+ aftertransient causing aftercontraction and DAD 
carried by [Ca2+]cyt-dependent INa-Ca and ICl(Ca). Based on known reversal potentials for SACNS and SACK, 
mechano-dependent inward ISAC could contribute to DAD during aftercontraction. Right, systolic Ca2+ 
aftertransient (*) underlying aftercontraction and initial repolarization delay (EAD-conditioning phase by 
[Ca2+]cyt-dependent INa-Ca and inactivating ICaL) versus the EAD upstroke (reactivating ICaL and/or INa). Based on 
known reversal potentials for SACNS and SACK, mechano-dependent inward ISAC can be present throughout 
both EAD-conditioning and upstroke phase when aftercontraction occurs. 
ARRHYTHMOGENIC CONSEQUENCES OF SPONTANEOUS CA2+ RELEASE 
Spontaneous SR Ca2+ release of sizeable magnitude can alter the membrane potential via 
two, mutually inclusive, mechanisms: [Ca2+]cyt-dependent Iti and mechano-dependent 
inward ion currents activated by aftercontractions. 
[CA2+]CYT-DEPENDENT ITI 
Spontaneous Ca2+ aftertransients can activate Ca2+-sensitive Iti to generate delayed 
afterdepolarizations253 and/or the “conditioning phase” of EADs, particularly during beta-
adrenergic stimulation98, depending on the phase in the cardiac cycle at which they occur 
(Figure 2.1B).  
 For DADs, several [Ca2+]cyt-dependent inward currents are implicated: INa-Ca, Ca2+-
activated Cl- current (ICl(Ca))96 and the non-selective cation current.254 The latter may be 
carried by transient receptor potential M4 (TRPM4) channels.255 
 For EADs, the ionic mechanisms are complex and diverse, depending on the cell type and 
conditions in which they occur. Different ionic mechanisms can contribute to the 
conditioning phase, i.e., the initial repolarization delay that sets the stage for EAD upstrokes. 
In the case of proarrhythmic IKr blockade (in the absence of beta-adrenergic stimulation) AP 
prolongation and EADs are caused by decreased repolarizing K+ currents in combination 
with reduced inactivation and subsequent reactivation of ICaL.92 This is in line with 
experiments with the ICaL agonist Bay K 8644 by January and coworkers, who observed a 
concentration-dependent AP lengthening followed by the generation of EADs at a non-
physiological 0.2-Hz stimulation frequency.256   
 By contrast, EADs generated during intense beta-adrenergic receptor stimulation often 
appear jointly with DADs and are fast-rate dependent, suggesting that [Ca2+]cyt overload and 
spontaneous Ca2+ aftertransients underlie both.98, 257, 258 IKs blockade potentiates the 
occurrence of these beta-adrenergic EADs that are almost always accompanied by DADs in 
the preceding diastole.259 Beta-adrenergic EADs coincide with early aftercontractions based 
on Ca2+ aftertransients. In fact, these aftercontractions commence approximately 30 ms 
earlier than the upstroke of their accompanying EAD and they arise often without EADs, but 
never without a concomitant delay in repolarization. In experiments with Ni2+, a non-specific 
inhibitor of NCX, early and delayed aftercontractions persisted despite complete inhibition 
of EADs and DADs.98 Others have shown (1) similar results using alternative NCX blockers,260, 
 28 | CHAPTER 2 
261 (2) that the photolysis of caged intracellular Ca2+ during or after a stimulated action 
potential can elicit an EAD or DAD, respectively,260 and (3) that early and delayed Ca2+ 
aftertransients persist in myocytes even when switching from current-clamp (stimulated 
action potentials with EADs and DADs) to voltage-clamp mode (applying action-potential 
command waveforms without EADs and DADs).261 Taken together, these observations 
strongly imply that beta-adrenergic-elicited early Ca2+ aftertransients are due to 
spontaneous SR Ca2+ release, and that these primary events drive Ca2+-dependent inward 
INa-Ca to delay repolarization during the conditioning phase prior to the actual EAD. Besides 
INa-Ca, beta-adrenergic-enhanced window ICaL also contributes to this phase (Figure 2.1B).262 
Actual EAD upstrokes are carried by reactivating ICaL. In-vivo observations in a canine model 
of drug-induced LQT1 and beta-adrenergic receptor stimulation112 are consistent with these 
cellular mechanisms, confirming their relevance in the beating heart. 
 Of course, in LQT3-mimicking conditions the importance of (late) INa is more prominent. 
This applies also to Purkinje cells in which (late) INa is intrinsically larger than in ventricular 
myocytes. As an important side note, Ca2+-activated TRPM4 channels, which are permeable 
to monovalent cations such as Na+ and K+,263, 264 have also been implicated in EAD (and DAD) 
generation, particularly during cardiac hypertrophy.265 
MECHANO-DEPENDENT INWARD CURRENTS: ROLE FOR STRETCH-ACTIVATED CHANNELS 
The notion that mechanical forces imposed on the myocardium can induce electrical 
responses is not new. In 1876, Nélaton reported a case of sudden death after a non-
penetrating mechanical impact to the precordium.266 Since then it has become increasingly 
clear that the heart has intrinsic mechano-sensory properties that can exhibit profound 
effects on membrane excitation, repolarization, abnormal impulse formation and 
conduction, and arrhythmia, as exemplified in the following section. 
 In isolated, chronically-infarcted canine hearts, acute volume loading increased 
dispersion of refractoriness and ventricular arrhythmias.267 Likewise, in isolated blood-
perfused canine hearts, an additional volume of 15 ± 1.6 mL on top of a holding volume of 
20 mL (end-diastolic pressure 5.3 ± 5.2 mm Hg) evoked a 50% probability of stretch-induced 
ventricular arrhythmia.268 The temporal delay between peak stretch volume and ventricular 
premature depolarization was approximately 38 ms. Electrophysiological responses are not 
only determined by the magnitude of the imposed mechanical stress, but are also reliant on 
myocardial wall compliance and spatiotemporal mechanical heterogeneity. The strain-
electric response relationship of myocardial tissue was elegantly demonstrated by Seo and 
co-workers using optical voltage mapping coupled to tissue-marker tracking techniques in 
the rabbit RV wall and in whole-heart preparations.269 Medium-sized (10-15%) stretch 
induced focal excitation that could develop into reentrant arrhythmias. Counterintuitively, 
when enlarging the mechanical stimulus the likelihood of arrhythmia induction decreased 
due to synchronous excitation of larger myocardial regions. This stretch-induced excitation 
was suppressed by 71% after pharmacological non-selective inhibition of stretch-activated 
channels with Gd3+. They observed predilection sites of focal activity in thin-walled regions 
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probably reflecting the heterogeneity in strain distribution due to complex ventricular 
geometry.269 This may relate to the observation that TdP in humans originates preferentially 
from the LV- and/or RV-outflow tract regions, which are thin-walled and often richly 
innervated.270  
 To elucidate the biophysical basis of mechano-electric coupling and arrhythmogenesis, 
extensive research has been done in various species, including mouse, rat, canine, lamb and 
human.268, 271-275 Stretch-activated channels (SACs) are the most likely candidates for 
mechano-electric transduction as these channels open their pores in response to 
mechanical deformation. SACs are ubiquitous in various organs including the heart where 
they are localized in T-tubules,276 in caveolae, and in intracellular membrane 
compartments.277 Since the discovery of SACs in embryonic chick skeletal muscle in 1984,278 
a broad diversity of mechano-sensitive channels has been reported. Some of these have 
been linked to myocardial stretch-evoked arrhythmogenic effects: of the canonical TRP 
subfamily, TRPC1279 and TRPC6;280 and of the melastatin TRP subfamily, mainly [Ca2+]cyt-
activated TRPM4.263 Of note, various ion channels primarily operated by voltage-gated 
mechanisms, also exhibit mechano-sensitive properties, including the ICaL channel,281 IKs 
channel,282 INa channel,283 and the Na+/H+ exchanger.284 Recently, it has been shown that the 
NaV1.5 antagonist ranolazine also effectively inhibits the mechano-sensitivity of the Na+ 
channel decreasing the pressure-induced window current and late current.285 The IKs 
channel is upregulated by hypotonic-induced myocyte stretch (besides stretch-induced 
increased Cl- current) causing action-potential shortening in guinea pig myocytes. 
Interestingly, a human stretch-sensitive KCNQ1 mutation (R14C) has been reported that is 
associated with shortened APD (in computer models) and familial atrial fibrillation upon 
atrial dilation.286 To the best of our knowledge, there is no evidence for stretch-induced 
modulation of the IKr channel. 
 At least two main classifications of SACs have been distinguished based on their ion 
selectivity: (1) cation non-selective stretch-activated channels (SACNS) that are permeable to 
a variety of cations including Na+, K+, and Ca2+, and can be inhibited by GsMtx-4 a small 
peptide found in the venom of the tarantula Grammostola spatulata;287 (2) K+ selective 
stretch-activated channels (SACK).278, 288 As is depicted in Figure 2.1B, SACNS have a reversal 
potential around 0 to -20 mV (AP-plateau level; current of approximately 25 pS), whereas 
SACK have a reversal potential at -90 to -95 mV (well below the cardiac myocyte resting 
membrane potential; 100 pS).276, 289, 290 
 SAC activation can either lengthen or shorten the APD, depending on the timing of the 
mechanical trigger during the AP.268, 280 A depolarizing current can be evoked when a 
transient stretch is applied near the end of the AP at voltages more negative than the SACNS 
reversal potential evolving into frank EADs under conditions of oxidative stress.272 However, 
although there is considerable evidence that SAC activation can alter AP amplitude, duration 
and resting potential, there is still a giant leap of understanding between cellular findings 
and clinical arrhythmias, especially regarding LQTS-associated arrhythmias. Based on (1) the 
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known reversal potentials of non-selective stretch-activated cation channels and K+-
selective stretch-activated channels, (2) the finding that stretch-activated inward currents 
promote EADs in myocytes under oxidative stress, (3) the involvement of stretch-activated 
membrane excitation and arrhythmias in canine and rabbit whole-heart preparations, and 
(4) the temporal relation between aftercontractions (as potential stretch activators), EAD 
upstrokes and T-wave deflections, we believe that such role is likely under specific 
torsadogenic conditions. We argue that fluctuating mechanical impact changes electrical 
characteristics,291 and if electrical properties are regionally heterogeneous, as in the 
congenital LQTS, or if tissue mechanosensitivity is inhomogeneous, then spontaneous 
mechanical events such as aftercontractions can elicit electrical responses that may trigger 
arrhythmia (see Figure 2.2). 
REGIONAL MOLECULAR AND CELLULAR HETEROGENEITY: EFFECTS ON MYOCARDIAL CA2+ 
HANDLING, REPOLARIZATION AND ARRHYTHMOGENESIS 
Across the LV-transmural wall, distinct morphologies of AP, cell shortening and intracellular 
Ca2+ transient are found, at least in cellular and tissue experiments. Epicardial APs have the 
most pronounced spike-and-dome morphology. The hallmark of midmyocardial APs is their 
ability to prolong with slowing of the pacing rate with much more accentuation than at the 
epi- and endocardium, although the extent to which this will happen in situ is a matter of 
ongoing debate.292 Epi- and midmyocardial cells express a shorter latency in the onset and 
time to peak of cell shortening than endocardial myocytes. The relaxation of cell shortening 
and Ca2+ transient lasts significantly longer in endo- than epicardial myocytes. As a possible 
consequence, Ca2+-transient alternans and increased diastolic levels of intracellular Ca2+ may 
occur preferentially closer to the endocardial surface. In line with this, pharmacological 
studies have shown that Ca2+-dependent DADs and EADs, as well as triggered activity, 
develop much more readily in tissues from the subendocardial/midmyocardial region than 
at the epicardium.102 
 Non-uniform expression of ion channels and other transporters underlies physiological 
transmural, interventricular, anteroposterior and apicobasal electric heterogeneity 
necessary for optimal excitation-contraction coupling.99, 100 Transmural molecular 
expression of NCX is found to be the largest in epi- and midmyocardium compared to 
endocardium103, 293 which is confirmed by prominent mRNA expression in epicardium.294 In 
non-failing myocardium, mRNA expression of the ryanodine receptor gene is largest in the 
midmyocardium105 and much lower at the endocardium.105, 295 mRNA expression of SERCA is 
significantly lower in the endocardial compared to the subepicardial region.101, 104, 295 These 
spatial heterogeneities in molecular expression of Ca2+-cycling proteins result (at least 
partly) in a lower peak of Ca2+ amplitude (-32%), a 16% longer rise time and slower Ca2+ 
reuptake, with a 24% larger Ca2+ decay time constant and 9% longer Ca2+ transient duration 
in endocardium versus epicardium. These transmural differences in Ca2+ cycling likely 
contribute to the heterogeneous APD characteristics of the myocardial layers and can be 
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important for arrhythmogenesis. Under conditions of enhanced Ca2+ entry such as during IKs 
blockade, beta-adrenergic stimulation and rapid pacing, [Ca2+]cyt increased more at the 
endocardium than at the epicardium.102 Spontaneous SR Ca2+ release occurred 
predominantly at the endocardium (earliest onset, largest amplitude) rendering this layer 
the most vulnerable for DAD- and EAD-mediated triggered activity. 
 Besides spatial heterogeneous expression and function of Ca2+-cycling proteins, there is 
physiological non-uniformity in the distribution of repolarizing potassium currents. The 
density of IKs is found lowest in the midmyocardium compared with the subepicardium and 
subendocardium.296 Also, IKs is more prevalent in basal than in apical regions.297 Finally, 
there is an interventricular difference with a 50% larger density of IKs in RV midmyocardium 
compared with LV midmyocardium.298 In ferret, ERG transcript and protein expression was 
most abundant in the epicardial cell layers throughout the ventricle, with the exception of 
the basal regions.299 Pharmacological inhibition and congenital defects (mutations in 
KCNQ1, KCNH2 or KCNE family) of IKr or IKs exaggerate this innate repolarization disparity 
facilitating arrhythmia under specific conditions. 
MECHANICAL DISPERSION IN HETEROGENEOUS REPOLARIZATION 
LQTS is often considered to be a “primary electrical” cardiomyopathy without deviant 
mechanical characteristics. However, if one considers the marked spatiotemporal 
heterogeneous repolarization and non-uniform regional Ca2+ transients with sporadic local 
Ca2+ releasing events, it would be highly unlikely that myocardial mechanical performance is 
unaffected, particularly during the dynamic beat-to-beat alterations prior to TdP.  
 In 1991, Schwartz and colleagues reported for the first time discrete aberrant mechanical 
behavior in symptomatic LQTS patients234 assessed by echographic M-mode imaging. 
Ventricular wall motion abnormalities, primarily located in, but not restricted to, the LV 
posterior wall, were characterized by faster early contraction kinetics and a protracted 
contraction plateau phase prior to rapid relaxation. These mechanical abnormalities were 
more prevalent in symptomatic than in asymptomatic LQTS patients (77% versus 19%), and 
were associated with a higher risk of cardiac arrhythmic events thus bearing prognostic 
value. In 55% of LQTS patients the late systolic phase harbored a secondary inward motion, 
or contraction, of the LV-endocardium, termed a ‘double-peaked’ pattern. This was even 
more strongly correlated with cardiac events as it was present in 91% of symptomatic 
subjects. Notched T waves were present in 88% of patients with mechanical abnormalities 
as opposed to 27% of the individuals with normal mechanics. Moreover, 92% of patients 
with the double-peaked pattern displayed T-wave notching. This suggests that altered 
mechanical dynamics influence cardiac repolarization via mechano-electric coupling. 
Whereas human sympathetic modulation via beta-adrenergic receptor blocker or left 
cardiac stellate denervation did not significantly influence the two mechanical indices, Ca2+-
channel blockade (verapamil 10 mg) had impressive effects on aberrant mechanical 
behavior, completely normalizing it.237 In addition, verapamil significantly reduced the QTc 
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interval in LQTS patients, again supporting a relationship between electrical activity and 
underlying mechanics. More evidence for the antiarrhythmic effects of Ca2+-blockade comes 
from a case report of a LQT2 patient in whom verapamil combined with permanent pacing 
prevented TdP.300 These findings suggest that altered cellular Ca2+ handling contributes to 
the contraction abnormalities in LQTS patients.  
 Recently, Haugaa and coworkers examined mechanical abnormalities in LQTS-mutation 
carriers using tissue-Doppler imaging (TDI).301 Myocardial contraction duration, as assessed 
by myocardial velocity or strain traces from Q onset on ECG to zero-crossing of the TDI 
velocity curve, was significantly longer in symptomatic LQTS mutation carriers than in 
asymptomatic carriers or healthy controls (460 ± 60 ms versus 400 ± 60 ms versus 360 ± 40 
ms, respectively). In LQTS, myocardial contraction exceeded the time to aortic valve closure 
and often a significantly pronounced post-ejection velocity was observed, defined as a post-
ejection peak after closure of the aortic valve. The latter was predominantly distributed in 
the posteroseptal region, but also in the anteroseptal, anterior and lateral wall. Importantly, 
receiver-operating-characteristic (ROC) curve analysis revealed that myocardial contraction 
duration identified genotyped symptomatic LQTS patients better than QTc interval. Also, in 
all symptomatic mutation carriers with a normal QTc interval, contraction duration was still 
prolonged. Mechanical dispersion, assessed as the standard deviation of contraction 
duration, was significantly greater in symptomatic than asymptomatic single-mutation 
carriers. Speckle-tracking enabled to non-invasively discriminate between subendocardial 
(or longitudinal) and midmyocardial (or circumferential) fiber mechanics. LQTS mutation 
carriers, either symptomatic or asymptomatic, demonstrated more pronounced transmural 
mechanical dispersion in the interventricular septum and anterior LV wall.302 In 
symptomatic patients the mean longitudinal contraction duration was longer than the 
circumferential (460 ± 45 ms versus 445 ± 45 ms), indicative of transmural mechanical 
dispersion. On the contrary, in healthy controls and asymptomatic carriers transmural 
mechanical inhomogeneity was negligible. This mechanical dispersion in LQTS likely reflects 
differences in repolarization and Ca2+ handling between adjacent myocardial regions. 
THE ELECTROMECHANICAL WINDOW  
In healthy subjects the duration of cardiac electrical and mechanical activity are closely 
matched. The electrical systole (equivalent to the QT interval) ends earlier than the 
completion of contractile relaxation, creating a positive electromechanical window. The 
EMW (in ms) can be measured invasively (end of LV pressure (LVPend) minus Tend) or non-
invasively by the time lag between Tend and the second heart sound (QS2 minus Tend; albeit 
without a final phase of relaxation), with mean values of 26 ± 13 ms.303 A negative EMW, 
formerly referred to as inversed QT/QS2 ratio or ‘QT>QS2 Syndrome’, occurs if either LV-
contraction duration shortens or if the QT-interval prolongs (or a combination of both). A 
negative EMW has been linked to increased mortality risk in various cardiac diseases, such 
as prolonged QT in the setting of coronary artery disease303 and mitral-valve prolapse,304 
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and can be pronounced during an increased autonomic tone.305, 306 Vincent and coworkers 
were the first to report on an increased baseline QT/QS2 ratio in an ungenotyped Romano-
Ward family.307 This ratio further augmented upon exercise. Recently, a markedly negative 
EMW preceding TdP onset was demonstrated in a canine model of drug-induced LQT1 and 
beta-adrenergic provocation (Figure 2.2).112, 113 Here, the temporal relationship of a 
negative EMW and the generation of late EADs is demonstrated. The EMW (highlighted in 
pink in Figure 2.2) was negative enough (reaching levels of -100 to -200 ms) to allow the 
occurrence of LV aftercontractions well before the end of repolarization. As such, we 
believe that the EMW, and particularly the occurrence of aftercontractions, could contribute 
to arrhythmogenesis via stretch-activated membrane excitation, at least on theoretical 
grounds. Obviously, more experimental work is necessary to examine this further. In the 
LQT1 model, the induction of TdP was prevented by verapamil, esmolol and atenolol, 
significantly increasing the EMW to less negative values and eliminating the 
aftercontractions. Recent clinical data obtained within our team reinforce the notion that 
ventricular mechano-electric interactions may conspire to induce TdP in the presence of a 
profoundly negative and very dynamic EMW (Figure 2.3).  
 As opposed to this dynamicity of the EMW during beat-to-beat instability prior to TdP 
onset, we have found in LQTS patients in stable clinical conditions and during sinus rhythm 
that the aortic valve closes on average 60 ms earlier than the end of the T wave. We 
assessed ventricular electromechanical disparity in 53 genotyped LQTS patients compared 
to 25.308 In the LQTS group, 31 carriers experienced ≥1 arrhythmic event, compared to 22 
event-free individuals and/or asymptomatic carriers. Mean EMW was significantly more 
negative in the LQTS-mutation carriers than in controls (-60 ± 59 ms versus 4 ± 27 ms), and 
was even more negative in symptomatic than in asymptomatic mutation carriers (-75 ± 68 
ms versus -39 ± 36 ms). Subgroup analysis of LQT1 and LQT2 mutation carriers did not show 
statistically different EMW values. 
 In summary, these findings strongly imply that a negative EMW per se is not the primum 
movens but it renders the intact heart vulnerable to additional arrhythmogenic impact such 
as aftercontractions elicited by sympathetic nervous stimulation. As such, the dynamicity of 
the EMW is a potentially important proarrhythmic parameter, but causal mechano-electric 
relations remain to be elucidated. 
SYMPATHETIC STIMULI OF TDP IN LQTS 
It is well-known that sudden or tonic sympathetic stimulation can provoke ventricular 
tachyarrhythmias, notably TdP, in congenital LQTS. Differential responsiveness to 
sympathetic stimuli by various triggers has been observed in LQT1 versus LQT2.   
 In LQT1 due to loss-of-function mutations in KCNQ1 encoding the alpha-subunit of IKs, 
68% of the lethal arrhythmias were encountered during episodes of exercise, 26% during 
emotion and only 3% during rest/sleep.151 IKs contributes trivially to repolarization under 
basal conditions, but is of paramount importance for repolarization shortening in setting of 
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sympathetic-mediated rate acceleration and through direct stimulatory effects.309 
Maladaptive IKs by a loss-of-function mutation fails to accommodate APD adequately and 
allows for the overriding of Ca2+-dependent inward currents, which facilitates EAD- and 
DAD-induced abnormal impulse formation and reentrant excitation by regional dispersion of 
repolarization. Increasing the outward current with nicorandil, an IK,ATP opener, improved 
repolarization abnormalities, abolished EADs and prevented ventricular premature 
complexes during epinephrine infusion in genotyped LQT1 patients with previous syncope, 
TdP and/or palpitations.310 Shimizu and coworkers provoked beta-adrenergic-EADs in LQTS 
patients, which prolonged monophasic action potentials (MAPs) and were accompanied by 
de-novo secondary T-wave components and arrhythmia.311, 312 Verapamil and propranolol 
effectively suppressed these arrhythmogenic responses. Unfortunately, no pressure 
recordings were obtained to examine mechanical events that might have accompanied the 
EADs. 
 By contrast, in LQT2 due to loss-of-function mutations of KCNH2 encoding the alpha-
subunit of IKr lethal arrhythmias occurred during exercise in only 13% of cases, during 
emotion in 43% and at rest/sleep in 29%.151 LQT2 patients were particularly vulnerable to 
auditory stimuli313 and this may differentiate them from LQT1 patients.314 Due to its rapid 
activation kinetics is IKr contributes prominently to repolarization under basal conditions. 
When it is defective, even slight decreases of [K+]o or bradycardia can dramatically prolong 
the APD and generates EADs.315 Additional sympathetic stimulation (such as during auditory 
stimuli) may provoke EADs due to predominant PKA-dependent upregulation of ICaL rather 
than IKs in the first seconds of response. This is a particularly vulnerable window for 
arrhythmogenesis. 
 In the case of LQT3, triggers of cardiac events occurred mostly during sleep or (39%), but 
exercise, emotion and other triggers were still accountable in a significant number of 
cases.151 
IN-VIVO OCCURRENCE OF AFTERCONTRACTIONS  
CANINE LQT1 MODEL 
In 2007, Gallacher and coworkers112 described an in-vivo anesthetized dog model of drug-
induced LQT1 by selective IKs blockade with HMR1556 (Figure 2.2). Beta-adrenergic receptor 
stimulation on top of IKs blockade evoked paradoxical QT and LV-endocardial repolarization 
prolongation during heart-rate acceleration, beat-to-beat endocardial repolarization 
instability, and TdP in 94% of the animals. Of note, neither programmed electrical 
stimulation nor electrical remodeling was required for TdP induction under these 
conditions.  
 Sizeable aftercontractions (black arrow heads in Figure 2.2) emerged during 
isoproterenol infusion, consistently preceding TdP in a crescendo manner. Aftercontraction 
amplitudes averaged peak pressures of 25 ± 6 mm Hg (17% of ‘normal’ AP-evoked 
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contractions, with incidental examples of even higher amplitudes).  Of note, these 
contractile eruptions appeared only in the LV, not in the RV. In MAP recordings, 
concomitant late EADs appeared on the endocardial surface of the LV, not on the LV 
epicardium or in the RV. These in-vivo findings match well with the results reported by Katra 
and Laurita102 of a predominant endocardial origin of triggered activity in a canine LV-wedge 
model of drug-induced LQT1 syndrome. In Figure 2.2, note the marked disparity (shaded 
pink areas) between the end of the electrical systole and the end of relaxation, appearing as 
a negative EMW, during IKs blockade and beta-adrenergic provocation compared to a 
completely different interrelation during IKs blockade alone (shaded green area). Focusing 
on temporal relationships, one should note that the initiation of LV aftercontractions 
preceded the MAP EADs by tens of ms (dashed black line), occurring even without EADs in 
some cases (data not shown). Interestingly, the de-novo secondary T wave components on 
the surface ECG (indicated by the diagonal black arrows in Figure 2.2) also appeared 
secondary to the initiation aftercontractions. 
 
 
Figure 2.2 In-vivo recordings of electromechanical heterogeneity in the final sinus beats prior to TdP onset 
(right most beat) in a canine model of drug-induced LQTS type 1 and isoproterenol challenge. Pink columns 
highlight a markedly negative EMW with crescendo aftercontractions emerging from the LVP signal (black 
arrow heads). By contrast, the narrow grey column at the left indicates a minimal positive EMW during IKs 
inhibition prior to isoproterenol. Dashed vertical black line, timing of events in relation to the initiation of LV 
aftercontractions. The black arrowheads in the LVP recording appoint emerging aftercontractions. The black 
arrows on the ECG point at the rising of a secondary component of the T wave that parallels the mounting 
amplitude of aftercontraction. LVP left ventricular pressure; LV MAP left ventricular monophasic action 
 
 36 | CHAPTER 2 
potential; RVP right ventricular pressure; RV MAP right ventricular monophasic action potential. [Reproduced 
and modified with permission from112].  
 
These in-vivo findings are in accordance with the temporal coincidence found in canine 
ventricular myocytes by Volders and coworkers,98 suggesting a common primary role for 
spontaneous regenerative SR Ca2+ release in delaying repolarization (conditioning phase). It 
is obvious that the electromechanical properties of a single myocyte are only a pale shadow 
of the complex biophysics of the intact beating heart, in which many additional factors such 
as spatial and temporal dispersion of myocardial repolarization, sympathetic nerve activity 
and regional nerve arborization, local electrolytes and electromechanical and mechano-
electric coupling are crucial for arrhythmogenesis. 
MECHANO-ELECTRIC HETEROGENEITY AND TDP IN HUMAN LQTS 
The first report on the clinical relevance of human mechano-electric arrhythmogenesis was 
recently described by Moers and Volders.114 A 51-year old patient with a prolonged resting 
QT interval of 600 ms and unexplained syncope was examined. Programmed electrical 
stimulation during invasive electrophysiological study failed to induce ventricular 
tachycardia, after which beta-adrenergic provocation testing with isoproterenol was 
performed. Upon isoproterenol, pseudonormalization of deviant T-wave morphology, 
inappropriate QT-interval accommodation and a substantially negative EMW of -50 to -100 
ms were noted. Interestingly, intracardiac pressure signals revealed LV (but not RV) 
aftercontractions during relaxation, frequently preceding ectopic impulse formation or non-
sustained ventricular tachycardia. These aftercontractions could reach impressive peak 
amplitudes up to 100 mm Hg (mean amplitudes of 29 mm Hg). Prolonged diastolic intervals, 
i.e. after pacing trains or premature ventricular beats, preceded the aftercontractions in a 
consistent manner. Infusion of esmolol or verapamil prevented the LV-systolic 
aftercontraction and related ventricular arrhythmia, in spite of preserved augmented 
inotropic en chronotropic state. These findings strongly suggest a prominent role for 
increased myocardial Ca2+ loading for mechano-electric events. The patient was treated 
with metoprolol and during 3 years of follow-up, no syncope occurred and no cardiac 
arrhythmic events were documented. To this date, no mutations in LQTS or 
catecholaminergic-polymorphic VT genes have been found yet.  
 We also assessed the complex interplay between mechanics and electrics in a 38-year-
old female, with LQT3 (SCN5A p.(Phe1617del)), admitted to our hospital because of 
electrical storm due to recurrent TdP (Figure 2.3).  
 Her baseline ECG showed marked QTc prolongation of 585 ms with biphasic T-waves. 
During isoproterenol infusion her heart rate increased to 90 bpm, shortening ventricular 
repolarization and preventing TdP. Within a few minutes after cessation of isoproterenol, 
short-long-short cycle-length sequences recurred, followed by TdP. Exactly at that moment, 
by coincidence, TDI signals were recorded from the basal anterolateral wall during 
echocardiography, which later allowed a critical analysis of the electrical and mechanical 
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phenomena prior to arrhythmic deterioration. Figure 2.3 shows these data, indicating the 
evident discrepancy between the duration of electrical (in green) and mechanical systole (in 
pink). Here, the EMW approximated -160 ms. In this vulnerable window one can appreciate 
sizeable secondary positive velocity increments (asterisks) after the initial descent in the 
velocity curve. As the vertical white lines indicate, the timing of these secondary mechanical 
contractions (asterisks) approximated or even preceded the corresponding ventricular 
premature beats. We propose that these are tissue-Doppler velocity derivatives of 
arrhythmogenic LV aftercontractions during a negative EMW. If these aftercontractions 
activated SACs, the resultant change in membrane excitation could evoke abnormal 
impulses, potentially triggering TdP.289 
 
 
 
Figure 2.3 Recordings of electromechanical instability in a patient with LQT3 (F; 38 yr) who suffered from 
recurrent TdP. The TdP shown here occurred shortly after the attempted withdrawal of antiarrhythmic β-
sympathomimetic therapy. The upper panel (ECG leads aVL and V4, and respiration signal (Resp.)) shows sinus 
rhythm with ventricular ectopic beats having mostly narrow QRS complexes with coupling intervals from 300 
to 650 ms. A classical short-long-short sequence ignites TdP. The lower panels display simultaneous TDI signals 
obtained from the basal lateral LV wall. The time sequence for excitation-contraction coupling is normal in the 
sinus beats. The duration of the mechanical systole (pink double arrow) is profoundly shorter than the 
electrical systole (green double arrow), rendering an electromechanical window of -190 ms. Two 
aftercontractions (*) are noted that start prior to the initiation of associated ventricular ectopic complexes 
(white lines). Both have a markedly short coupling interval of 300 ms. [Courtesy of Bas L.J.H. Kietselaer, MD, 
PhD and Dirk W. Donker, MD, PhD, Department of Cardiology, Maastricht University Medical Centre, The 
Netherlands]. 
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CONCLUDING REMARKS 
In present article, we reviewed the complex and dynamic interplay of electromechanical, 
mechano-electric, and sympathetic factors conspiring to torsadogenesis in the LQTS. The 
most important aspects are summarized in Figure 2.4. Intrinsic spatiotemporal dispersion of 
myocardial repolarization, Ca2+ handling and mechanics, present under normal conditions, is 
generally larger in LQTS. Cycle-length dependent amplification of repolarization dispersion 
and the generation of EADs promote reentrant excitation by causing functional block.316 
This prolonged repolarization-dependent reexcitation317 fuels the arrhythmogenic substrate, 
although cell-to-cell coupling smoothens disparities in the intact heart. Altered Ca2+ 
transients determined (at least partly) by prolonged APD impose an “inotropic”-like effect.  
 
 
Figure 2.4 Schematic of the central theme of this paper: mechano-electric heterogeneity, altered myocyte Ca2+ 
handling and spontaneous SR Ca2+ release conspiring to abnormal ventricular impulse formation and TdP in 
LQTS. Left, in normal individuals (normal) there is only modest transmural dispersion of repolarization, a small 
positive EMW (green column), a short time-to-peak strain, and simultaneous strain peaks of the transmural 
layers. Middle panels, in LQTS type 1 (LQT1), marked dispersion of repolarization, a prolonged Ca2+ transient 
with a longer time constant of relaxation at the endocardium than at the epicardium, and a negative EMW 
(pink column) are observed. Strain imaging displays the longest contraction duration at the subendocardium 
(subendo). Right panels, upon the addition of intense sympathetic stimulation (LQT1 + sympathetic stimul.), 
myocardial Ca2+ loading occurs that increases the probability of spontaneous SR Ca2+ release and the 
generation of DADs, EADs and aftercontractions during a profoundly negative EMW (pink column). These 
events promote abnormal ventricular impulse formation and the initiation of TdP via [Ca2+]cyt- and mechano-
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dependent pathways, and reentrant mechanisms (latter not shown). The LV-strain traces in the right lower 
panel are inferred by the authors. AP indicates action potential; AoP, aortic pressure; LVP, left-ventricular 
pressure; [Ca2+]cyt, cytoplasmic Ca2+ concentration, Ca2+ transient. 
 
In LQT1, sympathetic stimulation fails to upregulate IKs sufficiently, but promotes [Ca2+]cyt 
accumulation and enhanced lusitropy. Hence, the EMW decreases to negative values and 
ventricular repolarization dispersion increases (Figure 2.4). Spontaneous SR Ca2+ release 
underlies beta-adrenergic EADs and DADs, which may trigger abnormal impulses, and 
aftercontractions. The latter have been demonstrated in the intact beating heart.  
 After thorough review of the literature and analysis of original electromechanical 
recordings in experimental animals and humans, we argue that mechano-sensitive (besides 
[Ca2+]cyt-dependent) ion-channel activation contributes to torsadogenesis in LQTS, 
particularly if sizeable systolic and/or diastolic aftercontractions emerge in the presence of a 
negative EMW such as during enhanced sympathetic nerve activity. Here, mechano-
dependent proarrhythmia is very probable, an argument that is strengthened by (1) the 
known reversal potentials of SACNS and SACK, (2) the observation of stretch-induced EADs in 
myocytes under oxidative stress, (3) the documentation of stretch-activated membrane 
excitation and arrhythmias in whole-heart preparations, and (4) the temporal relation 
between aftercontractions (as potential stretch activators), EAD upstrokes and T-wave 
deflections just prior to TdP.  
 More than 20 years after Zipes’ referral to the Rosetta Stone for the understanding of 
sympathetic-induced ventricular tachyarrhythmias in the LQTS,318 we propose that 
“mechano-electric coupling” constitutes one of the proarrhythmic complexities of 
torsadogenesis.  
EDITORS’ NOTE 
Please see also related communications in this issue by Hales319 and Blazeski.320 
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ABSTRACT 
AIMS    
Prolonged and dispersed left-ventricular contraction is present in patients with long-QT 
syndrome. Electrical and mechanical abnormalities appear most pronounced in 
symptomatic individuals. We focus on the “electromechanical window” (duration of LV-
mechanical systole minus QT interval) in patients with genotyped LQTS. Profound EMW 
negativity heralds torsades de pointes in animal models of drug-induced LQTS.  
 
METHODS AND RESULTS  
We included 244 LQTS patients from three centres, of whom 97 had experienced arrhythmic 
events. Seventy-six matched healthy individuals served as controls. QT interval was 
subtracted from duration of Q-onset to aortic-valve closure midline assessed noninvasively 
by continuous-wave echocardiography, measured in the same beat. EMW was positive in 
controls but negative in LQTS patients (22 ± 19 versus -43 ± 46 ms; P<0.0001), being even 
more negative in symptomatic than event-free patients (-67 ± 42 versus -27 ± 41 ms; 
P<0.0001). QT, QTc, and QAoC were longer in LQTS subjects (451 ± 57, 465 ± 50, and 408 ± 
37 ms, P<0.0001). EMW was a better discriminator of patients with previous arrhythmic 
events than resting QTc (AUC 0.77 (95% CI, 0.71-0.83) and 0.71 (95% CI, 0.65-0.78); P=0.03). 
In multivariate analysis, EMW predicted arrhythmic events independently of QTc (odds ratio 
1.25; 95% CI, 1.11-1.40; P=0.001). Adding EMW to QTc for risk assessment led to a net 
reclassification improvement of 13.3% (P=0.03). No EMW differences were found between 
the three major LQTS genotypes.  
 
CONCLUSIONS   
Patients with genotype-positive LQTS express EMW negativity, which is most pronounced in 
patients with documented arrhythmic events.  
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INTRODUCTION 
The congenital long-QT syndromes are caused by mutations in genes encoding for cardiac 
ion-channel subunits or ion-channel-associated proteins. To date, at least 15 different genes 
have been causally implicated.321 LQTS-related ion-channel defects predispose to cardiac 
action-potential prolongation and accentuate regional and temporal dispersion of 
repolarization. Genotype-specific proarrhythmic conditions can exacerbate repolarization 
dispersion and lead to the occurrence of afterdepolarizations, premature ventricular ectopic 
beats and reentrant excitation. These mechanisms can precipitate torsades de pointes in 
susceptible LQTS patients, but their exact contribution to arrhythmogenesis remains often 
obscure. Additional mechanisms, including mechano-electrical triggers, appear relevant, but 
remain to be fully elucidated.322  
 There have been reports of altered ventricular mechanics in (subsets of) LQTS patients. 
Using M-mode, Nador et al234 demonstrated rapid early contraction and an extended phase 
of LV-wall thickening before rapid relaxation in 55% of LQTS patients, being most overt in 
symptomatic individuals. In some, mostly symptomatic, patients a peculiar double-peak 
pattern of LV-wall thickening was observed, possibly the mechanical correlate of early 
afterdepolarizations.234 These LQTS-related mechanical abnormalities were normalized by 
Ca2+-channel blocker treatment.237 Similar results were obtained using tissue-Doppler 
imaging techniques.236, 301 Strain-imaging revealed longer contraction duration in the 
subendocardium than midmyocardium of symptomatic LQTS-mutation carriers (but less so 
of asymptomatic or healthy individuals), indicating accentuated transmural mechanical 
dispersion in the former.301 Prolonged contraction duration and augmented longitudinal 
mechanical dispersion were superior to QTc for arrhythmia-risk assessment.301, 302 
 Only few studies have addressed indices of electromechanical coupling in LQTS patients 
to assess arrhythmia risk. In 1991, Vincent et al307 reported on the ratio of electrical to 
mechanical systole in an ungenotyped Romano-Ward family. By measuring QT interval and 
time from Q wave to second heart sound (QS2), they demonstrated a prolonged QT/QS2 
ratio in rest increasing during exercise (1.12 to 1.45) in Romano-Ward patients with a 
resting QTc of 490 ms. In controls, QT/QS2 increased only modestly from a rest ratio of <1.0. 
The relation of QT/QS2 to major arrhythmic events was not examined.307 
 Experimentally, Gallacher et al112, 113 demonstrated in anesthetized dogs that under 
baseline conditions the LV-pressure duration outlasts both QT interval and LV-endocardial 
monophasic-action-potential duration, thus creating a positive so-called “electromechanical 
window”.113 EMW turned very negative during pharmacological IKs block just prior to the 
induction of TdP by beta-adrenergic stimulation.112, 113 Within this negative EMW, sizeable 
LV aftercontractions arose consistently if TdP ensued. 
 This led us to investigate EMW in a large population of LQTS probands and their 
asymptomatic genotype-positive family members, under clinically stable conditions. We 
compared LQTS patients with healthy controls, with and without beta-blocking therapy. All 
underwent echocardiography with simultaneous standard 3-lead ECG recording to 
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determine the EMW noninvasively. We hypothesized that EMW is more negative in LQTS 
patients than in healthy controls, and that profound EMW negativity correlates significantly 
with major arrhythmic events. 
METHODS 
This study was carried out in accordance with the ethical guidelines of the Declaration of 
Helsinki. Patients gave written informed consent for DNA diagnostics and echocardiographic 
research. IRB approval for the retrospective analysis of genotype and echocardiographic 
phenotype data was provided for the patients evaluated at Mayo Clinic.  
STUDY POPULATION 
In this case-control, multicentre study, 244 genotype-positive LQTS index cases and 
asymptomatic family members, and 76 healthy controls were included. A heterozygous 
KCNQ1 mutation was present in 107 individuals (LQT1), a KCNH2 mutation in 84 (LQT2), a 
SCN5A mutation in 41 (LQT3), a KCNE1 mutation in 8 (LQT5), a KCNE2 mutation in 1 (LQT6), 
and double heterozygous mutations (KCNQ1 + KCNH2) in 2 patients. The remaining patient 
was double heterozygote for KCNQ1 mutations with clinical features of Jervell and Lange-
Nielsen syndrome. Mutations were considered “pathogenic” or “variants of uncertain 
significance” (VUS) based on literature reports and molecular-genetic assessment. Class-3 
VUS-positive patients were included after exclusion of other causative gene mutations. 
 In all probands, the clinical diagnosis of LQTS was made using the Schwartz criteria.323 
Arrhythmic events were scored as syncope, documented ventricular tachyarrhythmia, 
aborted cardiac arrest, and/or sudden death. We included subjects older than 10 years. The 
use of antiarrhythmic drugs and history of ICD or pacemaker implantation at the time of 
echocardiography were noted. If possible, EMW measurements were made prior to the 
initiation of antiarrhythmic therapy. 
 The healthy control group consisted of seventy-six age- and gender-matched individuals, 
who underwent 12-lead ECG recording and echocardiography because of unexplained 
dyspnea, palpitations or atypical chest complaints, but with normal findings. None were 
using QT-prolonging medication. Furthermore, we included 18 individuals, temporarily 
treated with beta-blockers for suspected angina pectoris, ahead of elective coronary 
angiography, but with non-significant findings. 
ECHOCARDIOGRAPHY 
Echocardiographic examinations were performed on a Vivid 7 (General Electric Healthcare, 
Horten, Norway) or IE33 system (Philips, Eindhoven, The Netherlands) and data were 
analyzed by R.M.A.t.B. and K.H.H., blinded to the patient’s diagnosis. 
EMW CALCULATION 
Continuous-wave Doppler images in the apical long-axis view assessing the aortic-valve flow 
and concurrent 3-lead ECG tracings were used for EMW calculations (Figure 3.1). We 
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measured (1) the interval from QRS onset to the aortic-valve closure midline (QAoC 
interval), (2) QT interval in lead II, for the same beat. The EMW (ms) was calculated by 
subtracting QT from the QAoC interval. QAoC incorporates the LV-excitation contraction 
coupling delay, isovolumetric contraction, and ejection time and is taken as an arbitrary 
derivative of the duration of LV-mechanical systole.306 It is generally accepted to measure 
the QT interval in ECG lead II or any longest QT time at the precordium. Here, we assessed 
lead II because this is also available in commercial ultrasound systems, whereas precordial 
ECG recordings are normally not. Hypothetically, a longer precordially-derived QT would 
lead to more profound EMW negativity when QAoC remains unaltered. In 6% of our 
subjects, the 3-lead-echo-related QT interval could not be determined accurately. Instead, 
contiguous 12-lead ECG-derived QT was obtained at an equivalent RR interval (≤25 ms 
difference). Bazett’s formula was used to correct QT for heart rate.  
 
 
Figure 3.1 Representative EMW calculations in the same beat during continuous-wave Doppler 
echocardiography of the LV-outflow tract. Left panel, EMW positivity (yellow bar) in a healthy individual. 
Middle panel, EMW negativity (red bar) in an asymptomatic LQTS subject. Right panel, Profound EMW 
negativity in a symptomatic patient. QAoC, interval from initiation of QRS to aortic-valve closure; EMW, 
electromechanical window; RV, right ventricle; LV, left ventricle; LA, left atrium; Ao, ascending aorta. 
STATISTICAL ANALYSIS 
Continuous data were tested for normality of distribution and depicted as mean ± SD. 
Comparison of means in Gaussian-distributed groups was performed by unpaired Student’s 
t testing. For nonparametric methods the Mann-Whitney U test was used. For multiple 
comparisons, one-way ANOVA was applied. ROC curve and logistic regression analysis were 
established to assess predictive accuracy. The optimal cut-off value for EMW at highest 
accuracy, sensitivity, and specificity for the optimal cut-off value was determined. The area 
under the curve (AUC) and 95%-confidence interval (CI) were determined for EMW/QTc/QT. 
Comparison of ROC curves was performed using the DeLong and DeLong method. The net 
reclassification improvement (NRI) was calculated using the following risk categories for 
arrhythmic events: low probability of arrhythmic events (<20%), intermediate (20-60%), 
high (>60%). The number of patients correctly reclassified when EMW was added to the 
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QTc-based model was determined and from that the NRI was calculated. P values presented 
were two-sided and considered significant if <0.05. 
RESULTS 
CLINICAL CHARACTERISTICS  
Clinical characteristics of the LQTS population and healthy controls are illustrated in Table 
3.1. Of the LQTS population 163 (67%) were female and 97 (40%) were classified as 
“symptomatic”, with 31 having cardiac arrest (documented TdP/VF in 23; mean TdP/VF 
episodes per patient 2.8 ± 5.9; electrical storm in six), resulting in death in two. The 
remaining 66 patients experienced at least one syncopal event, with documented 
nonsustained (polymorphic) VT in nine. LQTS patients had lower mean heart rates (66 ± 13 
versus 73 ± 14 bpm in controls; P<0.0001).  
 
Table 3.1 Characteristics of healthy individuals and LQTS patients  
 Healthy individuals 
(n=76) 
LQTS patients 
(n=244) 
P value 
Age, y 37 ± 12 38 ± 16 0.57 
Female sex, n (%) 51 (67) 163 (67) 0.97 
Antiarrhythmic drug at time of echocardiogram    
      beta-blocker, n (%) 0 100 (41)  
      mexiletine, n (%) 0 6 (2)  
ECG     
      RR interval, ms 845 ± 157 950 ± 182 <0.0001 
      QT interval, ms 357 ± 29 451 ± 57 <0.0001 
      QTc, ms 391 ± 27 465 ± 50 <0.0001 
Echocardiogram    
      LV-ejection fraction, % 63 ± 7 63 ± 5 0.83 
      QAoC interval, ms 379 ± 31 408 ± 37 <0.0001 
      EMW, ms 22 ± 19 -43 ± 46 <0.0001 
 
LQTS, long-QT syndrome; LV, left ventricular; QAoC, interval from QRS-onset to aortic-valve closure; EMW, 
electromechanical window.  
 
Forty-one percent of patients were on beta-blocker therapy at the time of 
echocardiography (for EMW calculation), 23% had been implanted with an ICD, 2% with a 
pacemaker, and 1 individual had undergone left-cardiac sympathetic denervation. None of 
the patients were ventricularly paced at the time of investigation. Seventy-five percent 
harbored a pathogenic mutation in one or more LQTS-related genes, whereas 25% had a 
VUS, being equally present in symptomatic and event-free subjects. LQTS patients had 
longer QT intervals and QTc compared to controls (QT: 451 ± 57 versus 357 ± 29 ms; QTc: 
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465 ± 50 versus 391 ± 27 ms; P<0.0001), with less exaggerated QTc because of inclusion of 
asymptomatic mutation-positive relatives (i.e., a representative population at the 
Cardiogenetics Clinic). QAoC was significantly longer in LQTS patients (408 ± 37 versus 379 ± 
31 ms; P<0.0001). Combined, these parameters led to negative EMWs in LQTS patients as 
opposed to positive values in controls (-43 ± 46 versus 22 ± 19 ms; P<0.0001; Figure 3.2). 
 
 
Figure 3.2 Boxplots illustrating the interquartile range and outliers of (A) QTc and (B) EMW in controls and 
LQTS patients with and without arrhythmic events, **P<0.0001. 
 
Patients (n=16) with double LQTS mutations, a history of pacemaker implantation or 
stellectomy, or on mexiletine treatment did not influence the general outcomes of this 
study. The inter- and intra-observer variability of EMW measurements had a correlation 
coefficient of 0.91 (95% CI, 0.65-0.98) and 0.99 (95% CI, 0.97-1.0). Serial EMW 
measurements were similar in 25 clinically-stable patients, after a mean of 48 ± 37 months 
(-30 ± 49 versus -24 ± 30 ms; P=0.33). There was no difference between echocardiogram-
related and standard-ECG lead-II-derived QT and RR intervals (QT: 450 ± 57 versus 459 ± 59 
ms, P=0.76; RR: 949 ± 181 versus 973 ± 185 ms; P=0.15). Subgroup analysis of 76 patients 
with concealed LQTS (i.e., QTc <440 ms, being on average 412 ± 23 ms) yielded an EMW of -
8 ± 32 ms (P<0.0001 versus controls), which was most pronounced in symptomatic 
individuals (Figure 3.2).  
EMW AND ARRHYTHMIC EVENTS 
Age, gender and genetic diagnosis were similar for symptomatic and asymptomatic LQTS 
patients (61 versus 28% beta-blocker therapy, respectively, at the time of 
echocardiography; Table 3.2). QT and QTc were longer in the former (QT: 479 ± 56 versus 
432 ± 49 ms; QTc: 488 ± 50 versus 450 ± 44 ms; P<0.0001). QAoCs were similar in both 
groups. Consequently, symptomatic LQTS patients had a more negative EMW: -67 ± 42 
versus -27 ± 41 ms (P<0.0001; Table 3.2, Figure 3.2). Interestingly, when plotting EMW 
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against QTc (Figure 3.3), symptomatic and asymptomatic LQTS patients had more negative 
EMWs for any given QTc than control subjects, which coincided with a more negative slope 
of the linear relation and a leftward shift of its crossing of the abscissa. 
 
 
Figure 3.3 EMW as a function of QTc for controls (blue) and LQTS patients with (red) and without (green) 
previous arrhythmic events. Dotted line indicates QTc 440 ms. 
 
By ROC analysis, EMW proved a better discriminator for arrhythmic events than QTc, with 
an AUCEMW 0.77 (95% CI, 0.71-0.83), AUCQTc 0.71 (95% CI, 0.65-0.78) and AUCQT 0.74 (95% CI, 
0.68-0.81; P=0.03; Figure 3.4). The optimal cut-off value for EMW with 72% accuracy was -
62 ms, identifying symptomatic patients with 84% sensitivity and 54% specificity. Logistic 
regression analysis identified EMW, QTc, and beta-blocker therapy as univariate predictors 
of arrhythmic events (Table 3.3). After multivariate analysis, EMW (but not QTc) remained 
an independent predictor (odds ratio for 10-ms EMW decrease 1.25 (95% CI, 1.11-1.40; 
P=0.001)). Adding EMW to QTc in LQTS risk assessment resulted in 12 individuals being 
correctly reclassified into a higher risk category, as compared to a model without EMW. 
Seven subjects were incorrectly reclassified into a lower risk category. Similarly, 25 
asymptomatic individuals were correctly reclassified into a lower risk category, whereas 13 
were incorrectly reclassified into a higher risk category. The net reclassification 
improvement was 13.3% (P=0.03) when adding EMW. 
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Figure 3.4 ROC curves of EMW/QTc/QT for arrhythmic events in LQTS. EMW has a better discriminatory power 
than QTc, *P=0.03.  
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Table 3.2 Characteristics of LQTS patients according to previous arrhythmic events (n=244) 
 
 Asymptomatic 
(n=147) 
Symptomatic 
(n=97) 
P value 
Age, y 39 ± 16 37 ± 17 0.37 
Female sex, n (%) 92 (63) 71 (73) 0.15 
Genotypic characteristics    
      KCNQ1 (LQT1), n (%) 69 (47) 38 (39) 0.30 
      KCNH2 (LQT2), n (%) 42 (28) 42 (43) 0.05 
      SCN5A (LQT3), n (%) 31 (21) 10 (10) 0.14 
      KCNE1 (LQT5), n (%) 5 (3) 3 (3)  
      KCNE2 (LQT6), n (%) 0 1 (1)  
      Double heterozygous carriers/JLNS, n (%) 0 3 (3)  
      Pathogenic mutation, n (%) 108 (73) 73 (75) 0.86 
      Variant of unknown significance, n (%) 39 (27) 24 (25) 0.66 
Antiarrhythmic drug at time of echocardiogr.     
      beta-blocker, n (%) 41 (28) 59 (61) <0.0001 
      mexiletine, n (%) 6 (4) 0  
ECG    
      RR interval, ms 931 ± 175 976 ± 189 0.06 
      QT interval, ms 432 ± 49 479 ± 56 <0.0001 
      QTc, ms 450 ± 44 488 ± 50 <0.0001 
Echocardiogram    
      QAoC interval, ms 405 ± 33 412 ± 42 0.16 
      EMW, ms -27 ± 41 -67 ± 42 <0.0001 
 
Abbreviations as in Table 3.1. 
  
 Table 3.3 Predictors of arrhythmic events 
 
 Univariate Multivariate 
 B SE OR (95% CI) Wald B SE OR (95% CI) Wald 
EMW per 10 ms decr. 0.24 0.04 1.27 (1.17-1.37)* 36 0.22 0.06 1.25 (1.11-1.40)* 13 
QTc per 10 ms increase 0.18 0.03 1.19 (1.12-1.27)* 29 0.02 0.05 1.02 (0.92-1.13) 0.1 
QAoC per 10 ms decr. -0.05 0.04 0.95 (0.88-1.02) 2 -0.06 0.04 0.94 (0.86-1.03) 2 
QT per 10 ms increase 0.18 0.03 1.20 (1.13-1.28)* 33 redundant   
Beta-blocker 1.39 0.28 4.01 (2.33-6.92)* 25 1.26 0.32 3.53 (1.89-6.61)* 16 
Age -0.01 0.01 1.00 (0.98-1.01) 0.5 -0.01 0.01 0.99 (0.97-1.01) 0.8 
Gender 0.49 0.29 1.63 (0.93-2.86) 3 0.32 0.35 1.38 (0.69-2.74) 0.8 
 
EMW, electromechanical window; B, exponential component; SE, standard error; OR, odds ratio; CI, 
confidence interval. *P<0.05. 
 
BETA-BLOCKER THERAPY 
In healthy individuals, beta-blocker treatment was associated with longer QAoC despite 
similar QT/QTc (QAoC: 413 ± 42 versus 379 ± 31 ms; P<0.01; QT: 371 ± 42 versus 357 ± 29 
ms; P=0.20; QTc: 377 ± 34 versus 391 ± 27 ms; P=0.06). Consequently, their EMW increased 
to 43 ± 25 ms (P<0.01). For beta-blocker-treated LQTS subjects, both QT and QAoC were 
longer than in untreated patients (QT: 470 ± 57 versus 437 ± 52 ms; QAoC: 416 ± 33 versus 
400 ± 32 ms; P<0.001 for both), rendering the EMW more negative (-54 ± 51 versus -36 ± 41 
ms; P=0.004). Also, QTc was longer (478 ± 53 versus 457 ± 46 ms; P=0.002). In 26 
symptomatic patients, beta-blocker therapy was initiated directly after echocardiography. In 
15 of these, mostly LQT1 and LQT5 patients, repeat echocardiography confirmed 
preferential QAoC (over QT) prolongation by the addition of therapy, resulting in a trend 
towards reduced EMW negativity (EMWpreBB -32 ± 33 versus EMWpostBB -19 ± 33 ms; P=0.06). 
In total, 88% of the symptomatic patients of this study were ultimately treated with beta-
blockers. 
GENOTYPE SUBGROUP ANALYSIS 
For 107 LQT1, 84 LQT2, and 41 LQT3, averaged QTc was similar (467 ± 55, 467 ± 47, and 462 
± 45 ms; 40%, 51%, 7% beta-blocker therapy, respectively), Table 3.4. QAoC was slightly 
shorter in LQT3 (LQT3: 394 ± 37, LQT1: 413 ± 40, LQT2: 409 ± 33 ms; P=0.02), which may be 
related to shorter RR and QT intervals in this subgroup. Altered IKs/IKr-dependent pacemaker 
activity324 and imbalanced negative chronotropic therapy may have contributed to this. 
EMW negativity was similar for LQT1, LQT2, and LQT3, (-43 ± 47, -47 ± 44, and -37 ± 47 ms) 
with longer QTc and unaltered QAoC in symptomatics, resulting in more profound EMW 
negativity (Table 3.4). Exclusion of the mexiletine-treated LQT3 patients did not alter these 
findings significantly.  
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The double-mutation and Jervell and Lange-Nielsen (JLNS) patients had the most profound 
EMW negativity: -91 ± 46 ms (n=3, all symptomatic). For the remaining 8 KCNE1 (LQT5) and 
1 KCNE2 (LQT6)-mutation positive patients, an EMW of -16 ± 34 ms was found. 
 
Table 3.4 Genotype subgroup analysis 
 LQT1 
(n=107) 
LQT2 
(n=84) 
LQT3 
(n=41) 
P value 
Age, y 40 ± 16 38 ± 16 35 ± 18 0.21 
Female sex, n (%) 68 (64) 57 (68) 28 (68) 0.77 
Antiarrhythmic drug at echo     
      beta-blocker, n (%) 43 (40) 43 (51) 8 (7) 0.003 
      mexiletine, n (%) 0 (0) 0 (0) 6 (19)  
ECG     
      RR interval, ms 964 ± 179 961 ± 182 888 ± 178 0.05 
      QT interval, ms 456 ± 59 456 ± 56 431 ± 47 0.04 
      QTc, ms 467 ± 55 467 ± 47 462 ± 45 0.80 
Echocardiogram     
      QAoC interval, ms 413 ± 40 409 ± 33 394 ± 37 0.02 
      EMW, ms -43 ± 47 -47 ± 44 -37 ± 47 0.57 
 
QAoC, interval from QRS-onset to aortic-valve closure; LQT, long QT; EMW, electromechanical window.  
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EMW DYNAMICITY IN A LQTS PATIENT WITH ELECTRICAL STORM 
In a SCN5A-mutation-positive female (c.4850-4852delTCT; p.(Phe1617del)), we determined 
the EMW serially by means of tissue- and continuous-wave Doppler imaging during a phase 
with electrical storm, and after clinical stabilization (Figure 3.5). Acute TdP suppression was 
achieved by ß-sympathomimetic treatment with isoproterenol, increasing her heart rate to 
87 bpm. At that moment, EMW was -83 ms (after 27-ms correction for TDI-derived timing of 
aortic-valve closure,325 QTc 538 ms). After interruption of isoproterenol, EMW values 
deteriorated further to -163 ms within minutes (QTc 505 ms), followed by the recurrence of 
TdP. During these very negative EMWs, just prior to TdP, premature ventricular beats arose 
with mechanical activity initiating earlier than the measurable start of QRS, suggesting a 
mechanism other than excitation-contraction coupling.322 The patient was restabilized with 
isoproterenol and permanent right-atrial pacing after ICD implantation. In the months 
thereafter her EMW during intrinsic sinus rhythm markedly increased to -50 ms (QTc 508 
ms) and no ventricular arrhythmias occurred. 
 
 
Figure 3.5 Serial EMW measurements in a LQT3 patient during different stages of treatment for recurrent TdP, 
and after clinical stabilization. (A) Beta-sympathomimetic therapy with isoproterenol resulted in marked EMW 
negativity without TdP. (B) Interruption of isoproterenol with progressive EMW negativity. (C) During extreme 
EMW negativity TdP recurred. (D) “Normalized”, non-paced EMW values after clinical stabilization. 
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DISCUSSION 
The present study focuses on electromechanical coupling in genotyped LQTS patients, 
particularly the EMW, in relation to major arrhythmic events. Our results demonstrate that 
the physiological LV electromechanical sequence, in which aortic-valve closure occurs after 
T-wave completion, is reversed in LQTS. The consequent negative EMW occurs primarily by 
a prolonged QT interval in the absence of a correspondingly increased QAoC. Interestingly, 
in LQTS the EMW is more negative for any QTc suggesting repolarization-independent 
influences. 
 EMW negativity was most pronounced in patients with documented arrhythmic events 
and those with double heterozygous mutations (two KCNQ1 + KCNH2; one JLNS). Moreover, 
it appeared a better and independent discriminator of previous arrhythmic events than QTc. 
In one case with electrical storm, EMW was dynamic and very negative prior to TdP, but 
increased significantly after clinical stabilization. Our data confirm that inherited 
repolarization prolongation and instability are crucial factors for TdP, but they also hint 
towards the importance of mechano-electric triggers, particularly in symptomatic LQTS 
patients at instances during their cardiac cycle when mechanical systole has ceased, but 
repolarization is still ongoing.322 Diastolic spontaneous Ca2+ release from the sarcoplasmic 
reticulum and mechanical aftercontractions can be pivotal arrhythmogenic factors, 
particularly when myocardial Ca2+ load is enhanced, as shown experimentally.97, 112 
INTERACTION OF ELECTRICAL AND MECHANICAL SYSTOLE 
Under normal conditions, myocardial membrane depolarization precedes and initiates 
contraction through Ca2+-induced Ca2+ release from the SR, a process termed excitation-
contraction coupling. Repolarization prolongation can increase cellular Ca2+ content by 
prolonging the inactivation phase of L-type Ca2+ current. Sympathetic stimulation, 
circulating catecholamines, and various positive-inotropic drugs enhance Ca2+ load. At the 
integrative level, preload and afterload are major determinants of myocardial inotropic 
state. To govern these mechanisms, electrical and mechanical activity are tightly linked. In 
healthy myocardium, mechanical relaxation terminates tens of milliseconds after 
repolarization.303 Likewise, we demonstrated a positive EMW value of 22 ± 19 ms in healthy 
controls, corresponding to a QT/QS2 ratio of 0.94.307, 326 In clinical non-LQTS studies, the 
QT/QS2 ratio was used to investigate electromechanical coupling at resting heart rate, 
during adrenergic stimulation,305 changes in autonomic tone,306 and in coronary artery 
disease.303 In patients with prior myocardial infarction, the presence of QT>QS2 provided a 
risk indicator of mortality that was more potent than QTc.305 
 In this LQTS study consisting of probands and asymptomatic family members, we 
observed an average EMW of -43 ± 46 ms (QT/QS2 ratio of 1.10), with symptomatic patients 
having more negative EMWs for a wide QTc range. We speculate that heterogeneous 
autonomic innervation327 and/or sympathetic hyperactivity could provoke EMW negativity 
by enhanced lusitropy in the presence of QT maladaptation, particularly in LQT1, LQT5, JLNS 
or other conditions when cAMP-dependent IKs cannot be adequately recruited to shorten 
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repolarization. This may also apply to other LQTS genotypes if IKs is intrinsically weak. In 
LQT3, increased late Na+ current may contribute to electromechanical divergence via 
altered myocardial Na+ and Ca2+ handling.110 Interestingly, a shorter QAoC was found to 
underlie the EMW in LQT3, being even shorter in symptomatic individuals (despite longer 
QTc). Any of these potential mechanisms requires further investigation.  
 Beta-blockade is more efficacious in preventing recurrence of major arrhythmic events in 
LQT1 than LQT2 or LQT3 patients. While beta-blockers lend their antiarrhythmic actions 
primarily by dampening myocardial responses to sympathetic stimuli, shortening of QTc has 
also been demonstrated, mainly through heart rate slowing with minimal effects on QT.168 
Based on our results in LQTS patients and controls, increased contraction duration and a less 
negative EMW may confer additional antiarrhythmic protection in LQTS, in line with 
experimental data.113 
EMW NEGATIVITY AND PROARRHYTHMIC PROCLIVITY 
Proarrhythmic aspects of EMW negativity have been evaluated in animal models of drug-
induced LQTS.112, 113, 328 In anesthetized drug-induced LQT1 dogs, IKs blockade with HMR1556 
or JNJ 303 markedly reduced EMW, but did not evoke TdP.112, 113 Additional beta-adrenergic 
provocation with isoproterenol, exacerbated EMW negativity (to -109 ms) and led to the 
emergence of LV aftercontractions within the window, and subsequent TdP onset.112 
Interventions (e.g., verapamil, esmolol, atenolol) that successfully prevented 
aftercontractions and/or rendered EMW less negative also prevented TdP.112, 113, 329 In 
anesthetized guinea-pigs, the administration of drugs with documented TdP liability (i.e., 
quinidine, haloperidol, terfenadine, moxifloxacin, ciprofloxacin, and dofetilide) produced 
TdP only after substantial EMW negativity (<-50 ms) and infusion of adrenaline.328 Negative-
control compounds did not cause EMW negativity or arrhythmia, even though 
repolarization prolongation was observed. TdP was typically preceded by aftercontractions. 
These aftercontractions, and their relation to TdP, suggest mechano-electric influences 
during arrhythmogenesis.322  
CLINICAL IMPLICATIONS 
Along with other reports on the importance of mechanical abnormalities in LQTS,330 our 
data indicate that the assessment of electromechanical coupling has added value for 
arrhythmia-risk analysis. The EMW, an easy-to-obtain parameter, proved a better and 
independent discriminator than resting QTc in our large LQTS population. A cut-off value of 
<-62 ms predicted arrhythmic events with 72% accuracy. As such, it may be helpful to assess 
arrhythmia risk, guide antiarrhythmic maintenance therapy, and facilitate the timing of 
acute interventions in LQTS.  
LIMITATIONS 
The retrospective study design may have led to potential selection bias and confounding 
factors, among them possible under- and overestimation of arrhythmic events. 
Echocardiographic examinations were performed at various times without standardization 
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for diurnal sympathetic modulation of QT/QAoC and potential respiratory-cycle variation. 
This study did not allow for stratification according to beta-blocker therapy. A prospective 
cohort should confirm the association between EMW negativity and arrhythmic events, and 
address EMW dynamics over time. 
CONCLUSIONS 
There is mounting evidence of mechanical abnormalities in LQTS. Their quantitative 
analysis, besides QTc, has added value for arrhythmia-risk prediction. Using transthoracic 
echocardiography, we find that LQTS patients have a markedly negative EMW over a wide 
QTc range, which is most pronounced in those with documented arrhythmic events. In this 
study population, EMW proves superior to and independent from QTc in discriminating 
between a LQTS patient’s historical arrhythmic events. Hence, we propose to consider this 
parameter in the clinical management of LQTS patients. 
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VOX CLAMANTIS IN DESERTO.  
WE SPOKE BUT NOBODY WAS LISTENING: 
ECHOCARDIOGRAPHY CAN HELP RISK STRATIFICATION  
OF THE LONG-QT SYNDROME. 
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Over 20 years ago we reported for the first time the presence of mechanical abnormalities 
in the contraction pattern of patients with the long QT syndrome, showing both the 
presence of rapid early contraction and of an extended “plateau” phase well visible at M-
mode Doppler before rapid relaxation.234 These abnormalities were almost absent in 
controls and more prevalent among symptomatic than asymptomatic patients (77% versus 
19%, RR 2.75) suggesting their potential value for diagnosis and risk stratification of LQTS 
patients. This report and our subsequent evidence that these abnormalities were abolished 
by calcium blockers237 and could be the mechanical counterparts of early 
afterdepolarizations, thus being markers of arrhythmic propensity, were received with 
skepticism and essentially ignored. Eventually, an abnormal contraction pattern was 
confirmed by others mostly using tissue Doppler imaging235, 236, 301 thus ending the era in 
which LQTS was considered a pure electrical disease.330 
 Once set in motion, the ball keeps rolling. In this issue of the Journal, ter Bekke et al331 
describe the presence of a negative “electromechanical window” in LQTS patients and report 
a strong association between a markedly negative value and arrhythmic events. One strength 
lies in the size of population, almost 250 genotype-positive LQTS patients and 74 controls, 
much larger than previous studies.234-237, 301 This allowed to conclusively demonstrate that the 
vast majority of LQTS patients do have abnormal echocardiographic features, with 
approximately 2/3 of LQTS patients showing EMW values >2SD below the values of controls, 
despite pharmacological treatment (found to reduce EMW negativity) in >40% of patients. 
This important study, carried out by 3 expert groups, shows that even in the era of intensive 
genotyping, echocardiography can provide valuable information, and within few minutes. 
 Importantly, the almost 100 patients with arrhythmic events allowed a reliable estimate 
of sensitivity and specificity of the echocardiographic indexes and the execution of 
multivariable analyses. Adding EMW to QTc resulted in a significant improvement in the 
identification of symptomatic patients; EMW but not QTc was an independent predictor of 
arrhythmic events. This finding is in agreement with the demonstration by Haugaa et al301 
that echocardiographic contraction duration identified symptomatic patients with better 
sensitivity and specificity compared to QTc (79% and 74% versus 70% and 50%, 
respectively), and with our original indication that echocardiography was superior to ECG.234 
 The time has come to start using echocardiographic indexes in addition to QTc in the risk 
stratification of patients with LQTS. It is unclear, however, which parameter performs best 
and in this regard neither the study by Haugaa et al301 nor the present one are very helpful 
because they did not compare their index, EMW, with those previously described.234-237 The 
use of EMW was suggested as a risk marker for Torsades des Pointes in experimental 
studies113, 328 but its superiority to QTc has been questioned.332 
 The choice of the best mechanical index would be facilitated if we had a good 
understanding of the pathophysiology underlying the contraction and relaxation 
abnormalities present in LQTS patients. This is one weakness of the present manuscript, 
which suggests that LQTS patients may have enhanced lusitropy as a consequence of 
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heterogeneous sympathetic activation.331 As a matter of fact, this is unlikely because LQTS 
patients actually show abnormally impaired rather that enhanced relaxation. 
 Ranolazine, a late INa blocker, shortened QTc by 4.5% from 578 ± 55 ms and by a 
significant 13% a previously prolonged isovolumic relaxation time of 125 ± 27 ms173 in 12 
patients with LQT3,173 the LQTS subtype caused by enhanced late INa current.321 A delay in LV 
relaxation was shown also in an animal model of LQT2.333 Post-systolic shortening and a 
significant biventricular diastolic dysfunction were found in LQT3 patients, suggesting that 
the diastolic dysfunction could be either secondary to systolic dysfunction, i.e. post-systolic 
shortening encroaching on diastole, or to deranged calcium homeostasis.334  
 Actually, the two mechanisms are not mutually exclusive. Our initial hypothesis that in 
patients with a “double peak” morphology the second shortening could have been the 
mechanical equivalent of an early after depolarization234 appeared to be confirmed by the 
subsequent demonstration that intravenous verapamil normalized the contraction pattern 
by abolishing both “plateau-like” and “double peak” morphologies.237 By focusing on the 
calcium transients linked to EADs in isolated cardiomyocytes we then showed that phase 2 
EADs caused a marked secondary calcium rise (with accompanying contraction) by occurring 
at a time when [Ca]i is decreasing but not back to baseline335 (Figure 3.6A). Our combined 
studies supported the hypothesis of a mechanical counterpart of subthreshold EADs and, 
more broadly, our interpretation that the contraction/relaxation abnormality was a 
consequence of altered calcium handling.237, 335 A pivotal role for abnormal calcium handling 
was suggested also by Guns et al328 who advocated the necessity of a negative EMW to allow 
the occurrence of TdP. Notably, they found after-contractions in the left ventricular pressure 
(LVP) signal. Indeed, the EADs cause both a significant QT interval prolongation and 
secondary pressure rises in LVP, which are however unable to delay aortic valve closure 
(Figure 3.6B). The ensuing QT prolongation with unmodified systolic time produces a 
negative EMW. Even in the absence of EADs, increased calcium influx because of prolonged 
action-potential duration may alter late contraction pattern and impair diastole, but this will 
likely be highly correlated with QT interval, thus not providing additional prognostic value. 
Notably, even in the absence of EADs an inhomogeneity in the end of contraction among 
different areas of the ventricle may exist (such as a transmural inhomogeneity, caused by 
markedly different APDs) causing the abnormal contraction pattern. Since the developed 
tension would be insufficient to maintain aortic valve opening, this phenomenon may explain 
the presence of myocardial contraction after aortic valve closure.  
 What often escapes clinical cardiologists is the fact that these non-homogeneous 
contractions and aftercontractions alter the geometry of the beating heart and activate the 
sensory endings of cardiac sympathetic mechanoreceptors336 thus eliciting an excitatory 
sympathetic reflex.337 This leads to the arrhythmogenic localized release of norepinephrine 
which further increases the heterogeneity of ventricular repolarization, already present in 
LQTS,338, 339, thus favoring reentry.340 This sequence of events also helps understanding the 
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antifibrillatory efficacy of left cardiac sympathetic denervation for LQTS and other 
cardiovascular diseases associated with risk for sudden cardiac death.149  
 In conclusion, the well- conceived report by ter Bekke et al331 further demonstrates the 
critical role that echocardiography deserves in the clinical evaluation and management of 
LQTS patients and highlights how mechanical abnormalities can significantly contribute to 
risk stratification because, they appear linked to the mechanisms underlying TdP and can 
themselves trigger arrhythmogenic sympathetic activation. What remains to be defined, 
after proper comparison and prospective validation in an appropriately sized population, is 
which of the various echocardiographic parameters can represent the best marker of 
arrhythmic risk. 
 
 
 
Figure 3.6 Left, Electrical signal and normalized calcium-fluorescence signal from isolated patch-clamped 
guinea-pig ventricular myocyte paced at 1 Hz. Marked [Ca]i rise associated with EAD. Modified from De Ferrari 
GM, et al. Circulation 1995;91:2510-2515 [reproduced with permission]. 
Figure 3.6 Right, Example of TdP triggered by adrenaline+torsadogenic agents in closed chest guinea-pigs. 
Arrows indicate aftercontractions in LVP signal. Modified from Guns P-J, et al. J. Pharmacol. Toxicol. Methods 
2012;66:125-134 [reproduced with permission]. 
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ABSTRACT 
BACKGROUND      
Left-stellate ganglion stimulation (LSGS) can modify regional dispersion of ventricular 
refractoriness, promote triggered activity, and reduce the threshold for ventricular 
fibrillation. Sympathetic hyperactivity precipitates torsades de pointes and VF in susceptible 
patients with long-QT syndrome type 1. 
 
OBJECTIVE  
To investigate the effects of LSGS and right-stellate ganglion stimulation (RSGS) in 
anesthetized dogs with drug-induced LQT1 to unmask ventricular arrhythmogenic 
mechanisms. 
 
METHODS  
In nine mongrel dogs, the left and right stellate ganglia were exposed for electrical 
stimulation. ECG, left- and right-ventricular endocardial monophasic action potentials and 
intracavitary pressures were recorded simultaneously. The electromechanical window (Q to 
LVP at 90% relaxation minus QT) was calculated. LQT1 was mimicked by infusion of the 
KCNQ1 blocker HMR1556. 
 
RESULTS  
Under baseline conditions, LSGS and RSGS caused similar heart-rate acceleration and QT 
shortening. Positive inotropic and lusitropic effects were more pronounced under LSGS than 
RSGS. In-vivo IKs blockade prolonged QTc, triggered MAP-early afterdepolarizations and 
rendered the EMW negative, but ventricular tachyarrhythmias did not occur. Superimposed 
LSGS exaggerated EMW negativity and evoked TdP in 5/9 dogs within 30 s. Preceding 
extrasystoles originated mostly from the outflow-tracts region. TdP deteriorated into 
therapy-refractory VF in 4/5 animals. RSGS did not provoke TdP. 
 
CONCLUSION      
In this model of drug-induced LQT1, LSGS readily induced TdP and VF during repolarization 
prolongation and MAP-EAD generation, but only during marked LSGS-related EMW 
negativity and outflow-tract ventricular ectopy. Thus, mechano-electric coupling may be 
involved in the triggering of extrasystoles and/or exaggeration of regional dispersion of 
refractoriness.  
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INTRODUCTION 
Stimulation of the left and right stellate ganglion produces generalized cardiovascular (i.e., 
heart-rate and blood-pressure rise) and localized myocardial effects. Marked differences in 
chronotropic, inotropic, lusitropic, and dromotropic effects among species, including 
humans, have been reported.142, 143 Electrophysiologically, LSGS mainly activates the left-
ventricular inferior and lateral regions, whereas RSGS modulates predominantly the anterior 
sides of both ventricles.341 Sympathetic hyperactivity and/or regionally dispersed 
sympathetic innervation impinge on ventricular electrophysiological properties,143 
potentially exaggerating dispersion of excitation and refractoriness. This facilitates triggered 
activity,92 shortens ventricular refractoriness,342 and reduces the threshold for ventricular 
fibrillation.343, 344 There is also mounting evidence of significant parasympathetic 
postganglionic innervation of the ventricles in humans and canines.345 Vagal nerve 
stimulation operates mainly by antagonizing cardiac sympathetic activity. It reverses its 
action on the effective refractory period of canine LV myocardium via cholinergic-muscarinic 
pathways, increases the threshold for VF, and increases the variability of the dominant VF 
frequency.145-147 However, co-activation of both limbs of the autonomic nervous system can 
provoke various arrhythmias, including torsades de pointes.148  
 Sympathetic-related ventricular tachyarrhythmias are a hallmark of the long-QT 
syndrome type 1, as arrhythmic events are mostly provoked during exercise and/or emotion 
(~90% of symptomatic LQT1 patients).151 The precise timing of such events in relation to the 
initiation, duration or cessation of the physical or mental stress is often not clear, but could 
provide crucial information about the arrhythmogenic contribution of sympathetic and 
vagal hyperactivity superimposed on loss-of-function of the slowly-activating delayed-
rectifier potassium current (IKs). 
 Previous studies in canine LQTS models addressed the effects of unilateral or bilateral 
stellate ganglion stimulation during cesium-chloride-induced QT prolongation346 and d-
sotalol-induced LQT2,347 but not LQT1. In anesthetized dogs with drug-induced LQT1, 
however, TdP was readily evoked by the beta-adrenergic agonist isoproterenol.112 In those 
experiments, TdP was preceded by a reversed relationship between the duration of 
electrical and mechanical systole (i.e., electromechanical window negativity), and the 
occurrence of postsystolic aftercontractions. In LQTS patients, EMW negativity is a strong 
indicator of arrhythmic risk.331  
 In the present investigation, we applied LSGS and RSGS to unmask ventricular 
arrhythmogenic mechanisms in the anesthetized canine model of drug-induced LQT1.112 
Electrical stimulation of the LSG and RSG was performed with sympathetic and vagal nerves 
left intact, during an anesthetic regime with minimal influence on beta-adrenergic 
responsiveness and baroreflex sensitivity, allowing near-to-normal autonomic reflexes 
during sympathetic stimulation. Simultaneous recordings of ECGs, monophasic action 
potentials and pressures from the left and right ventricle served to examine 
electromechanical coupling during LSGS and RSGS. 
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METHODS 
Animal handling was in accordance with the Dutch Law on Animal Experimentation and the 
European Directive for the Protection of Vertebrate Animals used for experimental and 
other scientific purposes (European Union Directive 86/609/CEE). The Committee for 
Experiments on Animals of Maastricht University approved the experimental protocol 
(2008-116). 
GENERAL 
Nine adult mongrel dogs of either sex (body weight 32 ± 3 kg, Marshall BioResources) were 
used for this study. Food was withheld 12 hours before the experiment. General anesthesia 
was induced by a slow singular intravenous injection of remifentanil (0.1 µg/kg), etomidate 
(0.5-1.5 mg/kg), and succinylcholine (1 mg/kg). A cuffed endotracheal tube was inserted and 
connected to a respirator with 30% oxygen in pressurized air to maintain normocapnia, 
PaCO2 30-50 mm Hg. A thermal mattress was used to maintain body temperature and 1.25 
mL/kg/h 0.9% NaCl was administered to compensate for the perioperative fluid loss. 
Anticoagulation was achieved with 500 IU/kg unfractionated heparin. 
 During the experiment, anesthesia was maintained by continuous infusion of etomidate 
(1.0-3.0 mg/kg/h) and remifentanil (0.6-1.0 µg/kg/min). This anesthetic regime was chosen 
because of minimal effects on beta-adrenergic responsiveness, baroreflex sensitivity, and 
basal hemodynamic parameters.112, 113, 348 
IN-VIVO EXPERIMENTAL DESIGN 
In all experiments standard-lead ECGs were continuously registered. Additionally, MAP 
catheters (Hugo Sachs Elektronik, Harvard Bioscience, Inc.) were positioned in the LV and 
RV. Endocardial MAP signals were accepted on the basis of amplitude, morphology and 
stability. Two 7F pigtail tip-micromanometer catheters (Sentron, Cordis®) were advanced via 
arterial and venous (femoral or carotid) access into the LV and RV cavity for pressure 
recordings. 
 In all dogs, the left cardiac sympathetic chain was exposed beneath the parietal pleura by 
left thoracotomy between the first and second ribs, posteriorly. In three dogs, the 
contralateral stellate ganglion was also exposed and prepared for electrical stimulation. The 
vagal nerves were left intact, and sympathetic neural decentralization was not performed. 
 Custom-made bipolar electrodes were used for unilateral stellate stimulations. Pulses 
generated were 2-4 mA in amplitude, 2 ms in duration, 10-15 Hz in frequency, and were 
maintained for 33 ± 12 s. If both sympathetic stellate ganglia were to be stimulated in an 
experiment, the RSG was stimulated first. At least five minutes between successive 
stimulations were allowed for full recovery of the nerve, and hemodynamic and 
electrophysiological parameters. In three dogs, an isoproterenol bolus (1.2-2.5 µg) was 
given. 
 All modules (ECG registration, MAP signals, pressure recording, and pacer) were 
connected to the IdeeQ Data Acquisition Program (version 2.49.0 Maastricht Instruments 
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BV) for continuous and synchronous signal recording, electrical stimulation, and offline 
analysis. 
 Once a reproducible response to either stellate ganglion was established in at least two 
consecutive stimulations, HMR1556, an IKs blocker targeting KCNQ1,349 was administered 
intravenously at 25-50 µg/kg/min (mean 46 ± 10 µg/kg/min) to mimic LQT1. HMR1556 was 
titrated to reach maximal IKs inhibition, as assessed by stable QT prolongation >25% from 
baseline,112 before stellate ganglion stimulation was repeated. If TdP or VF was induced, 
electrical stimulation and HMR1556 infusion were discontinued immediately, followed by 
magnesium administration and external electrical cardioversion in attempts to restore sinus 
rhythm. 
DATA ANALYSIS 
Electrophysiological, hemodynamic and electromechanical parameters described below 
were analyzed during ten consecutive sinus-rhythm (or supraventricular) beats, 
momentarily before and at maximal SGS, both under baseline conditions and during IKs 
blockade. 
 Heart rate and QT interval were measured from an extremity lead (usually lead II) with a 
discernible T-wave ending and the longest QT interval. Heart-rate corrected QT (QTc) was 
calculated using van de Water’s formula, QTc=QT-0.087(RR-1000), which is superior to 
Bazett’s in anesthetized dogs.350 Tpeak-Tend was calculated as a marker of spatial dispersion of 
ventricular repolarization. 
 LV and RV MAP durations were measured at 90% repolarization (MAPD90). Beat-to-beat 
variability of repolarization was measured on LV and RV MAP recordings during 10 
consecutive beats in the absence of ventricular ectopy. Short-term variability was calculated 
as: STV=∑(|MAPDn-MAPDn-1|)/(10*√2). Long-term variability as: LTV=∑(|MAPDn+MAPDn-1-
2*MAPDmean|)/(10*√2).351 Also, the occurrence of early afterdepolarizations (EADs) in 
MAPs, and EAD-preceding transient repolarization delays (i.e., when dVMAP/dt turned less 
negative or zero) were noted.  
 Ventricular peak systolic and end-diastolic pressure, duration of ventricular contraction 
at 90% relaxation (QLVP90), and the dP/dtmax, dP/dtmin were measured. The EMW was 
calculated by subtracting the QT interval from the QLVP90. The pressure signals were 
carefully screened for (low-amplitude) aftercontractions.112 
 If ventricular tachyarrhythmia occurred, we located the origin of the triggering 
premature ventricular complex by analyzing the QRS morphology and the sequence of RV 
and LV MAP activation. The last supraventricular beat before TdP/VF was designated beat 
“0” with the preceding intervals being I(-n) (Figure 4.1). These RR intervals were measured to 
determine the pause dependency of arrhythmia initiation, defined as I(-1) ≥150% I(-2).106 QT, 
EMW, and QLVP90 were compared between TdP-inducible and noninducible stimulations. 
Dogs were designated “resistant” if no TdP/VF could be induced during SGS. 
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Figure 4.1 Method of ECG analysis. RR intervals are numbered in relation to the last supraventricular beat “0” 
prior to TdP/VF, with I(-n) referring to previous intervals. 
STATISTICAL ANALYSIS 
Data were measured in 10 consecutive beats, using the average for further statistical 
analysis. Pooled data were expressed as mean±standard deviation. Normality was assessed 
for each dataset using the Shapiro-Wilk test. Differences of parameters in paired data were 
assessed using the paired-samples t-test or the Wilcoxon signed rank test as appropriate. 
Intergroup comparison was performed using the student’s t-test or the Kruskal-Wallis test. 
A P value of <0.05 was considered statistically significant. 
RESULTS 
STELLATE GANGLION STIMULATION OF THE NORMAL CANINE HEART 
Figure 4.2 depicts representative examples of the cardiac effects of LSGS and RSGS at 
baseline. During LSGS, heart rate increased by 79% and the QT interval shortened by 23%, 
effectively reducing QTc from 290 ± 24 to 253 ± 13 ms (P=0.0003; Table 4.1). LV and RV 
MAPD90 analysis did not reveal augmented interventricular or temporal (i.e., beat-to-beat) 
dispersion of repolarization. In both ventricles, inotropy increased significantly: LV peak 
systolic pressure by 37% and RVP by 157%. LV dP/dtmax increased by 394%. LV dP/dtmin 
decreased by 110%, indicating increased lusitropy, and effectively leading QLVP90 to shorten 
from 373 ± 65 to 214 ± 46 ms (-43%, P=0.006; Table 4.1). Changes in diastolic LVP did not 
reach statistical significance. LV EMW decreased from 95 ± 53 to 9 ± 42 ms (P=0.009). RV 
inotropy and lusitropy also increased significantly (Table 4.1).  
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Figure 4.2 Representative examples of effects of LSGS and RSGS on ECG, LVP, and RVP characteristics. Upon 
LSGS, a junctional tachycardia appeared after 6 s (*) interspersed by ventricular extrasystoles. The EMW, being 
positive at baseline, turned negative during LSGS (-40 ms, red), but not during RSGS (89 ms, green). LSG 
indicates left stellate ganglion; RSG, right stellate ganglion; LVP, left-ventricular pressure; RVP, right-ventricular 
pressure. 
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Table 4.1 Electrophysiological and hemodynamic effects of unilateral stellate ganglion 
stimulation at baseline 
 
 Baseline + LSGS P value + RSGS P value 
RR interval (ms) 667 ± 58 383 ± 79 <0.0001 341 ± 91 0.024 
Heart rate (bpm) 91 ± 8 162 ± 32 <0.0001 188 ± 55 0.024 
QT interval (ms) 261 ± 23 200 ± 18 <0.0001 198 ± 34 0.0004 
QTc (ms) 290 ± 24 253 ± 13 0.0003 256 ± 27 0.002 
Tp-Te (ms) 37 ± 13 36 ± 10 0.78 37 ± 7 0.21 
Left ventricle      
MAPD90 (ms) 222 ± 25 175 ± 26 0.0001 176 ± 30 0.001 
MAP-STV 4.8 ± 4.2 4.0 ± 2.9 0.24 1.8 ± 1.0 0.10 
MAP-LTV 5.7 ± 3.3 5.1 ± 5.6 0.63 1.4 ± 0.5 0.03 
LVP syst. (mm Hg) 94 ± 18 150 ± 23 <0.0001 137 ± 11 0.02 
LVP diast. (mm Hg) 11 ± 4 9 ± 7 0.12 13 ± 11 0.008 
dP/dtmax (mm Hg/s) 1750 ± 918 8649 ± 3583 0.0007 3665 ± 2295 0.048 
dP/dtmin (mm Hg/s) -2323 ± 1236 -4893 ± 2268 0.013 -3235 ± 1592 0.058 
QLVP90 (ms) 373 ± 65 214 ± 46 0.006 245 ± 63 0.0008 
EMW (ms) 95 ± 53 9 ± 42 0.009 47 ± 30 0.007 
Right ventricle      
MAPD90 (ms) 211 ± 24 177 ± 27 0.02 168 ± 31 0.0009 
RVP syst. (mm Hg) 23 ± 10 59 ± 13 0.0008 37 ± 18 0.09 
RVP diast. (mm Hg) 4 ± 3 1 ± 3 0.002 4 ± 4 0.007 
dP/dtmax (mm Hg/s) 597 ± 349 4005 ± 770 0.001 1435 ± 1200 0.04 
dP/dtmin (mm Hg/s) -323 ± 148 -1920 ± 1105 0.06 -889 ± 519 0.06 
 
STV indicates short-term variability; LTV, long-term variability; MAPD90, monophasic action potential duration 
at 90% repolarization; LVP, left-ventricular pressure; QLVP90, time from QRS onset to 90% LV pressure 
normalization; EMW, electromechanical window.  
 
LSGS readily evoked a junctional (or low-atrial) tachycardia, overriding the LSGS-induced 
accelerated sinus rhythm after 6 ± 3 s (asterisks in Figure 4.2). Occasionally, solitary RV/LV 
ectopic activity occurred during LSGS, but MAP-EADs, aftercontractions, or (non)sustained 
ventricular tachyarrhythmias (NSVT) were not observed. In approximately one third of LSG 
stimulations a short-lived paradoxical heart-rate slowing was observed, which could be 
counteracted by atropine. 
 We observed an immediate and protracted (87 ± 41 s) vagal rebound following LSGS 
(Figure 4.3), which was characterized by sinus bradycardia, ventricular ectopy, and episodes 
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of idioventricular rhythm. The post-LSGS systolic LVP remained elevated during this vagal 
episode, and returned to steady-state values parallel with the restoration of sinus rhythm. 
Vagal rebound was not observed after isoproterenol infusion, which may be explained by 
the absence of an inotropic response (113 ± 17 to 109 ± 12 mm Hg; P=0.51), despite heart-
rate acceleration (+57%). 
 
 
Figure 4.3 Vagal rebound post-LSGS at baseline. Upon termination of LSGS, and during a protracted positive 
inotropic response (upper panel), sinus and junctional bradycardia, ventricular extrasystoles and 
idioventricular rhythm occurred, indicating a vagal response by a baroreflex loop and/or sympathetic 
withdrawal. The lower ECG traces A, B, C, and D are ECG examples at different stages of the vagal rebound. 
LVP indicates left-ventricular pressure. 
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RSGS (n=3, Figure 4.2) caused comparable heart-rate accelerations (188 ± 55 bpm) as LSGS 
(in the absence of decentralization), without provoking supraventricular arrhythmias. Both 
QT and QTc intervals shortened significantly (by 29% and 18% respectively), but these were 
not different from the effects of LSGS. Endocardial MAPD90 decreased similarly in both 
ventricles (Table 4.1). RSGS-evoked positive inotropy was less prominent than during LSGS. 
Similarly, we observed only limited QLVP90 shortening upon RSGS, resulting in less EMW 
reduction (Table 4.1). 
REPOLARIZATION INSTABILITY DURING IKS INHIBITION 
Intravenous administration of HMR1556 prolonged QT and QTc to 373 ± 65 and 371 ± 61 
ms, respectively (+21% and +20%; P=0.002 and P=0.007, Table 4.2).  Heart rate decreased to 
60 ± 11 bpm (P=0.0003). Preferential LV over RV MAPD90 prolongation (335 ± 74 and 286 ± 
50 ms; P<0.0001) resulted in augmented interventricular dispersion of repolarization. This 
was paralleled by a more pronounced LV temporal dispersion of repolarization with STV-
MAPD90 increasing by 129% and LTV-MAPD90 by 173%. LV EADs emerged in four dogs at a 
wide range of cycle lengths; RV EADs in three (Figure 4.4). Upon IKs inhibition, the LV-peak 
systolic pressure and LV dP/dtmax increased to 114 ± 19 mm Hg (+23%; P=0.01) and 2373 ± 
1159 mm Hg/s (+27%; P=0.001). Despite a significant prolongation of the electrical systole, 
QLVP90 remained unaltered, providing an EMW negativity of -14 ± 69 ms (P=0.001). No 
sizeable aftercontractions or spontaneous ventricular arrhythmias were noted under these 
conditions. 
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Figure 4.4 Top, LV MAPs and first derivative (dV/dt) of MAP signal. After HMR1556, EADs followed after an 
initial delay in repolarization (arrowheads). Upon concomitant LSGS at 10-15 Hz, frank EAD upstrokes were 
absent but a discernable delay in repolarization (arrows) remained present, contributing to MAPD90 
prolongation. Bottom, rate dependency of MAPD90 at baseline (square), during HMR1556 (circle) and 
simultaneous LSGS (triangle). Black symbols: EAD present; gray symbols: initial delay in repolarization. LSGS 
indicates left-stellate ganglion stimulation; APD90, action potential duration at 90% repolarization; CL, cycle 
length. 
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PROARRHYTHMIC PROCLIVITY OF LSGS DURING DRUG-INDUCED LQT1 
LSGS during IKs inhibition provoked TdP/VF in 5 of 9 dogs after 26 ± 6 s (Figure 4.5). Once 
TdP occurred, it rapidly degenerated into VF that was resistant to magnesium infusion and 
did not respond to immediate and repeated electrical cardioversion in all but one case. In 
that dog, after termination of VF, a protracted vagal period with intermittent episodes of 
nonsustained VT was observed. RSGS was never torsadogenic.  
 
 
Figure 4.5 Induction of TdP, degenerating into VF, by LSGS in drug-induced LQT1. MAP indicates monophasic 
action potential; LVP, left-ventricular pressure; LSGS, left-stellate ganglion stimulation. 
 
In the dogs with inducible TdP/VF, pre-LSGS QT was significantly more prolonged, and LV 
EMW more negative, than in resistant animals: 440 ± 67 versus 344 ± 56 ms (P=0.007) and -
64 ± 87 versus 27 ± 40 ms (P=0.04), respectively (Figure 4.6). EMW negativity decreased 
significantly in the final beats preceding TdP/VF (reaching -94 ± 31 ms at I(0)), compared with 
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the non-inducible group (-43 ± 25 ms; P=0.002, Figure 4.6). QLVP90 did not differ between 
these groups. QT prolongation was more exaggerated (282 ± 53 ms; P=0.02) in the beats 
prior to TdP when compared to pre-NSVT (225 ± 21 ms) or solitary PVCs (229 ± 39 ms) in 
susceptible animals, and EMW was more negative -94 ± 31 ms prior to TdP/VF (P=0.005) 
versus -23 ± 37 ms (pre-NSVT), and -38 ± 37 ms (PVC).  
 
 
 
Figure 4.6 Top, beat-to-beat changes in RR interval, QT interval, QLVP90, and EMW during HMR1556 and LSGS 
just prior to TdP (left) or at 26 s and maximal chronotropic response (no TdP; right). Pre-LSGS QT and EMW 
were significantly more pronounced in TdP-susceptible animals. # indicates P<0.05. Below, simultaneous 
recording of ECG lead II and LVP to illustrate EMW variations. 
 
An initial delay in MAP repolarization was present throughout a broad range of RR cycle 
lengths during LSGS and IKs blockade, but EADs did not occur (Figure 4.4). Increased diastolic 
slopes suggesting delayed afterdepolarizations were also not observed. During this 
condition with fast-rate dependent electrical instability and mechano-electric 
heterogeneity, relatively short-coupled non-pause dependent PVCs occurred (Figures 4.5-
4.7). Macroscopic aftercontractions preceded TdP in one dog. The TdP/VF-triggering PVCs 
typically had an intermediate QRS axis, large QRS amplitudes, and their earliest endocardial 
activation at the RV MAP signal (in 4/5 dogs, Figure 4.7), suggesting focal activation in the 
outflow tracts region. In one animal, TdP initiation emerged from the inferior LV. TdP onset 
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was non-pause dependent with I(-1) never exceeding I(-2). In some cases ventricular ectopy 
occurred prior to I(-2). 
 
Figure 4.7 Outflow-tract origins of TdP/VF-triggering PVC. Left, 6-lead ECG recording showing an intermediate 
QRS axis with a relatively short duration. Right, box plot of interventricular activation delay of the junctional 
beats versus the TdP/VF-triggering extrasystoles demonstrating the earliest electrical activation in the RV in all 
but one case. 
DISCUSSION 
This is the first study to demonstrate the proarrhythmic consequences of LSGS in an in-vivo 
model of drug-induced LQT1112 in which autonomic reflexes, neurocardiac transmission and 
cardiac electromechanical coupling are only mildly influenced by the applied anesthesia. In-
vivo IKs blockade prolonged ventricular repolarization duration and augmented spatial and 
temporal repolarization dispersion, recapitulating LQT1 aspects. Only with concomitant 
LSGS did TdP occur. Arrhythmia initiation was always fast-rate (non-pause) dependent, with 
the majority of triggering beats originating in the outflow-tracts region. This is consistent 
with the site of TdP onset in the majority of LQTS patients.270  
 In most susceptible dogs with drug-induced LQT1 and LSGS, TdP rapidly deteriorated into 
defibrillation-resistant VF. In this undecentralized set-up, LSGS as well as RSGS caused 
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positive chronotropic effects, but inotropic and particularly lusitropic influences were more 
dominant by LSGS than by RSGS. Because of this, and in the face of repolarization 
prolongation by IKs blockade, LSGS exaggerated EMW disparity, mostly so in the seconds 
before TdP. RSGS was not torsadogenic under these conditions. 
 In a previous study in the same model, with isoproterenol as provocative agent, the 
combination of prolonged repolarization and shortened LVP favored the emergence of LV 
aftercontractions at instances with pending TdP.112 In the present study, macroscopic 
aftercontractions were infrequently observed, but we speculate that the regional 
myocardial effects of LSGS could have produced low-amplitude aftercontractile events 
(below the radar of global intracavitary pressure) with similar arrhythmogenic significance 
during negative EMW. Pronounced EMW negativity related to TdP occurrence has also been 
observed by others during beta-adrenergic stimulation in experimental LQT1113 and by us in 
clinical studies on symptomatic patients with congenital LQTS.322, 331 Future studies could 
concentrate on examining mechano-electric triggers of arrhythmia in LQTS. 
PROARRHYTHMIC PROCLIVITY OF LSGS DURING IKS INHIBITION 
The present findings confirm the arrhythmogenic role of left-sided cardiac sympathetic 
hyperactivity in a clinically-relevant LQT1 model, like was demonstrated in other 
experimental preparations.352 We found remarkable differences in the arrhythmogenic 
outcome between blood-borne beta-adrenergic and sympathetic stimulation in the 
anesthetized LQT1 model. In the former, the successful cardioversion of induced TdP allowed 
multiple provocations per dog,112 whereas the sympathetically-induced TdP/VF were highly 
resistant to defibrillation attempts. Sympathetic hyperactivity, releasing norepinephrine 
locally at the myocardial nerve endings, accentuates heterogeneity in ventricular 
repolarization under these conditions, and favors reentrant excitation, whereas circulating 
catecholamines or infused isoproterenol act more uniformly.340 These differences are 
accompanied by a considerably larger positive inotropic (but similar chronotropic) response 
upon LSGS followed by a protracted vagal rebound in contrast to our observations with 
isoproterenol in the same model.112 This vagal accentuation could be explained by the 
sudden sympathetic withdrawal and/or by baroreflex activation in response to the elevated 
arterial pressures. Assuming that a similar response occurs upon LSGS during drug-induced 
LQT1, and supported by the observation of a prominent vagal rebound in the rare case of 
successful cardioversion of VF, our results suggest that reflex vagal activation may have 
promoted the LQT1-related TdP to deteriorate into VF. Indeed, vagal nerve stimulation 
increases ventricular dispersion of repolarization and it has been demonstrated that this 
exacerbates in drug-induced LQT2.160 Moreover, when applied during induced VF in pigs or 
sheep, vagal nerve stimulation increases the variability of the dominant VF frequency, 
potentially sustaining the arrhythmia.147  
 The triggers for most life-threatening events for LQT1 patients are either physical (75%) 
or emotional stress (15%) while rest/sleep accounts for only 10%.151 One third of patients 
has events during swimming.151 These arrhythmias are effectively prevented in most LQT1 
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patients by beta-blockade353 or by left-cardiac sympathetic denervation.186, 353 On the other 
hand, strong vagal reflexes have been implicated in high-risk LQT1 patients,154, 155 and cold-
water submersion and swimming, a genotype-specific trigger, provokes powerful co-
stimulation of both sympathetic and parasympathetic limbs, at least in the first instances.354 
Our experimental results do not allow firm conclusions on the contribution of vagal 
stimulation to ventricular proarrhythmia in LQTS, but they lend indirect support to the 
concept of “autonomic conflict”,148 which indicates that a more convoluted vago-
sympathetic interaction can facilitate ventricular tachyarrhythmia.  
LIMITATIONS 
The present study involved a relatively small number of animals, which was driven by ethical 
considerations. However, the differences in results obtained in paired analysis or group 
comparisons were so profound that they readily reached statistical significance. 
 The use of an anesthesia model always brings into question the cardiovascular and 
autonomic effects of anesthesia, especially when dealing with autonomic interventions. In 
the present study, we minimized potentially confounding effects113, 348 by the choice of 
anesthetics. 
CONCLUSIONS 
In this in-vivo canine model of drug-induced LQT1, LSGS readily induced TdP and VF in the 
presence of repolarization prolongation, MAP-EADs generation and exaggerated 
spatiotemporal dispersion of repolarization. Triggering PVCs most often emerged from the LV 
and RV outflow-tract regions. LSGS always rendered the EMW more negative prior to 
arrhythmia induction, which suggests that mechano-electric instability is somehow involved 
in the proarrhythmic proclivity. Our results offer novel mechanistic understanding of LQT1-
related arrhythmogenesis and strengthen the rationale for left-cardiac sympathetic 
denervation in the prevention of life-threatening arrhythmias in several cardiac disorders, 
ranging from channelopathies149 to structural heart diseases.149, 355 
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ABSTRACT 
BACKGROUND  
Heritable cardiac sodium-channel dysfunction is associated with various arrhythmia 
syndromes, some predisposing to ventricular fibrillation. Phenotypic diversity among 
carriers of identical-by-descent mutations is often remarkable, suggesting influences of 
genetic modifiers. 
  
OBJECTIVE  
We identified a unique SCN5A-mutation founder population with mixed clinical phenotypes 
and sudden cardiac death, and investigated the heritability of electromechanical traits 
besides the SCN5A-mutation effect. 
 
METHODS  
The 16-generation founder population segregating SCN5A c.4850_4852delTCT, 
p.(Phe1617del), was comprehensively phenotyped. Variance component analysis was used 
to evaluate the mutation’s effects and assess heritability. 
 
RESULTS    
In 45 p.(Phe1617del) positives, the mutation associated strongly with QTc prolongation, 472 
± 60 versus 423 ± 35 ms in 26 mutation negatives (P<0.001; OR for LQTS [95% C.I.]=22.4 
[4.5-224.2]; P<0.001), and electromechanical window negativity, -29 ± 47 versus 34 ± 26 ms 
(P<0.001). Overlapping phenotypes including conduction delay and Brugada syndrome were 
noted in 19. Polymorphic ventricular tachyarrhythmias occurred mostly at daytime, after 
arousal-evoked heart-rate acceleration and repolarization prolongation. Cox proportional 
hazards regression analysis revealed female gender as an independent risk factor for cardiac 
events (HR [95% C.I.]=5.1 [1.6-16.3]; P=0.006). p.(Phe1617del) was an important 
determinant of QTcbaseline, QTcmax, and EMW, explaining 18%, 28%, and 37% respectively of 
trait’s variance. Significant heritability was observed for PQ interval (P=0.003), after 
accounting for the p.(Phe1617del) effect. 
 
CONCLUSION  
This SCN5A-p.(Phe1617del) founder population with phenotypic divergence and overlap 
reveals LQTS-related and arousal-evoked ventricular tachyarrhythmias with a female 
preponderance. Variance component analysis indicates additional genetic variance for PQ 
interval hidden in the genome, besides a dominant p.(Phe1617del) effect on QTc and EMW. 
  | 85 
INTRODUCTION 
Sudden cardiac death accounts for a significant proportion of natural mortality in 
industrialized societies and imposes a sizable socioeconomic and psychosocial burden. VF is 
the main cause of SCD and occurs often in the setting of acute coronary events.9, 356 A 
prominent familial component contributing to the risk of SCD by ischemic VF has been 
recognized,8, 17, 18 but the underlying genetic mechanisms remain largely unclear. 
 The unraveling of genetic contributors to arrhythmia phenotypes is important for 
diagnostic purposes, risk stratification, elucidation of molecular pathways, and the 
identification of potential therapeutic targets. However, limited sample sizes of 
representative populations, heterogeneity of the arrhythmogenic substrate and the 
difficulty of obtaining phenotype information after cardiac arrest make this a challenging 
quest. Moreover, prominent phenotypic heterogeneity, including SCD susceptibility, has 
been observed among affected individuals sharing the same mutation.57 This variability has 
been attributed to a low disease penetrance (25% in the long-QT syndrome58 and 16% in 
Brugada syndrome),63 differential expressivity, and non-genetic factors such as age,357 
gender,60 and the use of medication.59 One study observed compound heterozygosity in 
~8% of LQTS cases.61 Additionally, common variants in certain genes, such as SCN5A,85 
SCN10A and HEY2,86 can contribute to disease penetrance in sick-sinus and Brugada 
syndrome, which indicates a complex genetic architecture. To investigate such complex 
genetic factors, family cohorts provide substantial benefits: they are robust to false-positive 
findings due to population substructure, they typically share a large proportion of 
environmental factors, and they may be enriched for rare variants that are difficult to study 
in the general population.  
 In this study, we investigated a large Dutch-German founder population with excess SCD 
over multiple generations, segregating an amino-acid deletion in SCN5A (c.4850_4852 
delTCT, exon 28, p.(Phe1617del), rs749697698). Because cardiac differences between 
Phe1617del carriers appeared prominent, we used variance component analysis to first 
assess the effects imposed by the known SCN5A mutation and then calculate remaining 
heritabilities of various proarrhythmic phenotypes. Identifying new genetic risk factors can 
give profound insights into molecular mechanisms, assist in further diagnosis and yield novel 
information regarding the broader problem of SCD. 
METHODS 
All participants (≥18 years) gave written informed consent for clinical and genetic analyses. 
The Medical Research Ethics Committee of Maastricht University Medical Centre approved 
the study protocol. This study complies with the Declaration of Helsinki. It is registered 
under www.clinicaltrials.gov; NCT02014961. 
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STUDY POPULATION 
Between 2006 and 2015, seven probands presented independently at our Cardiogenetics 
Outpatient Clinic with QT prolongation, polymorphic ventricular tachycardia, prolonged-
repolarization associated TdP, or SCD of a first-degree relative. After obtaining informed 
consent, genomic DNA was extracted from peripheral blood. Using Sanger sequencing the 
pathogenic SCN5A mutation c.4850_4852delTCT, p.(Phe1617del), rs749697698 was 
identified in all probands on a haplotype that also contained rs1805124 (SCN5A c.1673A>G, 
exon 12, p.(His558Arg)). One additional variant, rs1805128 in KCNE1, c.253G>A, exon 3, 
p.(Asp85Asn),73 was found in two probands. Both had a prolonged QT interval, but no 
documented VT. The presence of this KCNE1 variant in the pedigree is unlikely to affect our 
general results, as its transmission is independent of the SCN5A-founder haplotype. No 
pathogenic mutations were found in ABCC9, AKAP9, ANK2, CACNA1C, CACNA2D1, CACNB2, 
CALM1, CASQ2, CAV3, DPP6 (only tested for 4 c.-340C>T), GPD1L, HCN4, KCNE2, KCNE3, 
KCNH2, KCNJ2, KCNJ8, KCNQ1, LMNA, RYR2, SCN1B, SCN3B, SCN5A, SNTA1, TNNT2, and 
TRDN. 
 Relatedness of all Phe1617del probands was ascertained using regional genealogical 
archives, parish registers, and private databases, and common ancestry was confirmed. 
Haplotype sharing at 8 microsatellite markers spanning the SCN5A locus, 5 upstream 
(D3S1768, D3S1561, D3S1298, D3S3639, D3S1260) and 3 downstream (D3S1100, D3S2407, 
D3S3559) confirmed these genealogical relationships. Cascade screening revealed an 
autosomal dominant inheritance pattern.  
PHENOTYPIC CHARACTERIZATION 
Comprehensive phenotyping of Phe1617del-positive and mutation-negative family 
members was performed. Syncope, documented VT/VF, aborted cardiac arrest, and/or SCD 
were scored as cardiac events. Baseline 12-lead ECGs were digitally magnified and analyzed 
using on-screen calipers. First (≥18 years) and maximal documented PQ and QT intervals 
were determined. The longest QT interval in lead II or any precordial lead was measured for 
calculation of the heart-rate corrected QTc according to Bazett’s formula. LQTS was 
diagnosed according to current guidelines.1 Isorhythmic atrioventricular dissociation was 
noted as the wandering of sinus P waves in and out of their associated QRS complexes. 
Overlap was defined as the concomitant presence of two of the following traits: LQTS, 
Brugada syndrome, cardiac conduction disease (CCD) or isorhythmic atrioventricular 
dissociation. Echocardiography and cardiac magnetic imaging were used to determine the 
presence of structural abnormalities. The electromechanical window, defined as QAoC 
minus the concomitantly measured QT interval, was calculated during continuous-wave 
Doppler flow assessment of the aortic valve.331 Ajmaline provocation testing (1 mg/kg in 10 
minutes) was performed to unmask concealed Brugada syndrome. ICD readouts were 
analyzed for arrhythmia characteristics. 
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STATISTICAL AND VARIANCE COMPONENT ANALYSES 
The normality of phenotype and residual distributions was assessed by the inspection of 
density plots and by the Shapiro-Wilk test. For continuous traits, mean differences between 
subgroups were tested using the Mann-Whitney U test. Odds ratios comparing the 
prevalence of dichotomous traits among subgroups were estimated using Fisher’s exact 
test. Cox proportional hazards models were implemented to conduct survival analyses, and 
testing of the Schoenfeld residuals was performed. Analyses were conducted using the base 
R package (https://www.R-project.org) and the survival package (https://CRAN.R-
project.org/package=survival). 
 To estimate the effects of the SCN5A-p.(Phe1617del) mutation, as well as trait 
heritabilities, a variance component approach, as implemented in the sequential oligogenic 
linkage analysis routines (SOLAR) software package, was used. Thus, we assessed the 
narrow-sense heritability estimate (h2), referred to as “residual heritability”, representing 
the percentage of variance of a quantitative phenotypic trait attributable to additional 
genetic factors. To satisfy distributional assumptions inherent to this method, phenotypes 
were regressed on age, sex, and height using linear regression models. The residuals from 
those models were transformed using the rank-based inverse normal transformation 
function in GenABEL and used as phenotypes for analysis in models including the SCN5A 
deletion.358 To correct for multiple comparisons, while accounting for the correlation 
between phenotypes, the effective number of independent traits was estimated. First, a 
Spearman’s correlation matrix was constructed from all analyzed phenotypes in R. Then, 
matrix spectral decomposition was applied to these correlations using matSpD 
(http://gump.qimr.edu.au/general/daleN/matSpD/)359 to derive the number of effective 
tests (n=12); the nominal P value of 0.05 was divided by this number yielding a significance 
threshold of P=0.004. From the normalized residuals we computed the effect size (β, in 
standard deviations) attributed to the SCN5A mutation, the p.(H558R) polymorphism, and 
the familial component (h2) by means of a kinship matrix, which was constructed utilizing 
the pedigree structure. 
RESULTS 
GENEALOGY, PEDIGREE STRUCTURE AND MORTALITY DATA 
Figure 5.1 illustrates the 16-generation pedigree of the Phe1617del-positive family, which 
mainly resides in Limburg (The Netherlands) and North Rhine-Westphalia (Germany). 
Carriers living in Lund (Sweden) and Munich (Germany) had comparable DNA profiles, 
confirming relatedness but their lines of descent remained unclear. Genealogical research 
identified two ancestral couples that lived near the river Worm, at the south-eastern border 
of The Netherlands with Germany (hence our designation “Worm Study” to this research), 
in the 16th century.  
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Figure 5.1 Pedigree of SCN5A-p.(Phe1617del)-mutation carriers for seven family groups. Black lines of descent 
for presumed founder couple A; grey lines for couple B. Deaths before 51 years of age are noted. Squares 
represent males (in bold: homozygous carrier), circles females. Only carriers are depicted. VT = ventricular 
tachycardia; VF = ventricular fibrillation. 
 
Ancestral couple A connects five probands, and couple B four (Figure 5.1). Despite extensive 
efforts, a single founding couple connecting all probands has not yet been identified. In all 
likelihood, the SCN5A mutation emerged prior to 1600. Figure 5.2 demonstrates the 
chronological migration of the mutation from its presumed first occurrence. At present, the 
total number of known family members exceeds 4,800. 
 The pedigree depicts interfamilial marriages within the third or fourth degree of 
consanguinity. A male proband born of consanguineous parents was found to be 
homozygous for SCN5A-p.(Phe1617del), Figures 5.1 and 5.3. 
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Figure 5.2 Geographic distribution and spread of SCN5A-p.(Phe1617del) in the Dutch-German-Belgian Euregion 
during the last 4 centuries. Asterisks mark the living areas of founder couples A and B. 
 
 PHENOTYPIC HETEROGENEITY AND OVERLAP 
Clinical characteristics of the study population are presented in Table 5.1. Four main 
phenotypes were observed: LQTS, CCD, Brugada syndrome, and isorhythmic atrioventricular 
dissociation (Figure 5.3), with striking phenotypic heterogeneity among Phe1617del-positive 
patients, even between siblings (see I-IV in Figure 5.1).  
 As is illustrated by the color codes in Figure 5.1, LQTS was the prevailing phenotype, 
present throughout the pedigree. LQTS was diagnosed in 28 carriers and a strong 
association between Phe1617del and risk of LQTS was seen (OR [95% C.I.]=22.4 [4.5-224.2]; 
P<0.001). Prolonged repolarization, with a mean difference (∆μ) of 48 ms (P<0.001) 
compared to non-carriers, was present at a wide variety of heart rates (Figure 5.4).  
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Figure 5.3 SCN5A-p.(Phe1617del)-related electrocardiographic phenotypes. During isorhythmic 
atrioventricular dissociation, long and short bars indicate QRS and P onset, respectively. Top numbers indicate 
RR intervals; bottom QT intervals. 
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Table 5.1 Clinical characteristics of the study population 
 
 Worm study population Phe1617del positives 
 mut. neg. mut. pos. P value asympt. sympt. P value 
Number, n 26 45  24 21  
Age, years 51 ± 18 49 ± 16 0.68 49 ± 17 50 ± 16 0.86 
Female sex, n (%) 16 (62) 24 (53) 0.81 8 (33) 16 (76) 0.007 
Height, cm 171 ± 13 174 ± 11 0.34 176 ± 9 170 ± 12 0.036 
Weight, kg 73 ± 15 73 ± 13 0.71 75 ± 11 68 ± 15 0.048 
Cardiac events, n (%) 5 (19) 21 (47) 0.022 0 21  
Beta-blocker, n (%) 8 (31) 13 (29) 0.78 5 (24) 8 (38) 0.18 
Cardiac phenotype       
   Normal, n (%) 15 (58) 8 (18) 0.003 6 (25) 2 (10) 0.43 
   LQTS, n (%) 2 (8) 28 (62) <0.001 14 (58) 14 (67) 0.18 
   CCD, n (%) 10 (38) 15 (33) 1.00 8 (33) 7 (33) 0.75 
   Brugada syndr., n (%) 0 (0) 5 (11) 0.15 3 (13) 2 (10) 1.00 
   Isorhythm. diss., n (%) 0 (0) 9 (20) 0.010 5 (21) 4 (19) 1.00 
   Overlap, n (%) 1 (4) 19 (42) <0.001 9 (38) 10 (48) 0.34 
   Unknown, n (%)  4 (9)   4 (19)  
ECG       
   PQ, ms 164 ± 31 161 ± 25 0.80 166 ± 24 153 ± 24 0.076 
   PQmax, ms 176 ± 37 186 ± 41 0.29 193 ± 48 177 ± 28 0.31 
   RR, ms 934 ± 150 910 ± 181 0.57 909 ± 192 912 ± 170 0.91 
   QRS, ms 100 ± 16 93 ± 14 0.12 92 ± 8 96 ± 19 0.94 
   QT, ms 408 ± 42 450 ± 74 0.008 424 ± 49 487 ± 88 0.03 
   QTc, ms 423 ± 35 472 ± 60 <0.001 448 ± 37 505 ± 71 0.006 
   QTcmax, ms 459 ± 46 523 ± 69 <0.001 499 ± 46 557 ± 83 0.043 
Echocardiography       
   LVEF, % 60 ± 6 62 ± 5 0.11 62 ± 5 61 ± 5 0.39 
   RVEDD, mm 34 ± 6 34 ± 4 0.71 33 ± 8 35 ± 4 0.60 
   QAoC, ms 420 ± 31 400 ± 32 0.029 399 ± 25 402 ± 42 0.68 
   RR, ms 957 ± 171 900 ± 123 0.14 897 ± 110 906 ± 146 0.84 
   QT, ms 386 ± 38 428 ± 54 0.001 410 ± 28 456 ± 72 0.037 
   EMW, ms 34 ± 26 -29 ± 47 <0.001 -11 ± 26 -56 ± 60 0.008 
 
For continuous traits, mean differences were tested using the Mann-Whitney U test. Differences in prevalence 
of dichotomous traits were compared using Fisher’s exact test. Four phenotypes were missing due to SCD. 
LQTS = long-QT syndrome; CCD = cardiac conduction disease; LVEF = left-ventricular ejection fraction; RVEDD = 
right-ventricular end-diastolic diameter; QAoC = time interval between onset QRS and aortic-valve closure; 
EMW = electromechanical window.  
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Figure 5.4 QTc/RR and PQ/QRS relationships of SCN5A-p.(Phe1617del) carries and non-carriers. Upper limits of 
normal values are indicated by the dotted lines. 
 
Phe1617del positives with previous cardiac events exhibited a significantly longer QTc and 
were more often female compared to event-free carriers (QTc 505 ± 71 versus 448 ± 37 ms, 
P=0.006; female gender 76 versus 33%, P=0.007). On echocardiography, QAoCs were 
significantly shorter (∆μ=20 ms, P=0.028) despite (simultaneously measured) longer QT 
intervals, causing more pronounced EMW negativity in mutation positives (Table 5.1; ∆μ=-
63 ms). Symptomatic cases had more negative EMWs compared to asymptomatic 
individuals, -56 ± 60 versus -11 ± 26 ms, P=0.008.331 SCN5A-p.(Phe1617del) carriers 
frequently exhibited broad-based T-wave inversion or bifid T waves (Figure 5.3), unlike 
“classic” LQT3 repolarization patterns. Interestingly, two Phe1617del-negative individuals 
also exhibited long QT intervals (Figure 5.5 and Figure 7.9); mutations in known arrhythmia 
genes were excluded in them.  
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Figure 5.5 ECG of SCN5A-p.(Phe1617del)-negative individual with a long QT interval. 
 
Whereas baseline PQ and QRS intervals generally remained within normal limits (Figure 
5.4), transient atrioventricular conduction delay was observed in ten Phe1617del positives, 
second degree atrioventricular block in three, left-bundle branch block in three, and right-
bundle branch block in one. A few mutation negatives demonstrated mild forms of CCD. 
Unique to the Phe1617del-positive cohort, spontaneous coved-type ST-segment elevation 
fitting with Brugada syndrome (n=1; Figure 5.3) and ajmaline-provoked type-1 Brugada-ECG 
pattern were observed (n=4; for example Figure 5.6).  
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Figure 5.6 Ajmaline provocation testing. Left, SCN5A-p.(Phe1617del) heterozygous individual. Right, the 
p.(Phe1617del) homozygous patient. 
 
A novel phenotype, isorhythmic atrioventricular dissociation, was present in 9/45 mutation 
carriers, but absent in non-carrying relatives (Figures 5.3 and 5.7; PFisher’s=0.010). It occurred 
in three out of seven family subgroups mainly at night, between 9 PM and 10 AM, at a mean 
sinus/atrial rate of 41 ± 7 bpm. Besides episodic sinus and atrial bradycardia, no distinct 
atrial electropathology (such as atrial standstill or atrial fibrillation) was observed. SCN5A-
related dilated cardiomyopathy was not seen.  
 The Venn diagram (Figure 5.7) demonstrates that most Phe1617del carriers, notably 
those with LQTS, exhibited overlap with other phenotypes, namely CCD, Brugada syndrome 
and/or isorhythmic atrioventricular dissociation (n=19). In eight Phe1617del-positive 
individuals we could not discern any cardiac abnormalities, despite thorough phenotyping, 
including ajmaline provocation testing.  
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Figure 5.7 Venn diagram illustrating cardiac phenotypes and their overlap in the presence or absence of 
SCN5A-p.(Phe1617del). In both panels, some numbers are missing, because of incomplete cardiac recordings. 
LQTS = long-QT syndrome. 
VENTRICULAR ARRHYTHMOGENESIS 
In the last four decades, 47% of the Phe1617del positives experienced cardiac events (OR 
[95% C.I.]=3.8 [1.1-15.1]; P=0.022), including syncope in nine, non-sustained VT in three, 
polymorphic VT/VF in six (Figure 5.1, asterisks), and SCD without arrhythmia documentation 
in three. Five ungenotyped first-degree relatives of Phe1617del positives died suddenly. The 
mean age at which SCD or VT/VF occurred first was 50 ± 10 years. ICD recordings of VT/VF in 
three patients, all females, are depicted in Figure 5.8.  
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Figure 5.8 ICD recordings of polymorphic ventricular tachycardia in three females. Top, spontaneous recovery. 
Middle, cardioversion by antitachycardia pacing (ATP). Bottom, cardioversion by shock therapy. Time (h:min) 
indicates VT/VF occurrence. Squares = AA intervals; circles = VV intervals; VT = ventricular tachycardia; VF = 
ventricular fibrillation. 
 
VT/VF episodes required internal/external cardioversion (lower panel), i.v. magnesium and 
isoproterenol,322 antitachycardia pacing (middle), or recovered spontaneously (upper 
panel). Beta-Blocker treatment and high-rate atrial pacing did not prevent VT/VF in two 
patients. Ranolazine, however, reduced ventricular ectopy substantially. These life-
threatening arrhythmias were found to occur only during daytime, between 9 AM and 9 PM, 
in line with the daytime occurrence of SCD in other confirmed or obligatory Phe1617del 
positives in this population. Proarrhythmic triggers included auditory stimuli (phone ringing; 
Figure 5.8), strong emotions, exercise (skiing), a period of excessive dieting (lower panel), 
and events in early postoperative and postpartum periods. VT occurred rarely during rest or 
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sleep. Often, sinus-rate acceleration with concomitant repolarization prolongation preceded 
premature ventricular complexes and polymorphic VT, as exemplified in Figure 5.8. TdP-like 
VT typically initiated after short-long-short RR intervals or could be non-pause-dependent.  
 We found a 15:1 female-to-male ratio of cardiac events (P=0.007) despite a similar mean 
QTc and EMW for both sexes (QTc: 470 ± 55 versus 474 ± 66 ms, P=0.83; EMW: -20 ± 43 and 
-36 ± 52 ms, P=0.31). Figure 5.9 shows survival curves estimated using Cox proportional 
hazards models for event-free survival adjusted for gender, LQTS, EMW negativity (<-62 
ms331), and beta-blocker therapy. The survival curves are conditional based on the 
covariates. Hazard ratios indicated an independently increased risk for females (HR [95% 
C.I.]=5.1 [1.6-16.3]; P=0.006) and for individuals with substantial EMW negativity (HR [95% 
C.I.]=4.3 [1.2-15.6]; P=0.024). Testing of the Schoenfeld residuals demonstrated that the 
proportionality assumption held (P=0.42). EMW negativity enabled risk stratification in male 
(P=0.004), but not in female Phe1617del carriers (P=0.15). 
 
 
 
Figure 5.9 Cox proportional hazards curves for event-free survival adjusted for beta-blocker therapy, gender, 
EMW (< or > -62 ms), and LQTS; stratified by gender and EMW negativity. EMW = electromechanical window. 
 
PHE1617DEL-RELATED EFFECTS AND RESIDUAL HERITABILITY 
Analyses conducted in SOLAR, to properly account for the pedigree structure, recapitulated 
the strength of the associations between p.(Phe1617del) and QTcbaseline, QTcmax, and EMW 
(Table 5.2). Effect sizes were large, on the order of magnitude of one standard deviation for 
QTcbaseline (β (SE) = 0.91 (0.23)), QTcmax (1.11 (0.22)), and EMW (-1.26 (0.19)), explaining 18%, 
28% and 37% of the trait’s variance, respectively. These estimates corresponded well with 
the observed mean differences. Nominal associations were seen for QRS, QT, and QAoC.  
 Heritability estimates for baseline PQ interval (h2 (SE) = 0.68 (0.25); P=0.003) showed that 
additive genetic effects accounted for a substantial proportion of PQ variation, independent 
of p.(Phe1617del). Nominally significant heritabilities were observed for PQmax (h2 (SE) = 
0.57 (0.27)), QTmax (0.43 (0.27)), and EMW (0.79 (0.29)).  
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Table 5.2 Residual heritabilities and effects of SCN5A-p.(Phe1617del) 
 
   SCN5A 
 h2 (SE) P value β (SE) P value 
ECG     
    PQ  0.68 (0.25) 0.003 -0.01 (0.24) 0.98 
    PQmax 0.57 (0.27) 0.010 0.47 (0.25) 0.056 
    RR  0.00 (NE) 0.50 -0.17 (0.27) 0.53 
    QRS  0.19 (0.23) 0.17 -0.52 (0.25) 0.040 
    QT  0.43 (0.27) 0.049 0.56 (0.24) 0.021 
    QTc  0.23 (0.37) 0.28 0.91 (0.23) <0.001 
    QTcmax 0.35 (0.63) 0.36 1.11 (0.22) <0.001 
Echocardiography     
    LVEF 0.59 (0.37) 0.19 0.28 (0.26) 0.27 
    RVEDD 0.08 (0.19) 0.31 0.09 (0.27) 0.75 
    QAoC  0.00 (NE) 0.50 -0.51 (0.25) 0.039 
    QT  0.55 (0.43) 0.10 0.94 (0.23) <0.001 
    EMW 0.79 (0.29) 0.020 -1.26 (0.19) <0.001 
 
A variance component approach as implemented in SOLAR was used. β = effect size in standard deviations for 
SCN5A-p.(Phe1617del) carriership; h2 = narrow-sense heritability; NE = not estimable; SE = standard error; 
other abbreviations as in Table 5.1. 
 
The additional inclusion of SCN5A-p.(His558Arg), rs1805124, did not significantly alter the 
results and provided no evidence of an independent effect on any of the traits studied (all 
P>0.10), with the possible exception of PQmax (P=0.064). Although the p.(His558Arg) 
polymorphism was in Hardy-Weinberg proportions in Phe1617del-negative family members 
(P=0.10), there was a significant enrichment for the R allele in mutant carriers compared to 
the EUR samples from the 1000 Genomes Project Phase 3 (35 versus 22%; PFisher’s<0.001). 
DISCUSSION 
UNIQUE FOUNDER POPULATION 
This SCN5A-p.(Phe1617del) founder population exhibited divergent and overlapping cardiac 
phenotypes, including LQTS, CCD, Brugada syndrome, and isorhythmic atrioventricular 
dissociation. Female carriers had a dominant susceptibility to ventricular arrhythmia and 
SCD, despite a similar QTc as males. Large p.(Phe1617del) effect sizes were found for QTc 
prolongation and EMW negativity. After accounting for the effects of the SCN5A deletion 
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mutation, significant heritability was identified for PQ interval, indicating the influence of 
additional genetic factor(s) on atrioventricular conduction. 
PHENOTYPIC VARIABILITY IN CARDIAC SODIUM CHANNELOPATHIES 
Since the first localization of the SCN5A locus to chromosome 3q21-24 and the description 
of the SCN5A mutation p.(KPQ1505-1507del) in 1995,44 multiple pathogenic SCN5A 
mutations have been implicated in LQT3, Brugada syndrome, idiopathic VF, CCD, sinus-node 
dysfunction, atrial fibrillation, and dilated cardiomyopathy.360 In the present study, LQTS was 
the most prevalent phenotype of Phe1617del-positive individuals and possibly the result of 
an INa gain-of-function defect. Phenotypes reminiscent of INa loss-of-function, such as 
Brugada syndrome and CCD, were also present but less prominent. Previous patch-clamp 
experiments of Phe1617del-transfected HEK cells demonstrated a 7.0 mV-negative shift of 
the steady-state channel availability and impaired recovery from inactivation, contributing 
to a reduced peak INa density.361 Those investigators found an increased late/peak INa ratio 
at positive command potentials, suggesting gain-of-function for part of the INa I-V curve. The 
presence of phenotypic divergence and phenotype-positive genotype-negative individuals 
alludes to the contribution of additional genetic variants. Furthermore, SCN5A-
p.(Phe1617del) was identified in two individuals of different ethnicity (gnomAD database), 
who had LQTS and syncope without LQTS/Brugada syndrome characteristics. SOLAR analysis 
revealed a large effect of the mutation on repolarization prolongation, which is underscored 
by the segregation pattern. Combined, these results indicate that a definitive or monogenic 
causality cannot be assumed, and this has instigated subsequent studies into the area of 
complex genetics.  
VARIANCE COMPONENT ANALYSIS AND HERITABILITY BEYOND SCN5A-P.(PHE1617DEL) 
Although the presence of SCN5A-p.(Phe1617del) associated strongly with QTc, QAoC, and 
EMW, we did find evidence of other genetic influences on PQ interval, and possibly QT and 
EMW. PQ heritability (0.68) was higher than in a general population family-based study 
(0.40) in The Netherlands,26 indicating strong genetic control in our pedigree. The SCN5A 
polymorphism p.(His558Arg) present in ~22% of EUR samples from the 1000 Genomes 
Project (http://www.internationalgenome.org), was significantly enriched in this population, 
35%. Variance component analysis incorporating p.(His558Arg) provided no evidence of an 
independent effect on any of the traits investigated, although enrichment for the p.(Arg558) 
allele supported the notion of population isolate effects, particularly founder effects and 
genetic drift. Functional variants in other genes or regulatory elements on chromosome 3, 
such as SCN10A,362 could also modulate regional SCN5A expression. Moreover, genetic 
modifiers on different chromosomes may be important. These aspects will be investigated in 
downstream high-density single nucleotide polymorphism genotyping and/or exome 
sequencing (Figure 5.10).  
SCN5A FOUNDER POPULATION  
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Figure 5.10 In-depth cardiac phenotyping coupled with variance component analysis explains 
electromechanical trait variation. The proportion of mutant and additional genetic variant (narrow-sense 
heritability)-imposed trait variation is estimated using SOLAR. As a perspective, subsequent studies will 
encompass linkage analysis and next-generation sequencing. Boxes/circles = males/females; open/filled = 
Phe1617del negatives/positives; BrS = Brugada syndrome; CCD = cardiac conduction disease; LQTS = long-QT 
syndrome; SD = standard deviation. 
ARRHYTHMIA SUSCEPTIBILITY AND FEMALE PREPONDERANCE 
Contrary to previously reported SCN5A-related arrhythmia features,360 we mainly observed 
stress-related, non-nocturnal VT/VF provoking cardiac arrest/SCD in our SCN5A-
p.(Phe1617del) population. Stress- and arousal-evoked heart-rate acceleration and 
repolarization prolongation often preceded the life-threatening arrhythmias. These patterns 
suggest a proarrhythmic role for enhanced sympathetic activity to fuel electrical instability, 
which is uncommon for sodium channelopathies. Secondly, unlike reported sex-specific risk 
patterns,60, 363 we found that women with SCN5A-p.(Phe1617del) experienced major cardiac 
events more frequently than men. Fifty percent had (one or more) syncope or VT/VF/SCD 
before the age of 45. This female arrhythmia susceptibility may be evoked by altered 
myocardial ion-channel expression through the modulation by (non)gonadal hormones.364 
Also, gene-gender interaction may play a role. 
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CONCLUSION 
This unique SCN5A-p.(Phe1617del) founder population with phenotypic heterogeneity and 
overlap syndrome reveals a large impact of p.(Phe1617del) on QTc, QAoC, and EMW. SCD and 
polymorphic VT/VF occur predominantly in females, during daytime, and often after arousal-
evoked heart-rate acceleration and repolarization prolongation. This suggests sympathetic 
arrhythmia triggering, unlike what is known for other sodium channelopathies. Substantial 
genetic variance for PQ (and possibly QT) after accounting for p.(Phe1617del) may contribute 
to the phenotypic diversity. Our approach of synergizing in-depth cardiac phenotyping with 
statistical genetics reveals crucial information on the electromechanical traits of this 
population and paves the way for linkage analysis and exome sequencing to pinpoint genetic 
variants associated with the arrhythmia syndrome.  
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EDITORIAL 
 
FOUNDER POPULATIONS WITH CHANNELOPATHIES AND CHURCH 
RECORDS REVEAL ALL SORTS OF INTERESTING SECRETS:  
SOME ARE SCIENTIFICALLY RELEVANT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peter J. Schwartz and Lia Crotti 
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For those interested in channelopathies, and especially in the long QT syndrome, the simple 
and happy times of “ignorance bliss” are over. Things are getting more complex any day. If 
Thom James had been right, LQTS would be classified among infectious diseases. Genetics 
have changed everything, and one must admit, to try to understand what is going on has 
become a more stimulating and intellectually rewarding game, besides enabling a better 
and personalized management to patients.321 
 A quick look backward sometimes helps put things in the proper context. We started 
with 3 genes, which, when mutated, would cause LQTS, but soon we found that if mutations 
on these same genes increased instead of reducing function, one would have short instead 
of long QT syndrome.216 As to the cardiac sodium channel gene SCN5A, stormy weather 
started in the morning hours. First, it appeared that if the mutation instead of being a gain 
of function was a loss of function, then we would have had Brugada syndrome (BrS).62 It was 
just the beginning of trouble. We then learned that many variants on SCN5A were just 
either common or of uncertain significance (the dreadful variant of uncertain significance—
a nightmare for anyone who must make a clinical decision based on their presence) and 
furthermore that mutations on SCN5A could associate with other diseases such as cardiac 
conduction disease (CCD), sick sinus syndrome, and others. Worst of all was the peace-
shattering discovery made by Bezzina et al:365 that even the same SCN5A mutation could 
produce different cardiac disorders. Unfortunately, their finding did not remain isolated and 
we now face several SCN5A mutations having all divergent effects.366 Among them are 
1759insD,365 G1406R,366 delK1500,366 E161K,366 E1784K.367 Indeed, the discovery of these so-
called overlap syndromes has brought our confusion to the zenith. 
 How can a single mutation on SCN5A produce either a gain-of-function phenotype (LQTS) 
or multiple phenotypes associated with a loss of function (BrS, CCD, and sick sinus 
syndrome)? In vitro functional studies suggested that this could be explained by the 
coexistence of a steady-state Na+ channel inactivation and a propensity to enhanced tonic 
block by class IC drugs.367 Studies in mice carrying the equivalent mutation of human SCN5A-
1795insD proved that the presence of a single mutation is indeed sufficient to cause an 
overlap syndrome368 and that the genetic background plays a role.369 Indeed, if this 
mutation is inserted in 2 distinct mouse strains, the phenotype is different.369 Nonetheless, 
why a single patient develops one or another phenotype remains unclear. 
 In this issue of Heart Rhythm, ter Bekke et al370 present a 16-generation family with a 
founder effect, in which the SCN5A-Phe1617del mutation is associated with overlapping 
cardiac phenotypes including LQTS, CCD, BrS, and isorhythmic atrioventricular dissociation. 
The authors should be congratulated on their painstaking search for the origin of this family. 
They identified 2 ancestral couples who lived in the 16th century in proximity to a small 
river, appropriately called Worm river, which runs between the Netherlands and Germany. 
Mostly through church records they identified a very large number of family members. The 
clinical manifestations in this family differ from those of most families with SCN5A 
mutations described previously. Indeed, polymorphic ventricular tachyarrhythmias occurred 
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mostly at daytime; proarrhythmic triggers included auditory stimuli, strong emotions, 
exercise, and postpartum periods; and female sex was an independent risk factor for cardiac 
events (hazard ratio 5.1; 95% confidence interval 1.6–16.3). Furthermore, T-wave 
morphology exhibited broad-based T-wave inversion or bifid T waves. Therefore, all LQTS-
related clinical manifestations appear, without an explanation, more typical for a LQTS type 
2 phenotype than for a LQTS type 3 phenotype.151 Equally puzzling are 11 subjects with a 
LQTS and/or a CCD phenotype but without the SCN5A-Phe1617del mutation. A second 
mutation in the family would have been an explanation, but was excluded because the 
authors screened all other known LQTS genes. Two possible but unlikely possibilities are 
that common screening tools are unable to detect large insertions and deletions, a rare 
cause of LQTS,371 and that some intronic variants located outside the canonical donor and 
acceptor splice sites may not be immediately recognized as a cause of aberrant isoform 
expression and trafficking defect.372, 373 The atypical phenotypic features of this founder 
population match the variable expressivity already observed in other overlap families with 
SCN5A mutations, which probably reflects a combination of genetic, epigenetic, and 
environmental factors. Understanding the composition of this mysterious cocktail could 
help predict the individual risk associated with a given disease-causing mutation. 
 Ter Bekke, Volders, and their associates have an additional merit: to have provided 1 
more piece of evidence for the gnostic value of founder populations. Founder populations 
are characterized by a single ancestor affected by the disease under study and by a large 
number of individuals and families, all related to the ancestor and carrying the same 
disease-causing mutation. They represent the ideal human model for the identification of 
“modifier genes”.374 And, indeed, the initial identification of genetic variants capable of 
modifying the risk of life-threatening arrhythmias83 was made possible by the availability of 
a well-characterized LQTS South African founder population.375, 376 As well confirmed by ter 
Bekke’s study, the identification of founder populations requires a significant effort and the 
inborn gift of a special “hunting instinct”,16 but the rewards may be large. 
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“Vaak moet er iets gebeuren om in te zien wat echt belangrijk is,  
wacht niet tot het te laat is: begin nu met leven!”  
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BEAUTY AND THE BEAT: 
A COMPLICATED CASE OF MULTIFOCAL ECTOPIC 
PURKINJE-RELATED PREMATURE CONTRACTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manuscript accepted in Heart Rhythm Case Reports, 2018  
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CASE PRESENTATION 
A 24-year-old female of Polish descent presented at the emergency department with 
exertional syncope that had occurred during housekeeping. Her unconsciousness struck 
without prior palpitations, chest discomfort or light-headedness. She regained full 
consciousness after several seconds, without confusion or amnesia. She had no tongue 
bite or incontinence. In the days before, no diarrhea, vomiting or febrile events had 
occurred. Her medical history was unremarkable. She did not take medication and denied 
the use of recreational drugs. 
 
Exertional syncope without prodromi in young adults should raise the suspicion of 
ventricular arrhythmias with sympathetic susceptibility, such as in long-QT syndrome, 
catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic (right-ventricular) 
cardiomyopathy, and Gallavardin’s VT. Structural heart diseases that may be considered are 
obstructive hypertrophic cardiomyopathy, severe aortic valve stenosis, premature coronary 
artery stenosis or spasm, and coronary artery anomalies. Epileptic seizures can manifest 
without generalized convulsions, but often cause aura, tongue injury, and involuntary loss of 
bladder/bowel control. It is important to obtain a detailed family history on the occurrence 
of unexplained sudden (infant) death or cardiac arrest and other cardiac abnormalities, as 
this may allude to the presence of inherited arrhythmia syndromes.  
 
The patient was a slender woman with a normal blood pressure. She smoked and was not 
active in sports. There was no hypercholesterolemia or diabetes mellitus. Over a period of 
months, she had experienced progressive fatigue with slight exertional dyspnea and 
sporadic light-headedness. Mother and a maternal aunt were known with frequent 
premature ventricular complexes of left-fascicular origin, a normal QTc, mild ventricular 
dilatation (mother) and impaired left-ventricular function (maternal aunt) since 
adolescence. Mother’s twin sister and brother died postnatally after full-term gestation. 
The maternal grandmother died suddenly at age 33.  
 
The family history of sudden death and ventricular arrhythmia may indicate an inherited 
arrhythmia syndrome or structural cardiomyopathy. The suspicion of premature coronary 
artery disease with ischemia is low, as her cardiovascular risk profile appears small. 
Coronary artery anomalies usually do not show familial clustering. Coronary spasm cannot 
yet be excluded.  
 
Physical examination revealed a blood pressure of 120/70 mm Hg with an irregular heart 
rate of 114 beats per minute and a body temperature of 36.0°C (96.8°F). Breathing rate 
and oxygen saturation were normal. Body height was 180 cm and weight 68 kg. The ictus 
cordis was displaced laterally with a grade 2/6 blowing holosystolic murmur at the apex, 
and a third heart sound. Her jugular venous pressure was not elevated. Pulmonary and 
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abdominal investigations were normal. The extremities were warm with intact pulses and 
without ankle edema. Besides elevated NT-proBNP levels, 266 pmol/L, extensive 
laboratory testing revealed no abnormalities. The patient’s 12-lead electrocardiogram 
showed sinus rhythm with frequent multiform PVCs and non-sustained VTs, with swift 
intrinsicoid deflections (Figure 6.1) and left- or right-bundle branch block-like 
morphologies. Ventricular ectopy increased upon emotional distress and excitement, and 
reached a daily burden of 25,000 (~17%). PQ and QT intervals were normal. The QRS 
amplitudes and inferolateral T-wave abnormalities fulfilled the criteria of LV hypertrophy: 
S V1 + R V5/V6 ≥35 mm (Sokolow-Lyon), and R V5/V6 ≥30 mm with typical ST-T wave 
changes (Romhilt-Estes).  
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Figure 6.1 12-Lead electrocardiogram on admission showing ventricular ectopy and non-sustained ventricular 
tachycardia.  
 
Patient’s physical and electrocardiographic findings suggest a sympathetically-driven 
primary electrical disorder or a proarrhythmic structural cardiomyopathy with signs of LV 
hypertrophy and reduced systolic function. Catecholaminergic polymorphic VT may be 
considered, but this is typically associated with preserved cardiac contractility. The 
morphology of the dominant PVCs is reminiscent of left-fascicular and/or Purkinje-related 
foci, which is not typical for arrhythmogenic (right ventricular) cardiomyopathy or 
Gallavardin’s VT. A normal QT duration does not rule out long-QT syndrome, but this is an 
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unlikely cause of the abundant ventricular ectopy observed. For subsequent diagnostic 
evaluation an echocardiogram would be appropriate.  
 
 
 
Figure 6.2 Dilated left-ventricular cardiomyopathy and mitral regurgitation on echocardiogram (A), without 
apparent myocardial fibrosis (delayed-enhancement magnetic resonance imaging) on short-axis (B), 4-
chamber (C) and 2-chamber views (D). 
 
On echocardiography, the LV was dilated (end-diastolic diameter 64 mm, end-systolic 
diameter 56 mm) and its ejection fraction (LVEF) reduced, 23%. A secondary grade B 
mitral regurgitation was found (Figure 6.2). No signs of active myocarditis, significant 
fibrosis, storage or infiltrative diseases were observed with cardiac magnetic resonance 
imaging and in right-ventricular septal endomyocardial biopsies. Coronary angiography 
was normal without aberrant coronary artery originations. Additional laboratory testing, 
including viral serology, autoimmune markers, thyroid function, iron status, 
corticosteroids, soluble IL-2 receptor, and urinary metanefrine concentrations remained 
unremarkable. During invasive electrophysiological study, intracardiac conduction times 
were normal, and no VT could be induced by programmed electrical stimulation. 
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Spontaneous PVCs were often preceded by high-frequency potentials in the ventricle, 
suggesting ectopic sites in the fascicular-Purkinje system. No ablation was attempted 
owing to the multifocality of the PVCs.  
The combination of multifocal fascicular-Purkinje-related ectopy, nonsustained VT, and 
dilated cardiomyopathy without identifiable structural substrate suggests irregulopathy as 
the cause of heart failure. Along with the autosomal dominant pattern of arrhythmic 
disease in the family, these features imply a genetic origin, warranting molecular-genetic 
analysis. 
 
With informed consent of the patient, genomic DNA was extracted and screened for gene 
mutations associated with inherited arrhythmia and/or cardiomyopathy. Meanwhile, 
several antiarrhythmic drugs proved inefficacious: metoprolol, carvedilol, labetalol, and 
lidocaine. Amiodarone administration successfully suppressed all ectopic activity, albeit at 
the expense of substantial QT prolongation (~730 ms; Figure 6.3A). Alas, recurrent 
episodes of torsades de pointes ((N-desethyl)amiodarone plasma level (0.4) 1.0 mg/L; 
Figure 6.3B) emerged after 9 days requiring immediate discontinuation of the drug; this 
normalized the QT interval within a week. Ventricular ectopy recurred and an ICD was 
inserted. Symptomatic hypotension and quinapril-induced angioedema hindered 
maintenance therapy with renin-angiotensin-aldosterone system blockers. 
 
 
 
 
Figure 6.3 Electrocardiograms at 48 hours (A) and 9 days (B) after initiation of amiodarone showing 
repolarization prolongation and pause-dependent onset of torsades de pointes.  
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Amiodarone has class I, II, III, and IV antiarrhythmic properties according to the Vaughan-
Williams classification and can be beneficially used in heart-failure patients. The incidence of 
amiodarone-induced proarrhythmia is low (0.7%), despite concomitant QT prolongation.377 
Patient’s TdP likely resulted from ventricular ectopics impacting on a substrate of 
amiodarone-exaggerated dispersion of repolarization in the setting of reduced 
repolarization reserve. 
 
DNA analysis revealed allelic variation in the SCN5A gene (c.2482C>T, p.(Leu828Phe)), 
KCNE1 gene (c.253G>A, p.(Asp85Asn)), and DES gene (c.638C>T, p.(Ala213Val)). In 36 
other cardiomyopathy- and arrhythmia-associated genes variations were excluded. 
Patient’s mother harbored the SCN5A and DES variant. 
 
Although at this point the effects of the novel SCN5A variant on the sodium current are 
unclear, these features are reminiscent of a SCN5A channelopathy coined “multifocal 
ectopic Purkinje-related premature contractions (MEPPC)”.130 In the first report of MEPPC 
the SCN5A mutation p.(Arg222Gln) was described, which caused hyperexcitability of 
Purkinje fibers and was associated with cardiac dilatation. In our case, dilated 
cardiomyopathy could have been exaggerated by the rare polymorphism in DES. According 
to the MOGES classification the patient would be classified as MD-PVCOHGADEG-SCN5A 
p.(Leu828Phe)+DES p.(Ala213Val)S(C-II).378 Heart-failure induced electrical remodeling in combination 
with reduced potassium current by likely-pathogenic KCNE1-p.(Asp85Asn) led to a 
diminished repolarization reserve.74 Amiodarone-induced proarrhythmia coincided with the 
time-dependent inhibition of the slowly-activating delayed rectifier potassium current.177  
 
The class-3 missense mutation SCN5A-p.(Leu828Phe) affected the highly-conserved 
leucine residue at domain II (S4-S5) of the cardiac sodium channel, juxtaposed to the 
voltage-sensing domain and was absent in the ExAC, gnomAD and ClinVar databases. We 
characterized SCN5A-p.(Leu828Phe) in transiently transfected Chinese hamster ovary cells 
(Figure 6.4). Heterozygous mutant INa showed similar amplitudes as wild-type INa, but with 
a significant leftward shift of the voltage dependence of activation. Because steady-state 
voltage-dependent inactivation remained unaltered, window INa increased, creating a 
broad voltage range of open-channel probability (between -80 and -50 mV), and a wide 
substrate for open and inactivated-state block by flecainide (10 µmol/L), reflected by 
increased tonic and blunted use-dependent SCN5A-p.(Leu828Phe) INa inhibition. 
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Figure 6.4 Functional characteristics of SCN5A-p.(Leu828Phe). (A) Current-voltage relationship normalized for 
cell capacitance in wild-type (WT), heterozygous (Het) and homozygous (Hom) mutant expression; beta 
subunits were not co-expressed. (B) Voltage-dependent steady-state (in)activation and enlarged window INa. 
(C) Tonic Leu828PheHet block at first test pulse (-20 mV). (D) Reduced Leu828PheHet current recovery from 
flecainide block. 
 
The functional consequences of SCN5A-p.(Leu828Phe) resemble those of the p.(Arg222Gln) 
variant.130 Flecainide’s preferential block of p.(Leu828Phe)-mutant INa at short recovery 
intervals, and at clinically-relevant concentrations, suggests beneficial treatment of the 
patient with a class-I antiarrhythmic agent. Screening for adverse class-I side effects is 
advisable. 
 
Short-acting sodium-channel inhibition with intravenous ajmaline (1 mg/kg in 10 minutes) 
almost completely suppressed PVCs without Brugada type-1 ECG abnormalities, QT 
prolongation, or other proarrhythmic characteristics. Oral maintenance therapy with 
flecainide (100 mg, twice daily) was successfully started thereafter. Vigilant monitoring of 
the patient revealed very low PVC counts and complete LV-function recovery within 
months. Now, nine years later, the patient is doing well and has not received ICD therapy. 
LVEF is 53%. 
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COMMENTARY 
Our translational approach with combined clinical, genetic and cellular investigations 
identified the Achilles’ heel of the disease of this patient, and it led to personalized therapy. 
Two important lessons were learned: 1) frequent multifocal fascicular-Purkinje-related PVCs 
with or without dilated cardiomyopathy should raise the suspicion of SCN5A channelopathy; 
2) amiodarone-associated excessive QT prolongation and TdP should prompt genotyping of 
the patient.379 
 Sporadic PVCs are common in the general population, affecting about 39% of people (in 
4% >100/day).380 They carry a favorable prognosis if occurring in the structurally normal 
heart. The risk of developing cardiomyopathy depends on the PVC burden (≥16-24%)381, 382 
and dyssynchronous myocardial activation, as is the case with wide PVC-QRS durations 
and/or epicardial foci,383 irrespective of a LV or right-ventricular origin. Multifocal PVCs 
originating in the conduction system often have narrow QRS widths and may be associated 
with familial sudden death (this study and 130). 
 MEPPC syndrome was first described in 2012 in three unrelated families segregating 
SCN5A-p.(Arg222Gln).130 Patients can present with irregular palpitations with light-
headedness, syncopal attacks, or sudden death (21% of affected family members, at mean 
age of 32 years).130 Symptoms of congestive cardiomyopathy can be present. The age at 
diagnosis varies from 24 weeks of gestation to 62 years (mean age 20 years) without gender 
predisposition.130 Multifocal PVCs occur in isolation, doublets, or non-sustained VT. 
Contractile dysfunction can accompany this syndrome.130, 384, 385 Differential diagnoses to be 
considered are ischemic cardiomyopathy, viral myocarditis, digitalis intoxication, genetic 
cardiomyopathies such as laminopathy, and primary arrhythmia syndromes like 
catecholaminergic polymorphic VT, and short-coupled PVCs and TdP.125  
 An erratic pattern of abundant junctional ectopics and PVCs with left- and right-bundle 
branch block-like morphologies but with sharp intrinsicoid deflections is characteristic and 
suggests an origin in the conduction system. Atrioventricular-node physiology and 
ventricular repolarization are unaffected. Although the echocardiographic features of LV 
dilatation and contractile dysfunction are non-specific, their co-occurrence with multilevel 
hyperexcitability should raise the suspicion of MEPPC syndrome. Typically, no signs of 
myocardial inflammation or fibrosis are found on cardiac magnetic resonance imaging. 
 DNA sequencing of the SCN5A gene hitherto identified two mutations associated with 
MEPPC: p.(Arg222Gln)130 and p.(Arg225Pro).385 These mutations reside in homologous 
positions of the voltage-sensor region (S4 segment, domain I) of the cardiac sodium 
channel. Our novel mutation p.(Leu828Phe) also lies close to the S4 segment of SCN5A 
domain II. Common to all three SCN5A mutations is the leftward shift of voltage-dependent 
activation with resultant triggering of inward INa at more negative resting membrane 
potentials. This can facilitate PVCs in fascicular and Purkinje fibers in which INa channels are 
more abundantly expressed compared to ventricular myocytes, and as is predicted by in-
silico analysis.130  
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 Sodium-channel blockade is the preferred therapy of this SCN5A disease to reduce the 
PVC burden. Besides flecainide, quinidine or amiodarone can be considered, but the latter 
can turn adverse in cases with an inherently reduced repolarization reserve. In our patient, 
the KCNE1-p.(Asp85Asn)74 with known effect on repolarizaing potassium currents IKs and IKr 
likely facilitated drug-induced repolarization prolongation and TdP.73 Proarrhythmic side-
effects of flecainide386 will be avoided by careful characterization (including class-I 
provocation testing) and on-treatment monitoring of the patient. Long-term outcome is 
beneficial if antiarrhythmic treatment suppresses the PVCs that cause the irregulopathy, 
thus enabling the recovery of LV function. Indeed, the recovery of dilated cardiomyopathy 
and reduced LVEF in our patients indicates an important pathogenic role of SCN5A-related 
irregulopathy. Besides, a disease-modifying effect of the DES variant in accompanying the 
SCN5A mutation cannot be excluded.387 
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Until recently, investigators focused mainly on purely electrical mechanisms to examine the 
arrhythmogenic consequences of cardiogenetic defects, with a prominent role for 
spatiotemporal dispersion of repolarization, afterdepolarizations, and reentrant 
excitation.111 In this thesis, additional non-electrical parameters contributing to the onset of 
life-threatening ventricular tachyarrhythmias are put forward. 
ARRHYTHMOGENIC MECHANO-ELECTRIC HETEROGENEITY 
In the intact heart, there is a tight link between electrical and mechanical functions to 
ensure electrical stability and adequate contractile performance. Under normal conditions, 
cardiac excitation-contraction coupling is followed by myocardial relaxation, which 
terminates within tens of milliseconds after the completion of repolarization. In other 
words, the ventricular electrical systole (represented by the QT interval on the ECG) 
terminates before the completion of contractile relaxation (invasive correlate: QLVPend; 
noninvasive: QAoC or QS2), thus creating a positive electromechanical window (in ms; Figure 
7.1). In normal subjects, we found an EMW of +22 ± 19 ms (QAoC minus QT).331  
 
 
Figure 7.1 Invasive measurement of the EMW in a normal subject undergoing diagnostic electrophysiological 
testing for symptomatic multiform PVCs. Here, the time difference between QT and QLVP90 creates a positive 
EMW of 83 ms. Of note, noninvasive measurement of the EMW using the QAoC would give a less positive 
result.  
 
In the case of genetic syndromes with pathologic ventricular repolarization prolongation 
(i.e., the long-QT syndromes), QT exceeds QAoC, which renders the EMW negative 
( ,  and  of this thesis, and refs322, 331, 370). An obvious question would be: does Chapters 2 3 4
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EMW negativity itself contribute to electrical instability?332 In order to find an answer, it is 
important to remember that the heart is not only an electrically-driven mechanical pump, 
but also an organ that can transform mechanical stimuli into electrical signals (i.e., 
mechano-electric feedback), with the general aim of maintaining beat-to-beat 
electromechanical homeostasis. In healthy hearts with normal electromechanical coupling, 
the majority of diastole is occupied by the passive and active filling of the ventricles, whilst 
maintaining low pressures (Figure 7.2, left panel). Electrically, this phase is paralleled by a 
large part of phase 4 of the ventricular AP and (on the ECG) the isoelectric segment between 
the T wave and the subsequent QRS complex, including the P wave. Electrical depolarization 
(Q/R onset on ECG) initiates ventricular contraction after a short electromechanical delay. 
Initially, contraction is isovolumetric until the increasing intraventricular pressure opens the 
semilunar valves. The QRS complex ends halfway this isovolumetric contraction phase, and 
the ST segment (paralleling phase 1-2 of the AP) ensues.  The ventricular ejection and part 
of the isovolumetric relaxation are paralleled by the T wave (or phase 3 of the AP). 
 
 
 
Figure 7.2 Electro-pressure-volume loops at baseline (left, EMW noninvasive +15 ms, invasive + 62 ms) and 
after IKr and IKs block with dofetilide and JNJ303, respectively (right, EMW noninvasive -221 ms, invasive -159 
ms). Dotted line: end-systolic pressure volume relationships indicating increased inotropy during 
repolarization prolongation. [Courtesy of H. van der Linde, Janssen Research & Development, a division of 
Janssen Pharmaceutica NV, Beerse, Belgium]. 
 
Owing to electromechanical alterations in drug-induced LQTS, the ventricular myocardium 
senses substantial volume loading during the prolonged and dispersed ventricular 
repolarization phase (Figure 7.2, right panel green line). Ventricular volume is a major 
determinant of myofiber stress (σf) and strain (ef),388 more than LVP (see formulas next 
page), and thus it imposes significant mechanical impact during this vulnerable cardiac 
phase.  
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Cardiac mechano-electrical coupling is coordinated by specialized cation-selective and 
nonselective stretch-activated ion channels, but it also involves ion channels with either 
voltage or ligand sensitivity, including Na+ channels,285 K+ channels,389 the ATP-sensitive K+ 
channel,390 If channels,391 large-conductance Ca2+-sensing K+ (BK) channels and L-type Ca2+ 
channels. Crucial is the timing of the mechanical impulse with respect to the trailing edge of 
repolarization,392 since SACNS accelerate repolarization in myocytes at membrane potentials 
>-10 mV and depolarize cells that have already reached a more negative membrane 
potential (Figure 2.1 and 291). Steep ventricular repolarization gradients that can be present 
in LQTS hearts339 may thus increase the vulnerability to arrhythmia by locally dispersed 
responses to mechanical influences. Related to this, in the canine model of chronic 
complete atrioventricular block and acquired QT prolongation, beat-to-beat variability in 
ventricular preload associated with beat-to-beat repolarization instability, which was 
abolished by streptomycin, a nonselective inhibitor of SACNS.393 In another canine model, 
that of drug-induced long-QT1 syndrome, incremental LV adrenergic-dependent 
aftercontractions emerged in a negative EMW and always just prior to TdP.112, 113 These 
aftercontractions, manifesting as humps in the nadir of concomitant T waves, preceded the 
onset of late MAP EADs and occurred even in the absence of EADs. Pharmacological 
intervention with esmolol or verapamil did not completely eliminate the EADs, but did 
abolish the aftercontractions and life-threatening TdP.112 The effect of SAC inhibition on the 
potential mechano-electric link during the negative EMW under these conditions has not yet 
been investigated.  
 Clinical confirmation of mechano-electric feedback and LQT-associated proarrhythmia is 
sparse. Using tissue-Doppler imaging we captured myocardial contractions preceding ectopy 
and TdP in a SCN5A-p.(Phe1617del) patient with electrical storm, which suggests that 
instantaneous mechano-electric instability is linked to arrhythmogenesis, at least in LQT3 
(  and ). Shimizu et al performed epinephrine challenges in genotyped LQT1 Chapters 2 3
patients and readily evoked adrenergic MAP EADs and large-sized U waves310 reminiscent of 
the electrical footprint of postsystolic aftercontractions in the canine LQTS model.112 Alas, 
no intraventricular pressure recordings were available to confirm the possible presence of 
underlying aftercontractions.310 Proarrhythmic aftercontractions (by beta-adrenergic 
receptor stimulation) were recorded in a patient with syncope and abnormal repolarization, 
just prior to ventricular ectopy and nonsustained VT (Figure 7.3).114 Verapamil and esmolol 
suppressed both the mechanical events and subsequent arrhythmias. 
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Figure 7.3 Aftercontractions in a LQTS patient provoked by beta-adrenergic stimulation. Esmolol and verapamil 
suppressed these aftercontractions and ventricular arrhythmias. [From “Cardiac Mechano-Electric Coupling 
and Arrhythmias”, reproduced with permission from Oxford University Press].114 
 
In 1991, Vincent and colleagues investigated the electromechanical interrelation during 
instances of congenital repolarization prolongation in an ungenotyped Romano-Ward 
family.307 They found increased QT/QS2 ratios indicative of EMW negativity in affected 
family members. In the present PhD thesis ( and ), I focused on the EMW Chapters 2  3
behavior in a large population of (mostly) LQT1, LQT2, and LQT3 patients in relation to 
cardiac events. Patients with prolonged repolarization demonstrated mean negative EMWs 
of -43 ± 46 ms, and EMW values were even more negative in symptomatic patients than 
event-free subjects (-67 ± 42 vs. -27 ± 41 ms; P<0.0001). Importantly, ROC analysis and 
multivariate logistic regression analysis revealed that EMW was a better discriminator of 
arrhythmic risk than the conventionally used QT/QTc (odds ratio for 10-ms EMW decrease 
of 1.25 (95% CI, 1.11–1.40; P=0.001)). Using this easy-to-obtain parameter on top of QTc 
resulted in a net reclassification index of 13%. The optimal cut-off value of <-62 ms 
predicted arrhythmic events with 72% accuracy. As such, the EMW is a usefool parameter to 
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assess arrhythmia risk, and it can potentially guide antiarrhythmic maintenance therapy in 
the LQT syndrome. 
 EMW negativity was similar in the three genotypes. In symptomatic patients with 
inherited IKs and IKr defects QT prolongation occurred in the setting of unchanged QAoCs, 
whereas LQT3 patients displayed shorter mechanical systoles during concomitant QT 
prolongation. This SCN5A-specific pattern suggests that the persistent sodium current can 
interfere with the cardiac contractile properties, potentially through altered cellular Ca2+ 
cycling.110 As expected, most negative EMWs were observed in compound heterozygosity 
and in autosomal recessive JLNS patients.  
 Anton Jervell and Fred Lange-Nielsen, when first describing the familial long-QT 
syndrome with concomitant congenital deaf-mutism in 1957,394 probably without realizing, 
were the first to illustrate EMW negativity in a 9-year-old symptomatic JLNS boy after 
quinidine provocation (Figure 7.4). 
 
 
 
Figure 7.4 Profound EMW negativity during quinidine challenge in a symptomatic JLNS patient recorded three 
weeks prior to his sudden demise [adapted from Jervell et al394 with permission from the American Heart 
Journal]. 
 
Simultaneous recording of the QT (620 ms) and QS2 (350 ms) intervals unmasked an 
extremely negative EMW of -270 ms that could have been augmented by the potassium-
channel blocking properties of quinidine. The young boy died suddenly 20 days later. 
 At the opposite end of the spectrum one can wonder about the electromechanical 
consequences of short-QT syndrome.395 SQTS patients exhibit EMW positivity primarily due 
to a shortened QT in the presence of an unchanged mechanical systolic duration.395 
Investigators have reported systolic impairment as assessed by a reduced global longitudinal 
strain and myocardial performance index, next to increased mechanical dispersion.396 
Whether there is a role for mechano-electric feedback in arrhythmogenesis in the SQTS is a 
largely uncharted area of research, although in-silico modeling of SQT1-KCNH2 
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p.(Asp588Lys) hinted on a modulation of repolarization by the incorporation of ISAC in the 
model.397 
 The results of this PhD thesis, together with other reports on aberrant cardiac mechanics 
in LQTS,236, 301, 302, 330, 335 thus refute the notion that LQTS is a ‘purely electrical disease’ and 
therefore, it is time to claim that LQTS is a disease with electromechanical and 
mechanoelectric consequences. 330, 398 
FUTURE PERSPECTIVES 
Future experiments could be directed to elucidate the link between EMW negativity, 
aftercontractions and arrhythmias in the LQTS. To co-locate electromechanical events in the 
myocardium, deformable non-contact multielectrode endocardial mapping (avoiding 
catheter-induced ectopy) could be combined with high-resolution epicardial mapping and 
high-resolution mechanical tracking in drug-induced LQTS. In this regard, the non-contact 
ultrasound basket catheter (Acutus Medical, Carlsbad, CA, USA) is an interesting tool as it 
encompasses high-resolution dipole density mapping and ultrasound techniques that could 
detect local myocardial deformation. Alternatively, mechanical deformations could be 
imaged by (3D) speckle-tracking echocardiography or by MRI techniques like phase-contrast 
imaging. Also, non-invasive ECG-imaging could potentially be adapted to reconstruct local 
epicardial repolarization times, and to yield gradients together with mechanical mapping. In 
such experimental set-up, during drug-induced QT prolongation, interventions that alter 
mechanical impact can be implemented: 1) mechanical stimuli timed exactly during a 
negative EMW and 2) non-selective (streptomycine) or selective pharmacological SAC 
inhibition (using the peptide GsMTx4, isolated from the venom of the tarantula 
Grammostola spatulata) during provocative conditions culminating in aftercontractions and 
ventricular ectopy/tachycardia. To this aim, the availability of large-animal models with 
preserved hemodynamic responses and autonomic reflexes is crucial. 
    Clinically, similar multimodality imaging techniques as just described could be applied to 
assess genotype-specific electromechanical heterogeneities at baseline and during smart 
provocations under controlled conditions. In specific VF cases, these non-invasive 
(epicardial-focused) investigations could be complemented with endocardial 
electrophysiological mapping to uncover transmural dispersion of activation/repolarization, 
and potentially guide acute pharmacological intervention or trigger ablation.  
 Besides, cardiac mechanoelectric feedback fueling electrical instability and arrhythmias 
has been sparsely addressed in other cardiac diseases. Stretch-induced depolarizations in 
the pulmonary veins or the atrium can evoke premature atrial activation in susceptible 
patients.286 In a human electrophysiology-force myocyte model of hypertrophic 
cardiomyopathy, myofilament protein mechanics affected EAD formation.399 Collectively, 
these results underscore the importance of assessing malignant mechanotransduction in 
cardiac arrhythmogenesis in the clinical and experimental electrophysiology laboratory. 
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NEUROCARDIAC MODULATION AND VENTRICULAR ARRHYTHMOGENESIS 
The autonomic nervous system is comprised of sympathetic and parasympathetic limbs and, 
classically, is thought to exert its cardiac control via a yin-and-yang reciprocal interaction, 
although co-activation occurs during many reflexes.400 The two autonomic components, 
individually, but also in conjunction, have been implicated in ventricular arrhythmogenesis. 
 Generally, an enhanced parasympathetic tone exerts antiarrhythmic and antifibrillatory 
effects on the heart.401, 402 The vagal nerves operate mainly by antagonizing cardiac 
sympathetic actions, but also modulate the myocardium directly by prolonging the effective 
refractory period146 and by increasing the variability of the dominant VF frequency.147 In 
Brugada syndrome, LQT3, and early repolarization syndrome, arrhythmic events occur 
predominantly in periods of rest or sleep, i.e., in conditions with an anticipated high vagal 
tone. Cholinergic stimulation incited ventricular tachycardia in an experimental LQT3 
model,159 but hitherto no direct recordings of vagal nerve activity are available in the 
conditions upstream to ventricular tachyarrhythmias.140, 151, 403 However, since intermittent 
strong sympathetic surges are present during REM sleep404 and an elevated sympathetic 
tone is often present in high-risk Brugada patients,405 a more complex vago-sympathetic 
proarrhythmic propensity is to be suspected.  
 Sympathetic hyperactivity is associated with increased susceptibility to ventricular 
tachyarrhythmias and SCD in acquired and inherited cardiac diseases.9 The circadian 
occurrence of SCD at times of anticipated high sympathetic tone (peak between 7 and 11 
AM) underscores this relation.406 LQT1 is considered exemplary for sympathetic-related 
ventricular tachyarrhythmias,151, 318 but also CPVT-related arrhythmias depend heavily on 
increased sympathetic cardiac stimulation.407, 408 Here, ventricular tachyarrhythmias during 
exercise are common, which is at variance with the LQT syndrome, in which they are less 
frequent despite pre- and postexercise QT malaccommodation.409 Mechanistically, 
sympathoexcitation impinges on ventricular electrophysiological properties by exaggerating 
dispersion of excitation and refractoriness,143 facilitating triggered activity,92 and reducing 
the threshold for VF.410 While there is some degree of overlap in sympathetic efferent 
postganglionic neurons arising from the major cardiac ganglionated plexus, there is 
significant laterality in the input from either stellate ganglion to the heart. Stimulation of 
postganglionic neurons by the LSG imposes more pronounced dispersion of repolarization 
mainly in the anterior411 and posterolateral regions.412 The proarrhythmic input of the LSG 
was further demonstrated by increased discharge activity of the left-sided ganglionated 
plexus prior to the onset of VT in a canine model of scar-related SCD.344 In other models, 
MAP DADs,413 triggered activity,413 and large-sized LV MAP EADs414,346 were elicited by 
enhanced left-sided sympathetic stimulation. The electromechanical and arrhythmogenic 
effects of enhanced left-sided ganglionated plexus activity in an in-vivo drug-induced LQT1 
model have been described in this thesis ( ). Anesthetized dogs were infused with Chapter 4
the IKs blocker HMR1556 and underwent unilateral sympathetic stimulation. LSG, not RSG, 
stimulation readily induced TdP, precipitating intractable VF. This irreversible nature of 
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sympathetic LQT1-VF arrhythmogenesis may be the experimental correlate of LQT1 patients 
dying at their (first) arrhythmic event. In the setting of IKs-block-induced QT prolongation 
and MAP EAD generation, TdP occurred only upon LSGS-exaggerated EMW negativity and 
after about 26 seconds of stimulation, suggesting the necessity of local norepinephrine 
accumulation.415  
 The association of a negative EMW with the induction of TdP suggests a role for 
mechano-electric coupling in the triggering of extrasystoles. During global beta-adrenergic 
receptor stimulation with i.v. isoproterenol such role appeared likely given the incremental 
aftercontractions that almost always preceded TdP.112 These aftercontractions emerged in 
the negative EMW and before the upstroke of concomitant EADs. During regional 
sympathetic stimulation from the LSG, macroscopic aftercontractions appeared largely 
absent, but we consider it likely that small Ca2+-mediated mechanical events, not picked up 
by the intracavitary pressure catheter, did occur. The physiological heterogeneous 
distribution of sympathetic nerve endings in the LV myocardium, with dispersed 
norepinephrine release upon LSG stimulation, could have diluted the concerted 
organization of sizable aftercontractions, along with the increased regional dispersion of 
repolarization under these conditions.412  
 TdP-initiating ventricular extrasystoles emerged predominantly from the RV and LV 
outflow-tracts region, in accordance with clinical observations.270 Several factors determine 
this susceptibility of this region: 1) a generally shorter APD and effective refractory 
period,416 2) a higher Ito density in the RV epicardium,136 3) a lower NaV1.5 expression in the 
RV outflow-tract subepicardium,417 4) the presence of slowly-conducting, nodal-like RV 
outflow-tract tissue with ICaL-dependent AP upstrokes,418 5) rich sympathetic innervation 
(ventromedial cardiac nerve),419 6) thin-walled anatomy with reduced electrotonic 
capacity,270 and thereby, hypothetically, an increased sensitivity to stretch and strain.322, 420  
 It has been increasingly recognized that simultaneous hyperactivity of both limbs of the 
autonomic nervous system can turn arrhythmogenic particularly in the susceptible heart.153, 
400 Cold-water submersion is a classical trigger of autonomic co-stimulation eliciting a 
simultaneous cold shock (sympathetic trigger) and a diving response (parasympathetic 
trigger).354 Cold-water swimming is a genotype-specific trigger of potentially lethal 
arrhythmia in LQT1,152, 421 but also in CPVT.422 Approximately 30% of victims of swimming-
related drowning harbor a KCNQ1 or RYR2 mutation.423 Additionally, some reports hint 
towards the proarrhythmic potential of high vagal tone/reflexes in LQT1 patients.154, 155 In 
our in-vivo anesthetized canine LQT1 model with preserved autonomic nervous system 
reflexes, I speculate that co-activation of the sympathetic and parasympathetic branches 
contributed to the observed VF in our in-vivo anesthetized canine LQT1 model. The present 
experimental results do not allow firm conclusions regarding this aspect. In other LQT2160 
and LQT3159 whole-heart models, vagal stimulation led to augmented dispersion of 
repolarization and the induction of VT. Some clinical data have suggested high 
parasympathetic activity even during or immediately after VF-induced blood pressure fall.424 
128 | CHAPTER 7 
Figure 7.5 illustrates examples of suspected vagal-mediated sinus bradycardia and 
atrioventricular block in two LQT patients after the spontaneous termination of TdP/VF.  
 
 
Figure 7.5 Suspected vagal hyperactivity in a patient with genetically elusive LQT syndrome (upper panel) and 
a LQT1 patient (lower panel) with sinus bradycardia and atrioventricular block after spontaneous termination 
of TdP/VF. 
 
In summary, left-sided sympatho-excitation during LQT1(-mimicking) conditions imposes 
electromechanical instabilities, that may facilitate reentrant excitation and provoke TdP/VF. 
The convoluted vago-sympathetic synergy conspiring to this arrhythmogenesis, while highly 
intriguing, is still poorly understood. Our findings underscore the importance of 
interventions aimed at dampening the effects of sympathocardiac stimulation, like beta-
blocking therapy1, 168 and LCSD.184, 185, 425 One small retrospective pilot study demonstrated 
increased (i.e., less negative) EMWs upon LCSD in LQT1 and LQT2, mainly by reducing the 
QT interval.426  
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FUTURE PERSPECTIVES 
Future studies could focus on the proarrhythmic contribution of parasympathetic 
stimulation on top of augmented sympathetic cardiac outflow in LQT syndrome. To this aim, 
vagal activity could be recorded during sympatho-excitation in an in-vivo canine LQT1 model 
like ours. At the cellular level, one could investigate the downstream effects of simultaneous 
stimulation of muscarinic and adrenergic receptors on ion currents targets like ICaL and IKs. 
For cholinergic stimulation, carbachol or the selective muscarinic inhibitor AFDX116 can be 
used. Ultimately, the impact of autonomic modulation on APD, beat-to-beat variability of 
repolarization, EMW and ventricular arrhythmogenesis could be investigated. In corollary to 
these experimental set-ups in LQT1-mimicking conditions, the vagosympathetic triggering of 
SCN5A-related arrhythmias warrants further investigation. 
 The contemporary diagnostic work-up of patients with inherited or acquired 
susceptibility to ventricular tachyarrhythmia should encompass an evaluation of the 
autonomic nervous system. Cardiac innervation maps using 123I-meta-iodobenzylguanidine 
scans can be incorporated besides standard high-density electro-anatomic maps to uncover 
neurocardialc substrates, if present, and potentially alter invasive and noninvasive 
treatment strategy.427 
COMPLEX GENETIC ARCHITECTURE UNDERLYING SCD 
The field of genetics, in particular the exploration of genetic determinants that increase the 
risk of SCD, is rapidly evolving and is increasingly incorporated in clinical-decision making. 
Starting from the 1990s when the primary focus was on high-effect size mutations with 
monogenic inheritance patterns, we have entered the era of complex genetics in which 
there is mounting understanding of the role of allelic variants with different effect sizes to 
explain missing heritability and disease expression. These emerging complexities will be 
illustrated in the next sections using SCN5A channelopathies as example. 
SCN5A-RELATED DISEASES: A TEMPLATE OF COMPLEXITY 
Allelic variants in the SCN5A gene encoding the NaV1.5 have been associated with a plethora 
of arrhythmia syndromes (Figure 7.6). Initially, SCN5A mutations were recognized for LQT344 
and Brugada syndrome.428, 429 Later other disease entities like cardiac conduction disease,429, 
430 sick-sinus node syndrome,431 atrial fibrillation,432 atrial standstill,433 dilated 
cardiomyopathy,384 and, more recently, multifocal Purkinje-related ectopy130 were added to 
the list. Extensive experimental electrophysiological characterization has revealed that 
NaV1.5 not only provides for AP upstrokes and conduction, but (when mutated) can also be 
involved in repolarization instability and structural cardiac abnormalities, depending on the 
variant-imposed functional consequences. NaV1.5 gain-of-function effects, like impaired 
channel inactivation with late INa or increased window INa can prolong ventricular 
repolarization resulting in LQT3 or can facilitate multifocal Purkinje-related ectopy, 
respectively. 
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Figure 7.6 Clinical phenotypes according to functional effect of SCN5A mutation. [Modified from434 with 
permission]. 
 
On the other hand, electropathological mechanisms underlying Brugada syndrome can 
comprise of reduced peak INa due to a hyperpolarizing shift of the voltage dependence of 
steady-state channel inactivation or decreased expression of INa channels in the membrane 
(loss of function). In overlap syndromes, mutation-induced loss- and gain-of-function INa 
features co-exist. 
 The heterogeneous phenotypic expression of SCN5A mutations is intruguing and 
complex. In order to gain further insights into the genetic inheritance patterns and 
functional abnormalities, it is crucial to consider NaV1.5’s modulators of expression, its 
binding partners and cellular regulators (Figure 7.7). NaV1.5 operates through a 
macromolecular signaling complex by interactions with its auxiliary beta-subunits, several 
proteins and other ion channels that modulate channel trafficking, expression, localization, 
and gating,435 and it is the target of extensive post-translational modifications.436, 437  
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Figure 7.7 Transcriptional, translational and posttranslational modulators of the NaV1.5 macromolecular 
channel and signaling complex. AnkG indicates ankyrin-G; CaM, calmoduline; CaMKII∂c, calcium calmoduline 
kinase II, cAMP, cyclic adenosine monophosphatase; Cav3, caveolin-3; CXADR, coxsackievirus and adenovirus 
receptor; FHF1B, fibroblast growth factor homologous factor 1; FOXO1, forkhead box protein O1; IFM, Ile-Phe-
Met; mRNA, messenger RNA; miRNA, microRNA; mito, mitochondria; MOG1, multicopy suppressor of Gsp1; 
Nedd4, neural precursor cell expressed developmentally downregulated protein 4; NOS, nitrous oxide systems; 
PDZ, postsynaptic density protein/Drosophila disk large tumor suppressor/zonula occludens-1; PKA, protein 
kinase A; PKC, protein kinase C; ROS, reactive oxygen species; SNTA1, alpha-1-syntrophin; TBX5, T-box 
transcription factor 5; VSD, voltage-sensing domain. [Modified from436 with permission]. 
 
Mechanical stress, regulatory kinases (PKA, protein kinase C), oxidative stress, Ca2+, 
calmoduline, and CaMKII are important post-translational regulators of NaV1.5 that can 
confer functional effects on INa.285, 436 Of interest is the CAMKII-dependent modulation of 
NaV1.5 as it imposes both a gain of late INa and a negative shift of the steady-state 
inactivation, enhanced accumulation of intermediate/slow inactivation and slowed recovery 
from inactivation.436 As such, CaMKII may increase the risk of VT and SCD in the setting of 
heart failure or ischemia-reperfusion, representing an acquired form of NaV1.5 dysfunction. 
Another channel-interacting protein is the coxsackie-and-adenovirus receptor that co-
localizes with NaV1.5 at the intercalated disks, modifies its current amplitude, and 
predisposes to ischemia-related arrhythmias.37 Furthermore, some authors claim that a 
second gating pore can be formed besides the physiological alpha pore by mutations to 
neutrally charged amino acids in the voltage-sensing domain.438, 439  
 Variation in the juxtaposed SCN10A gene on chromosome 3 can regulate the expression 
of SCN5A in cardiac tissue.362 Also, transcription factors like Forkhead box O 1 (FOXO1) and 
nuclear factor-κB (NF-κB) can reduce SCN5A transcription. T-box transcription factor 5 
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(TBX5) plays an essential role in the normal expression of NaV1.5 in the ventricular 
conduction system.440 Other important regulators of SCN5A transcription are miRNAs (e.g., 
125a/b, 195, 378)441, 442 that can either restrict transcription or induce mRNA degradation.  
 Collectively, these different NaV1.5 modulators with their potential common gene 
variants (or “genetic modifiers”) can complicate genotype-phenotype interpretation, which 
may explain the low disease penetrance of SCN5A channelopathies with a variable 
expressivity.63 In this context, it does not come as a surprise that SCN5A mutations are 
diagnosed in only 20-25% of Brugada patients, despite the autosomal dominant pattern of 
transmission of the syndrome.360 The complexity increases further if one realizes that family 
members of SCN5A-mutation indexes with Brugada syndrome may have spontaneous or 
drug-induced type-1 Brugada ECGs while not carrying the familial SCN5A mutation.64 This 
hints to an oligogenic mode of inheritance15 with an important role for genetic background 
in the pathogenesis of Brugada syndrome.  
 Large founder populations sharing an identical-by-descent gene mutation but with 
variable disease expression are gold mines for the elucidation of genetic modifiers that are 
difficult to uncover in a genetically-diverse population with a common phenotype.15, 16 We 
built on the availability of a SCN5A-p.(Phe1617del) founder population (this PhD thesis, 
) with an increased susceptibility to SCD and variable cardiac phenotypes, Chapter 5
including LQTS, Brugada syndrome, cardiac conduction disease, and isorhythmic 
atrioventricular dissociation with overlapping features. Besides the strong association 
between SCN5A-p.(Phe1617del) and LQTS, large mutation effect sizes on QTc (explaining 18-
28% of QTc variability), mechanical systole, and EMW were present. Somewhat 
unexpectedly, no persistent or late INa was present during whole-cell patch-clamp 
recordings in transiently transfected Chinese hamster ovary (CHO) cells, in experiments thus 
far.443 Mutant INa density for SCN5A-p.(Phe1617del)homo was reduced, which indicates loss-
of-function INa effects. This is partly in contrast with observations by Chen et al361 who found 
an increased voltage-dependent late/peak INa ratio at positive command potentials in 
p.(Phe1617del)-transfected tsA201 cells. Other known LQT-related gene variants did not 
segregate in this pedigree. The modifier gene SCN5A-p.(His558Arg), always on the same 
allele as the deletion (cis), appeared to partially rescue the mutant INa without increasing 
late INa.85  
 Conditions leading to cellular Ca2+ overload (sympathetic stimulation, tachycardia, short-
long-short RR cycles, i.e., conditions facilitating arrhythmia in vivo) could modulate NaV1.5 
via Ca2+, CaM, or CaMKII, and PKA and impair INa fast inactivation, effectively shifting INa 
availability to negative potentials.436 Alternatively, SCN10A-driven genomic expression of 
SCN5A could be dysregulated, and we cannot rule out that more distant genes and/or 
variants impact on the expression of NaV1.5. Some SCN5A mutations render a different 
sensitivity of NaV1.5 to INa-channel blockers (  and ref444). And, although Chapter 6
speculative at this point, NaV1.5’s mechanosensitivity may be subject to genetic modulation.  
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 Next, our variance component analysis ( ) alludes to missing heritabilities for PQ Chapter 5
interval on the ECG, and possibly for the QT interval and EMW, after accounting for the 
effects of SCN5A-p.(Phe1617del). The enrichment of p.(Arg558) strengthened the concept 
of founder effects and genetic drift, but did not exert an independent effect on the 
identified phenotypes (thus far). These genetic complexities are substantiated by the 
presence of LQTS and even TdP in p.(Phe1617del)-negative family members (Figure 7.8). 
Further refinement of the genetic and molecular underpinnings of altered INa benefits also 
patients with other SCN5A-gene mutations, and even patients with acquired cardiac 
diseases with a propensity to arrhythmias. 
 
Figure 7.8 LQTS and the induction of TdP in a p.(Phe1617del)-negative Worm study patient. No mutations 
were found in 24 arrhythmia-associated genes. 
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Careful analysis of arrhythmia mechanisms in the presence of the SCN5A-p.(Phe1617del) 
mutation brought forward unique (non-SCN5A typical) aspects with arousal-related, non-
nocturnal VT/VF and striking female preponderance ( ).60, 151, 360, 363, 365, 445 Sinus-Chapter 5
rate acceleration, QT prolongation and EMW negativity foreshadowed the instigation of 
polymorphic VT. In one case, tissue-Doppler-imaging correlates of postsystolic 
aftercontractions were present just prior to TdP. In contrast to other SCN5A 
channelopathies, this indicates that sympathetic surges fuel the arrhythmias in these 
patients. Triggered by these clinical observations, future patch-clamp experiments and in-
silico investigations will encompass PKA- and Ca2+-mediated regulation of the mutant 
sodium.159 Furthermore, the unexpected propensity of LQT3 females to VT occurred in the 
absence of baseline QTc/EMW gender differences.446 Previous cellular data point to 
increased transmural differences in ICaL (increased epicardial ICaL conductance) and ~20% 
lower IKr density in female cardiomyocytes that exaggerated dispersion of repolarization.447, 
448 This transmural ICaL gradient was attenuated by castration of female rabbits. In the 
future, altered ion-channel expression due to modulatory effects of (non)gonadal hormones 
or gene-gender interactions could be addressed. 
FUTURE PERSPECTIVES 
In the Worm study, preliminary non-parametric linkage analysis for the arrhythmia trait 
allocated a large proportion of the genetic risk to a specific locus on chromosome 3, 
containing the three juxtaposed SCN5A, SCN10A, and SCN11A genes encoding different NaV 
channels. The overall phenotypic complexity of the study population triggered us to 
investigate this chromosome-3 locus. Furthermore, the genome of the Worm population 
will be compared to the genome of the Dutch and Limburg population through 
collaborations with the GoNL Project consortium.449 Genetic association studies with linkage 
analysis of quantitative traits will be performed to identify remote allelic variants that 
contribute to the diverse phenotypic tableau and the susceptibility to SCD. We strive to 
validate and replicate our genetic findings in other populations with a well-defined risk of 
SCD, such as the Arrhythmia Genetics in The Netherlands Study (AGNES).36 The ultimate 
goal will be to identify genetic modifiers relevant for the prediction of SCD in the general 
population (Figure 7.9).  
 In the near future, understanding of the genetic determinants of VT/VF and translational 
mechanistic understanding will increase considerably, necessitating the use of disease 
expression systems that allow simultaneous multivariable assessment in models with 
preserved hemodynamic and autonomic reflexes. To account for oligogenic disease 
expression and/or genetic background, we will generate patient-specific induced 
pluripotent stem-cells (iPSC)-derived cardiomyocytes (CMs). By using iPSC-CMs, complex 
genotype-phenotype relationships can be investigated and gene-editing techniques like 
CRISPR/Cas9450 can be employed to correct for the mutation or insert the mutation in a 
specific genetic background. Sophisticated multiscale computational modeling incorporating 
 LIFE-THREATENING VENTRICULAR ARRHYTHMIAS IN THE GENETICALLY-SUSCEPTIBLE HEART | 135 
autonomic modulation and mechano-electric feedback mechanisms will provide additional 
new insights. 
 
 
 
Figure 7.9 Genotype-phenotype investigations in family-based cohorts will ascertain common variants with 
modest impact on disease manifestation alone, but with large influence during instances of additional stress. 
This way, gene discovery in a highly selected family can forward risk stratification and treatment of millions of 
patients.  
TOWARDS PERSONALIZED ARRHYTHMIA MANAGEMENT 
The accumulating knowledge on mechanisms of arrhythmia, partly surpassing the 
conventional electrophysiological arena, in combination with the unraveling of the 
individual genetic make-up increasingly provides the physician the tools for tailored 
arrhythmia treatment per genotype-phenotype combination. Such personalized arrhythmia 
management requires a dedicated translational arrhythmia team should be composed, 
consisting of clinical/translational/cellular electrophysiologists, molecular and clinical 
geneticists, cardiac-imaging and heart-failure specialists with expertise on mechanisms of 
arrhythmia in the setting of electrophysiological and hemodynamic instability, and with 
state-of-the-art knowledge on antiarrhythmic drug actions, biophysical properties of ion 
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channels and their mutations, neurocardiac modulation, and in-silico modeling (Figure 
7.10).  
 For complex VT/VF cases, once the arrhythmic trigger and substrate have been identified, 
a personalized antiarrhythmic management consisting of appropriate preventive, 
pharmacological, and/or invasive measures is designed. Preventive measures could 
encompass individualized lifestyle modifications, watchful waiting via periodic cardiac risk 
stratification but also arrhythmia-risk gene profiling.451, 452 In low-medium risk patients not 
suitable for prophylactic ICD implantation a wearable VF alarm with GPS locator would be 
beneficial.453 Unfortunately, such a device is not available yet. The choice of antiarrhythmic 
drug agent depends heavily on the arrhythmia mechanism(s) and the patient characteristics 
e.g., pre-existing conduction delay, LV dysfunction, or LV hypertrophy. Interestingly, 
ranolazine285 and bepridil454 possess mechano-inhibitory, besides conventional, 
antiarrhythmic drug actions. Secondary prevention of SCD often involves the implantation 
of an ICD, but this does not interfere with the mechanism of arrhythmia. If VTs recur despite 
antiarrhythmic drug therapy and ICD interventions follow, catheter-based radiofrequency 
ablation is indicated. As an adjuvant invasive strategy, there is increased interest for the 
modulation of the autonomic nervous system. Temporal or permanent block of the stellate 
ganglia suppresses malignant ventricular arrhythmias in LQTS, CPVT, and electrical storm.1, 
184-187, 455 Renal denervation, another neuromodulatory therapy, reduced VT burden in small 
studies.456-458  
 
 
 
Figure 7.10 Schematic representation of personalized arrhythmia management 
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In the midst of all this convoluted scientific knowledge we tend to overlook the most 
important radar: the patient and his/her reconciliation. Shared-decision making is the crux 
of patient-centered healthcare, improving quality, safety and patient satisfaction.459 The 
treating physician needs to avoid jargon to seek a patient’s participation, understanding, 
and collaboration. Communication skills of healthcare providers should be optimized with 
emphasis on choices, patient autonomy, and beneficence. Art-based or visual 
communication can add to this in a non-conventional way ( ). Chapter 8
 In Maastricht, we are adopting such integrative approach towards individual arrhythmia 
management. As an example, it was only through multidisciplinary teamwork that we 
successfully treated the patient with multifocal ectopic Purkinje-related contractions 
( ). Patch-clamp experiments demonstrating flecainide-sensitive increased window Chapter 6
INa current guided the successful administration of this sodium-channel blocker in the 
SCN5A-p.(Leu828Phe) patient. The Worm study is another example of integrative 
personalized arrhythmia management; consenting patients undergo a very thorough 
electrophysiological, cardiac-structural and genetic work-up. In the near future, the 
generation of patient-specific iPSC-CMs expressing patient’s unique genetic context will 
enhance individualized understanding and therapy. To ascertain shared-decision making, we 
have organized Worm Information Days, published news articles, and developed an online 
Worm study platform.  
 Finally, the HeArt project (Figure 7.11), a project on the synergy of art and science (and 
inspired by the Worm study), will provide an interactive playground to stimulate scientific 
physician-patient communication an exposition at the outpatient clinic of Maastricht 
University Medical Center+ ( ). Chapter 8
 
Figure 7.11 Logo of the HeArt project. 
 
FUTURE PERSPECTIVES 
Personalized arrhythmia management as depicted in Figure 7.10 should become standard 
for all arrhythmia patients seeking topreferral treatment at the MUMC+. With the arrival of 
the consumer society, better-informed patients (dr. Google, health apps) and increased 
pressure by Regulatory Authorities, we need to adapt and improve our communication and 
collaborative skills.459 This also applies to the participation in multidisciplinary, national and 
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international collaborations. Ideally, these shared-decision making skills should be taught 
during the medical training. At the Maastricht University, the program “Does Art Make You 
a Better Doctor” focuses on improving observational skills. We are currently exploring the 
possibilities to use art-based interventions to improve physician-patient/study subject 
contact and to stimulate creativity in PhD students ( ). Chapter 8
RELEVANCE FOR SCD IN GENERAL 
The aforementioned multidisciplinary management of ventricular arrhythmogenesis 
requires an individualized systems approach, much beyond the electrophysiological-
oriented examination alone. The incorporation of extra-electrophysiological parameters 
improved arrhythmia-risk prediction in LQTS and enhanced understanding of sympathetic-
related electromechanical instability (this thesis). Deep phenotyping and genotyping of a 
SCN5A founder population underscored that complex oligogenic phenotype-genotype 
relations underlie disease expression.  
 Similarly, integrative approaches will also apply to VT/VF in the setting of acquired 
structural heart disease. Mechanoelectric feedback fueling electrical instability is 
anticipated in patients with mitral valve prolapse and cardiac arrhythmias or in 
cardiomyopathy patients with overload-induced arrhythmias. Divergent electromechanical 
relations likely underlie (non)-ischemic cardiomyopathy, short-QT syndrome, Brugada 
syndrome, and acquired repolarization prolongation, including postmyocardial infarction QT 
prolongation. Postinfarction inhomogeneities in myocardial sympathetic innervation are 
deemed arrhythmogenic and can be targeted by catheter-based VT ablation.427 Finally, 
continued unraveling of the genetic risk factors for SCD will improve risk stratification and 
guide personalized arrhythmia management also in patients with scar-related VT/VF. Taken 
together, our integrative approaches, provide a road map for future antiarrhythmic 
management in patients with genetic susceptibility to SCD and VT/VF owing to structural 
heart diseases. 
CONCLUSIONS 
In this chapter, I elaborated on the contribution of mechano-electric instability besides 
primary electrical mechanisms of ventricular arrhythmogenesis in the genetically-
predisposed heart. Prolonged-repolarization-associated EMW negativity creates a substrate 
for life-threatening arrhythmias and commands immediate vigilance. EMW negativity, 
however, is a vehicle but not the sine qua non for arrhythmic deterioration. Superimposed 
triggers like sympathetic hyperactivity, dynamic cycle-length variations, and/or mechano-
electric impulses are required to exaggerate spatiotemporal dispersion of repolarization and 
promote myocardial Ca2+ (over) loading. This potentiates regenerative SR Ca2+ release that 
can feedback on [Ca2+]cyt-activated inward membrane currents but also on 
mechanosensitive elements via contractile events. The high lethality of enhanced left-sided 
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sympathetic activity, compared to adrenergic stimulation, during drug-induced LQT1 is 
explained by the heterogeneous electrophysiological response to sympathetic LV 
stimulation besides increased inotropic responses and electromechanical deviation. 
 Cardiologists, electrophysiologists and geneticists involved in VT/VF patient care are 
confronted with mounting mechanistic and genetic complexity. Even classical monogenic 
disease entities appear to have oligogenic or polygenic determinants of disease expressivity 
and SCD risk. Meticulous cardiac phenotyping is of key importance to unravel distinct 
genotype-phenotype relationships. In this way, novel disease entities, like SCN5A-associated 
MEPPC syndrome and isorhythmic dissociation, but also atypical arrhythmia-provoking 
triggers are identified. Isolated family cohorts facilitate the discovery of clinically relevant 
modifier genes that could also modulate disease expressivity in unrelated populations with 
comparable (severe) phenotypes. With the increased availability of next-generation DNA 
sequencing techniques, advanced bioinformatics, publicly accessible genealogy archives, 
and thorough cardiac clinical and cellular phenotyping, the electrophysiological field is 
maturating and personalized arrhythmia management is within reach. An ethical debate on 
the delicate balance between privacy laws and preventive medicine is ineluctable.  
 To conclude, my research, based on translational and integrative approaches, has 
provided novel insights in ventricular arrhythmogenesis in the genetically-susceptible heart, 
facilitated personalized arrhythmia management, and provided a useful itinerary for the 
management of arrhythmias owing to cardiac structural abnormalities. 
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THE HEART PROJECT 
The scientific endeavors to unravel arrhythmogenic mechanisms in the genetically-susceptible 
heart, described in - , were paralleled by artistic enterprises, designated as the Chapters 1 7
“HeArt project”. In the HeArt project, years of collaboration led to unconventional approaches 
to elevate scientific understanding and presentation by artistic input, and by using HeArt-
derived imaging to improve patient-doctor communication. Synergy between the scientist 
(Rachel ter Bekke) and the artist (Claudia Volders; www.claudiavolders.nl) was reached. 
Conversely, the excitement of scientific breakthroughs and cutting-edge technology often 
sparked artistic inspiration.  
 The HeArt project encompassed a variety of art-based interventions aimed at detaching 
the researcher out of her scientific comfort zone to stimulate creativity. Multiple art-and-
science brainstorm sessions (Figure 8.1 and 8.2) provoked out-of-the-box thinking, leading 
the scientist to evaluate her work from a different perspective. Original paintings, created 
for these sessions by the artist, served to trigger alternative reflections on scientific 
achievements and views on next developments (Figure 8.2). Outdoor expeditions were 
undertaken to get exposed to the historical and sociocultural contexts of research projects 
(Figure 8.3). Finally, the scientist’s artistic inclination was enhanced by joined painting 
studies (Figure 8.1 and 8.7) that reiterated insights into visuals. Such artistic assignments 
stimulated the feeling of humbly following in the footsteps of the greatest artistic scientist 
ever, Leonardo da Vinci. An impression of the different aspects of the HeArt project can be 
appreciated at http://www.youtube.com/watch?v=iLEklH28vlA. 
 As one concrete example of the HeArt project, we explored the birthplaces, living areas 
and memorial grounds of designated founders and relatives of the Worm pedigree (Chapter 
 of this PhD thesis), hypothesizing that physical visits would trigger new ideas for the 5
scientific and artistic progress of the Worm Study. An old door post with inscriptions 
commemorating the death of a presumed SCN5A-p.(delPhe1617) carrier (Figure 8.3) was 
found, symbolizing a gateway to the past where relevant pieces of the Worm puzzle came 
together.  
 Regarding the Worm ancestors and their regions of living, there were marked differences 
between Waubach (the Netherlands, birthplaces of ancestral couple A) and Bank 
(Unterherschaft Heiden, Kreis Aachen, Germany, birthplaces of ancestral couple B; Figure 
5.1); the latter being a hamlet in the midst of farmlands, and the former at a busy 
intersection of the important Roman main trade road called Via Belgica (Figure 8.4). The Via 
Belgica connected Boulogne-sur-Mer, France (Latin: Gesoriacum) with Cologne, Germany 
(Colonia Agrippina), and was crucial for the local and regional economy, the military 
defenses and governance (www.viabelgica.nl). We hypothesized that population, and thus 
also migration of the SCN5A mutation, occurred predominantly along these historical 
routes, namely in the East-West direction. Genealogical research confirmed these migration 
patterns (Figure 8.4). This led to the concentration of extramural medical communications 
and societal alerts to this Maastricht-Aachen-Liège Euregio. Personal encounters with 
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German inhabitants of the Bank area (Kreis Aachen) highlighted the psychosocial impact of 
increased susceptibility to cardiac arrest to a population unfamiliar with the origins of their 
problem. This enforced us to identify the genetic contributors to VF across the border, and 
to seek collaborations with heart researchers at the Uniklinik RWTH Aachen.  
 Under the motto “To Innovate One Has To Embrace History”, I investigated the history of 
medicine with the aim of rediscovering the “ikigai” (Japanese for “reason of existence”) of a 
doctor. In ancient cultures the “healing arts” comprised of tending and caring for the sick, 
besides applying primitive interventions. In the last centuries, medicine has evolved into an 
evidence-based and cost-effectiveness-driven medical science. Often, this came along with 
blunted emotional sensitivity to the patient’s needs, and (sometimes very) limited time for 
patient-doctor contacts. However, a hospital is more than a laboratory, and medicine is not 
an exact science. Because of this and because of the mounting complexities of medical 
science, health-care professionals are increasingly faced with challenges of adequate 
communication with their patients. Knowledge transfer from the physician to the patient 
and vice versa requires excellent communication skills, empathic abilities and expertise. It 
exceeds, by far, a simple “Dr. Google consultation”, and a patient is not simply a diagnosis. 
Sophisticated capacities such as the art of empathy, humanity, communication, 
observational skills, creativity, and outside-the-box thinking benefit knowledge transfer and 
patient-centered care with shared descision making. True communication comes often 
through a person’s eyes, as they show unfiltered emotion and state-of-mind. Figure 8.6 
shows a close-up of eye contact between a patient and the physician, exemplary of the 
value of non-verbal communication. 
 Experiments using abstract pieces of art, and artistic brainstorming, can enhance the 
physician’s self-awareness and explorative mind. They identify strengths and weaknesses, 
elements that are crucial for an expert communication, especially with patients at risk for 
sudden cardiac arrest. Next to conventional physician-patient communication tools like 
online platforms (https://hartenvaatcentrum.mumc.nl/de-worm-studie), we use objects of 
art as supplementary vehicles to transfer complex medical information and stimulate 
interaction. As an example, we mention the finding of the female propensity towards 
sudden cardiac arrest described in , and in this context the use of artistic symbols Chapter 5
like the ‘swnwt’ (hieroglyphic writing for the first known female physician, named Peseshet) 
including the half-spherical stepping stones (Figure 8.7). The “ieb”, the hieroglyphic symbol 
for heart, is also depicted. The handles of the ieb exemplify the arteries and veins to the 
organ. The water vase next to Virgin Mary during the Annunciation by Arthur Hacker (Figure 
8.7) reminds of the ieb and stands for the feminine source.  
 We hypothesize that jointly experienced scientific achievements create larger support by 
the general community and willingness to participate in any next study. As such, the HeArt 
project was exhibited at the Netherlands Society of Cardiology (NVVC) “Art from the Heart” 
exposition in 2013, has recently been shown to the public at the Heart+Vascular Center at 
Maastricht University Medical Centre (a selection of quotes of anonymous patients are 
144 | CHAPTER 8 
portrayed at the title pages preceding each chapter of this thesis), and can now (2018) be 
seen and experience at the Main Building of Maastricht University at the 
Minderbroedersberg. Our exhibition will travel onward to the outpatient clinic of 
Zuyderland Medical Center in Heerlen, the Netherlands. 
 Finally, the cover of this thesis. This encompasses all elements investigated in the thesis 
project: the complexity of cardiac arrhythmias, genetics and holistic patient care with a 
feminine touch. Figure 8.8 portrays different stages of the creation of the cover. 
 Our art-and-science xenogamy puts the scientist with her research activities in a broader 
societal context, much beyond the confined environment of the academia. We believe that 
the HeArt project can result in novel scientific perspectives, new research questions, pieces 
of arts, but also increased patient satisfaction and health. 
 
TO THE HEART OF THE MATTER 
As physicians we have the privilege and obligation to be the ”Saxum in Aquis Moventibus” 
for patients and family members during vulnerable phases in their life. Patients place their 
hearts in our hands, when a fiduciary bond is created. The scientific quest to answer their 
stilling “why” after the unexpected loss of a relative requires many skills and empathic 
capabilities. 
 Negative consequences of poor communication can severely impact on the patient’s belief 
in medical services, patient-doctor relations, patient disease ownership, and reduced 
compliance. At a broader scope, scientific malcommunication can cause misunderstanding on 
genetics, gene therapy, in-vitro fertilization, organ donation, vaccination and broader topic 
like climate change/global warming. To solve this conundrum, patients, doctors, scientists and 
community-engagement organizations can benefit from art-based projects aimed at 
stimulating interpersonal communication, knowledge transfer, respect, empathy and 
creativity.  
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HEART OBJECTS  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Left, Creative brainstorm sheet. Right, Joint creation: oil painting inspired by the cardiac  
Na+-channel subunit, encoded by SCN5A. 
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Figure 8.2 Interactive art-based coaching: the red square put on the painting (left and right panels) symbolizes 
the status of the current research activities by the scientist; the blue square indicates future endeavors.  
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Figure 8.3 Wooden transom with inscriptions commemorating the death of Maria Anna Merckelbach (1764, 
October 9 at the age of 37 years), a presumed p.(Phe1617del)-carrier, in Hotel Brull, Mechelen, The 
Netherlands. 
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Figure 8.4 Top left, “Land without Borders” of Limburg, the Netherlands, in the 18th century, with the 
presumed course of the Roman trade road Via Belgica. Top right, East-West spreading of the Worm population 
(over generations) occurred mainly along the Via Belgica,. Below left, “Tree of Life”, oil painting by Claudia 
Volders, inspired on the Worm Study. Below right, Soil from ancestors’ farm in Waubach, the Netherlands.  
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Figure 8.5 Art-based valorization and holistic HeArt paintings.  
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Figure 8.6 Eyes, the portals for empathic doctor-patient contact. 
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Figure 8.7 Upper left, “Manifest of the Meander”. Lower left, Hieroglyphic symbol for female physician or 
“swnwt”, the half-spherical stepping stone, and heart or ”ieb”, lower middle. Right, “The Annunciation” (1892) 
by Arthur Hacker with a water vase symbolizing the female fertility (Tate Britain, London, United Kingdom). 
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Figure 8.8 Top, Thesis cover in different stages of development. Below, Different scientific and personal 
perspectives on cover painting serve as tools for inspiration. 
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SUMMARY/SAMENVATTING 
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SUMMARY 
In the healthy heart, coordinated contraction is triggered by electrical impulses that initiate 
in the sinus node and travel to the atria and ventricles, timely and with synchronous 
coordination. Perturbations of ventricular electrical activity can lead to life-threatening 
arrhythmias and, if not treated appropriately, to sudden cardiac death. Such malignant 
arrhythmias can occur in the presence of a structural or functional arrhythmogenic 
substrate. Concomitant brisk autonomic-tone variations may facilitate arrhythmogenesis. 
Besides these and other classical proarrhythmic ingredients, it is increasingly recognized 
that electromechanical uncoupling and mechano-electric feedback contribute to 
proarrhythmic instability. The mechanisms and management of ventricular arrhythmias in 
the genetically-susceptible heart are the main topics of the present PhD thesis. 
 After a general introduction of the main topic “sudden cardiac arrest” in , Chapter 1
 recapitulates important aspects of ventricular arrhythmogenesis, and it provides Chapter 2
unique data demonstrating the presence of electromechanical disparity just prior to the 
onset of TdP in a patient with congenital LQTS. 
 Within an international consortium, we examined the relation between altered 
electromechanical coupling and arrhythmia susceptibility in a large cohort of LQTS patients. 
The results are described in  . We show, for the first time, that the EMW is a robust Chapter 3
arrhythmia risk indicator in these patients, irrespective of their genotype, and superior to 
QTc. The EMW was found constant during consecutive measurements in the same 
individual at clinically-stable conditions, but could turn very negative during instances of 
ventricular ectopy and prior to TdP. In , we report novel data collected in a Chapter 4
clinically-relevant canine model of drug-induced LQT1. In this model, LSGS has a high 
arrhythmic propensity, causing TdP and ventricular fibrillation during profound EMW 
negativity. We surmise that LSGS-induced positive lusitropy during QT prolongation cause 
this electromechanical disparity, and speculate that co-activation of the sympathetic and 
vagal nervous system occurs during LSGS (under undecentralized conditions), with both 
autonomic limbs contributing to arrhythmogenesis. 
 In , our results of the Worm Study are described. By investigating a large Chapter 5
founder population with the SCN5A mutation p.(Phe1617del), we identified novel SCN5A-
related phenotypes and arrhythmia patterns in this inherited sudden-cardiac-death 
syndrome. Heritability estimates provide a road map to downstream genetic analyses, 
aimed at identifying genetic modifiers genes that influence disease expression.  
 The “multifocal ectopic Purkinje-related premature contractions syndrome” that is 
described in  underscores the multifaceted phenotypic appearance of cardiac Chapter 6
sodium-channel mutations. This syndrome can lead to heart failure. In the case of the young 
woman described, the additional presence of a KCNE1 variant also contributed to drug-
induced TdP during treatment with amiodarone. By personalized translational arrhythmia 
management, this patient was successfully treated with flecainide, suppressing ectopy and 
restoring a poor LV ejection fraction. 
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 puts the insights obtained in this PhD project in broader perspective. Avenues  Chapter 7
for future scientific directions are projected. I propose that forthcoming investigations of 
the prevention of sudden cardiac arrest should encompass the multimodality integration of 
electrics, mechanics, autonomics, and complex genetics. 
  describes the synergy between an artist and a scientist. This unconventional Chapter 8
collaboration has elevated scientific processes to a new level, making it also more accessible 
to the general public.  
SAMENVATTING 
In het gezonde hart wordt de contractie voorafgegaan door tijdige en gesynchroniseerde 
elektrische impulsen die vanuit de sinusknoop naar de atria en ventrikels worden 
doorgegeven. Verstoringen van deze elektrische impulsen in de ventrikels kunnen 
aanleiding geven tot levensbedreigende kamerritmestoornissen en, indien niet adequaat 
behandeld, tot een acute hartstilstand. Dergelijke gevaarlijke ritmestoornissen kunnen 
ontstaan door een structureel of functioneel substraat in het kamermyocard. Gelijktijdige en 
plotse variaties in de autonome tonus kunnen aritmogene ontaarding voeden. Naast deze 
klassieke, proaritmische ingrediënten wordt in toenemende mate duidelijk dat 
elektromechanische koppeling en mechano-elektrische feedback bijdragen aan de 
proaritmische instabiliteit van het hart. Verschillende genetische factoren kunnen 
onderliggend zijn aan deze functionele heterogeniteiten. De mechanismen en behandeling 
van kamerritmestoornissen in het genetisch-gevoelige hart zijn de hoofdonderwerpen van 
dit proefschrift.  
 Na een algemene introductie over “plotse hartstilstand” in , worden Hoofdstuk 1
bovenstaande aspecten in  samengevat, en hun individuele bijdragen aan het Hoofdstuk 2
ontstaan van kamerritmestoornissen in detail bediscussieerd. Tevens bevat dit hoofdstuk 
unieke data over de elektromechanische dispersie in het hart vlak voor het optreden van 
TdP in een patiënt met congenitaal LQTS.  
 Binnen een internationaal consortium onderzochten wij de relatie tussen veranderde 
elektromechanische koppeling en aritmie-gevoeligheid in een grote populatie van LQTS 
patiënten. De resultaten worden beschreven in . Wij vonden dat het Hoofdstuk 3
zogenaamde “elektromechanische venster” (EMW) een robuste aritmie-risicomarker is voor 
LQTS patiënten, onafhankelijk van hun genotype, en dat de EMW superieur is ten opzichte 
van de QTc. Verder toonde de EMW constante waarden tijdens opeenvolgende metingen bij 
een stabiele patiënt, maar deze kon fors negatief worden tijdens momenten van 
ventriculaire ectopie en vlak voor TdP. In  beschrijven wij onze Hoofdstuk 4
onderzoeksbevindingen in een klinisch-relevant hondenmodel van het lange-QT1 syndroom. 
In dit model had linker stellatum-ganglion-stimulatie (LSGS) een hoge aritmische potentie, 
waarbij TdP en ventrikelfibrilleren werden uitgelokt op momenten dat de EMW fors 
negatief was. Wij postuleren dat LSGS-geïnduceerde positieve lusitropie tijdens QT-
verlenging deze elektromechanische dispersie veroorzaakt, en dat co-activatie van het 
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sympathische en vagale zenuwstelsel optreedt tijdens LSGS (onder niet-gedecentraliseerde 
omstandigheden), waarbij beide componenten van het autonome zenuwstelsel bijdragen 
aan de aritmogenese.  
 In  staan onze resultaten over de Worm-Studie beschreven. We Hoofdstuk 5
onderzochten een grote founderpopulatie met de SCN5A mutatie p.(Phe1617del) en vonden 
nieuwe SCN5A-gerelateerde fenotypes en aritmiepatronen in dit syndroom dat 
predisponeert voor plotse hartstilstand. Heritabiliteitsschattingen worden gebruikt als 
richtingaanduider voor verdere genetische analyse met het doel om aanvullende genen te 
identificeren die de ziekte-expressie en susceptibiliteit voor plotse hartstilstand 
beïnvloeden. 
 Het “multifocale ectopische Purkinje-gerelateerde contractie syndroom” wordt 
beschreven in . Dit is een andere aandoening die door SCN5A-mutaties kan Hoofdstuk 6
worden veroorzaakt, en tot hartfalen kan leiden. De beschreven casus betreft een jonge 
patiënte met dit syndroom door een nieuwe SCN5A-mutatie, die bovendien amiodarone-
geïnduceerde TdP ontwikkelde tijdens beoogde antiaritmische behandeling van haar 
excessieve ventriculaire ectopie. Additioneel dragerschap van een KCNE1-variant lag aan de 
basis van de TdP-gevoeligheid. Gepersonaliseerd translationeel aritmie-onderzoek leidde tot 
succesvolle behandeling met flecainide bij deze patiënte, en tot onderdrukking van de 
ectopie en herstel van het hartfalen. 
 In Hoofdstuk 7 worden de resultaten van dit proefschrift in breeder perspectief geplaatst. 
Richtingen voor toekomstige wetenschappelijke onderzoeken worden aangegeven. Daarbij is 
het naar mijn mening van groot belang dat nieuwe studies naar de preventive van plotse 
hartstilstand zich richten op de integratie van elektrische, mechanische, autonome en 
complex-genetische modaliteiten. 
  beschrijft de synergie tussen een kunstenaar en een wetenschapper. Een Hoofdstuk 8
dergelijk niet-alledaags verbond tilt het wetenschappelijke proces naar een hoger niveau. 
Daardoor het ook toegankelijker wordt voor het algemene publiek. 
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The insights obtained in this thesis are highly suitable for valorization and will be described 
in three parts: EMW, Worm study, HeArt project.  
SOCIO-ECONOMIC RELEVANCE 
Sudden cardiac death claims almost a million deaths annually in Western Europe and the 
United States. It accounts for one fifth of all natural deaths and up to 50% of all 
cardiovascular deaths.2, 3 In the Netherlands, out-of-hospital SCD occurs with a yearly 
incidence of approximately 1 per 1,000 individuals,5 with ~15 fatal cases per week in 
Limburg.6 The most common cause of SCD is ventricular fibrillation secondary to acute 
coronary ischemia. Inherited primary electrical arrhythmia syndromes account for 5-10% of 
VF cases and occur often, but not exclusively, in the young.10 In <5% of VF cases no cardiac 
structural or electrical abnormalities can be ascertained. It remains a challenge to 
adequately address the risk of apparently healthy, but genetically-susceptible, subjects for 
developing such life-threatening ventricular arrhythmias. It goes without saying that SCD 
imposes a substantial socio-economic burden, next to the devastating psychosocial impact 
on survivors of SCA and affected family members. 
ELECTROMECHANICAL WINDOW 
First, risk stratification in patients with the long-QT syndrome traditionally relies on the 
determination of the QTc, besides assessing the occurrence of previous syncopal or 
arrhythmic events. It is well-known that the ubiquitously applied Bazett’s formula to correct 
QT for the heart rate is less reliable at the higher or lower ends of cardiac cycle lengths. As is 
discussed in this PhD thesis, the noninvasive evaluation of the relation between the 
duration of the electrical and mechanical systole, notably the electromechanical window, is 
an easy-to-obtain parameter that improves risk stratification beyond QTc in patients with 
inherited repolarization defects. The EMW is not significantly affected by heart-rate 
variations.113 Improved risk assessment will (re)classify LQTS patients in either low or high 
risk categories, leading to reduced overtreatment of medium-to-low-risk subjects, for 
example by reducing prophylactic pharmacological or interventional treatment, but it may 
also justify a more aggressive approach in EMW-based high-risk patients. In the former, 
subjects may be reassured, need less intensive follow-up and will not be subjected to 
unnecessary therapies, whereas in the latter intensified follow-up will result in psychological 
reassurance and, ideally, reduced mortality. In both circumstances, socio-economic and 
psychosocial benefit is evident. Clinicians or technicians can easily perform EMW 
measurements during a standard echocardiogram at relatively low cost.  
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WORM STUDY 
Secondly, through genealogical investigation the Worm study has identified a large familial 
population at increased risk of SCD in South Limburg and North Rhine-Westphalia. The total 
number of related individuals approaches 10,000. The striking phenotypic heterogeneity 
within mutation carriers and the genotype-negative phenotype-positive family members 
indicate the effect of modifier genes besides the familial SCN5A deletion, which has triggered 
in-depth genetic analyses. These genetic modifiers may have a nontrivial allelic frequency in 
the “general population”, and may add to the risk of SCD in non-related patients, for instance 
in the setting of acquired heart disease. As such, the potential outreach of our family-based 
results can be large. Future genetic risk profiling could identify patients with an increased 
arrhythmic risk, advocating more stringent cardiovascular risk management and lifestyle 
amendments. Furthermore, by cardiogenetic scrutiny we uncovered p.(Phe1617del)-specific 
arrhythmia patterns reminiscent of LQT1-/LQT2-like behavior with sympathetic (often 
auditory) triggering. This has led to mutation-specific patient counseling and therapy, aiming 
to reduce sympathetic triggering. The p.(Phe1617del)-related female proarrhythmic 
proclivity was surprising, but it primed increased clinical vigilance towards mutation-carrying 
women by initiating preventive antiarrhythmic measures at an earlier age.  
HEART PROJECT 
Thirdly, we describe the synergism between art and science. Besides personal satisfaction 
for the artist or scientist, this venture may serve as an inspiring example for future academic 
entrepreneurs, clinicians, and patients. We are faced with an increasingly shallow patient-
doctor relationship, as the current trend of health-care organizations is to constrain patient-
doctor time slots, for financial reasons. Despite the availability of sophisticated 
communication tools, doctors often fail to be good conversationalists. High-standard patient 
care anno 2020 mandates careful communication with a clear definition of the patient’s 
expectations, knowledge sharing, advising on test results and treatment options, and 
shared-decision making. Art can facilitate this communicative process by stimulating 
empathy, insight, creativity and shift in motivation. 
TARGET GROUPS 
These three major valorization topics target different populations. Enhanced risk prediction 
using the EMW is relevant for patients with inherited or acquired repolarization 
prolongation worldwide, and this non-invasive tool is cheap and easy to measure. 
Genealogical and cardiogenetic profiling of the Worm population affects subjects in the 
larger Euregio. Moreover, we anticipate that the discovery of modifier genes could be of 
great importance for the general population, to screen out patients at risk for severe 
arrhythmias. The HeArt project targets academic entrepreneurs, clinicians, PhD candidates, 
residents, scientists, artists, and patients. 
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ACTIVITIES, PRODUCTS AND INNOVATION 
The mechanical part of determining the EMW is usually performed by continuous-wave 
Doppler imaging of the aortic-valve outflow. Attempts have been made to develop hand-
held devices that assess electromechanical coupling using phonocardiography. This will 
allow bedside risk evaluation and guidance of therapy. Future incorporation of 
phonocardiography (or techniques alike) into ICDs could enable diurnal EMW monitoring, 
alerting physicians to treat patients in case of a significant drop.  
 The Worm project has a strong impact on the (eu)regional cardiac and psychosocial 
health. In anticipation, we have informed the local community through articles in local news 
media (de Limburger, Nummer 1, Gezond Idee, Observant), a Belgian (Belang van Limburg) 
and a German newspaper (die Aachener Zeitung). Furthermore, we have developed a 
website for interested individuals who wish to receive additional information on the 
(cardiac) consequences of this SCN5A founder mutation, and the Worm study in general 
(www.hartenvaatcentrum.mumc.nl/de-worm-studie). Specific questions related to the 
Worm study can be asked directly by telephone or by mail at wormstudie@mumc.nl. In 
April 2015, we organized the first Worm Information Day for family members, where 
patients were informed about the latest scientific progress, but also were given a platform 
to meet distant family members and to share experiences. Finally, we currently face a 
situation of knowing thousands of names of relatives within the large Worm pedigree, but 
are unable to reach out to individuals because of privacy laws. This raises ethical challenges. 
To solve these matters, we will contact Dutch and German ethical and legal experts. 
 We plan to offer art-based interventions (preferably in a randomized fashion) to current 
PhD candidates at the Cardiology department, aiming to increase creativity, stimulate out-
of-the-box thinking and facilitate communication. Output variables like creativity, out-of-
the-box thinking and communication skills will be measured, for instance by using the 
Torrance Tests of Creative Thinking, which assesses fluency, flexibility, originality, and 
elaboration. Originality can be graded using the taxonomy of creative design 
(http://www.senseandsensation.com/2012/03/assessing-creativity.html). Finally, in my 
personal HeArt project, I have been involved in creating art objects that will be exhibited at 
the Heart+Vascular Center outpatient clinic from March 2018. In this innovative and 
unprecedented way, patients waiting for the consultation with their cardiovascular 
specialist will learn about the values of combining art and science, in this case through the 
HeArt project, and about the scientific findings of the Worm study. Also, they can actively 
participate in the creation of patient-scientist mindmaps displayed on hospital tables, in 
order to stimulate patient-scientist communication and get feedback (Figure A). This 
feedback will serve as a tool to improve patient-centered health care. This exhibition will 
travel fourth to the Main Building of Maastricht University at the Minderbroedersberg, and 
onward to Zuyderland Medical Centre later in 2018, aiming to reach as many patients and 
family members in the region as possible. Finally, we plan to further expand this art-based 
patient communication to other Dutch and European medical facilities. 
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Figure A. Complex scientific information, artistic objects and patient’s response to stimulate patient-doctor 
interaction, opening eyes in both of them. 
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Genealogist A.S.M. Patelski constructed detailed ancestors charts of all genotyped SCN5A-
p.(Phe1617del) indexes, aiming to identify the designated Worm study founder couple by 
the identification of common ancestors. Per family group 63-778 ancestors were identified. 
Subsequently, Patelski generated descendant charts to complete the pedigree as much as 
possible.  
    All genealogical data are edited and stored in the freely available program Aldfaer 
(www.aldfaer.net, version 6.2). Patelski’s private file is not accessible to the general public 
and contains amply 10.000 Worm study related-person cards. A person cards encloses the 
index’ name, date and place of birth, date of death including the similar information of their 
parents and offspring. The majority of the descendants are legitimate with few documented 
natural descents that have been acknowledged by the biological father. The data file mostly 
contains genealogical information on deceased persons. For the living individuals we relied 
on information provided by the index or their family members. When available, official 
documentation like a marriage license served to verify the verbally obtained genealogical 
information. Below, one can appreciate the consulted genealogical sources of the 
Netherlands, Belgium and Germany including consulted archival institutions, websites, and 
books. All documented relationships and lineages of descent have been confirmed from 
original sources and can be verified. In case of the slightest uncertainty, the presumed 
relationship was discarded. 
CONSULTED SOURCES 
THE NETHERLANDS 
Period from ± 1550 to ± 1800 
- Baptismal, marriage, and burial registers of Roman Catholic parishes, Protestant 
churches and other documents from parishes or community archives. 
- Judicial archives of aldermen, farmsteads and jurisdictional files from Limburg 
Centre of Regional History (RHCL) in Maastricht and Rijckheyt in Heerlen. 
- Archives of the Landen van Overmaas (RHCL, 01.075 LvO). 
- Archives of the feudatory of the bishop of Köln (Keurkeulse Mankamer) in 
Heerlen (RHCL, 01.075 LvO). 
- Archives of the feudatory of Dahlem (RHCL, 01.075 LvO). 
- Archives of the feudatory of ‘s-Hertogenrade (RHCL, 01.075 LvO). 
- Archives of the feudatory of Valkenburg (RHCL, 01.075 LvO). 
- Archives of the “Vrije Rijksheerlijkheid” Eijs (Eys) (RHCL, 01.195). 
- Archives of the “Vrije Rijksheerlijkheid” Wittem (RHCL, 01.194). 
- Archives of the “Rijksheerlijkheid” Wijlre (RHCL, 01.192). 
- Notarial and surveyor archives in the province Limburg, also beyond 1800 (RHCL). 
- Monastery archives of Hoog-Cruts (RHCL, 14.D057), Sint-Gerlach (RHCL, 
14.D003), abbey of Kloosterrade (Rolduc) (RHCL, 14.D004). 
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- Archive of the first Roman Catholic diocese of Roermond (RHCL, 14.A002A). 
- French archive (RHCL, 03.01). 
Period from ± 1795 to ± 1967 
- Birth records and certificates (from ± 1795 to ± 1917), marriage records and 
certificates, including marital attachments (from ± 1795 to ± 1942) and death 
records and certificates (from ± 1795 to ± 1967) of the civil registry of the 
municipalities of Amby (± 1795 to 1970), Amstenrade, Bemelen, Berg en Terblijt, 
Bingelrade, Bocholtz, Borgharen (± 1795 to 1970), Bunde, Breust (± 1795 to 
1828), Brunssum, Cadier (± 1795 to 1828), Cadier en Keer (from 1828), 
Eygelshoven, Gulpen, Itteren, (± 1795-1970), Jabeek, Heer, Heerlen, Hoensbroek, 
Horn, Houthem (± 1795 to 1940), Hulsberg, Kerkrade, Klimmen, Maastricht, 
Margraten, Meerssen, Merkelbeek, Mesch (± 1795 to 1942), Mheer, 
Nieuwenhagen, Noorbeek, Nuth, Oost (± 1795 to 1828), Oud-Valkenburg (± 1795 
to 1940), Oud-Vroenhoven (± 1795 to 1919), Rimburg (± 1795 to 1817), 
Nederlands Rimburg (1817 to 1886), Roermond, Rijckholt (± 1795 to 1942), 
Schaesberg, Schin op Geul (± 1795 to 1940), Schinnen, Schinveld, Schimmert, 
Sint-Pieter (± 1795 to 1919), Simpelveld, Sittard, Slenaken, Strucht (± 1795 to 
1878), Ubach over Worms, Ulestraten, Vaals, Vaesrade (± 1795 to 1821), 
Valkenburg (± 1795 to 1941), Valkenburg-Houthem (1941 to 1980), Venlo, 
Venray, Voerendaal, Wittem, Wijlre, Wijnandsrade. 
Period from 1818 to 1920 
- Archive Memories van Successie. 
Period from 1850 to 1920 
- Population registers of several municipalities. 
Period from 1920 to 1940 
- Family cards of relevant municipalities. 
Period from 1940 to 1994 
- Person cards of deceased individuals from the Central Bureau of Genealogy 
(CBG). 
Period from 1995 to 2016 
- Extracts from the municipal administration of the CBG (only from deceased 
individuals). 
 
Family announcements from Limburg newspapers, like “Het Limburgsch Dagblad” (Heerlen), 
“Dagblad de Limburger” (Maastricht), and the “Limburger koerier” which can be consulted 
on www.delpher.nl.  
Family announcements from archival institutions, online accessible. 
Genealogical documents from archival institutions, local history associations, and private 
persons. 
Interviews with indexes and their relatives. 
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BELGIUM 
Period from ± 1550 to ± 1800 
- Baptismal, marriage, and burial registers of Roman Catholic parishes, Protestant 
churches and other documents from parishes or community archives. 
- Judicial archives of aldermen, farmsteads and jurisdictional files. 
Period after ± 1800 
- Records of the civil and registries of the municipalities of Grivegnée, Hombourg, 
Liège (Luik), Lixhe, Poucet, Vaux-sous-Chèvremont. 
GERMANY 
Period from ± 1500 to ± 1795 
- Jülicher Gerichte, Amt Wilhelmstein (www.archiv.nrw.de). 
- Archive Paffendorf (www.archiv.nrw.de). 
- City archive Aachen, department of handwriting. 
- Baptismal, marriage, and burial registers of Roman Catholic parishes, Prostestant 
churches and other documents from parishes or community archives of Afden, 
Alsdorf, Bardenberg, Frelenberg, Herzogenrath, Marienberg, Merkstein, Übach, 
Weisweiler. 
Period from ± 1670 to ± 1800 
- Records of the civil and registries of the municipalities of Aachen, Bardenberg, 
Eschweiler, Gescher, Gladbeck, Kohlscheid, Herzogenrath, Merkstein, Preussisch 
Rimburg (1817 to 1911), Stolberg. 
CONSULTED ARCHIVAL INSTITUTIONS 
THE NETHERLANDS 
- Limburg Centre of Regional History in Maastricht, www.rhcl.nl  
- Social Historic Centre Limburg in Maastricht, www.shclimburg.nl 
- Rijckheyt in Heerlen, www.rijckheyt.nl 
- State archives of Limburg in Maastricht (situated in the RHCL). 
- Community archive Maastricht (situated in the RHCL). 
- Community archive Kerkrade, www.kerkrade.nl/de_stad_kerkrade/kerk 
rade_toen_en_nu/gemeentearchief 
- Community archive Sittard-Geleen, www.sittard-geleen.nl/Bestuur/overig 
/Archief en www.dedomijnen.nl/collecties  
- Community archive Roermond, www.roermond.nl/Gemeentearchief  
- O.C.G.L. Landgraaf (local history association with euregional documents), 
www.heemkundelandgraaf.nl 
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BELGIUM 
- State archives of Limburg in Hasselt, www.arch.be/index.php?1=nl&m= 
praktische-info&r=onze-leeszalen&d=hasselt 
- Archives of État de Liège, www.arch.be/index.php?1=nl&m=praktische 
info&r=onze-leeszalen&d=luik 
- City archive in Tongeren, www.stadsarchieftongeren.be 
- Algemeen Rijksarchief Brussel (ARA, “general state archive Brussel”), 
www.arch.be/index.php?1=nl&m=praktische-info&r=onze-leeszalen&d=ara 
GERMANY 
- City archive Aachen.  
- www.aachen.de/de/kultur_freizeit/kultur/stadtarchiv/index.html 
- Civil registry Nordrhein Westfalen, department Rheinland, Duisburg, 
www.archiv.nrw.de 
- Community archive Gladbeck. 
CONSULTED WEBSITES 
www.rhcl.nl    Limburg Centre of Regional History. 
www.wiewaswie.nl  portal website from Dutch civil registry containing general 
certificates. 
www.zoekakten.nl  portal website from Dutch civil registry containing the original 
certificates of the civil registry and church records. 
www.familysearch.com  website of Mormons with digitalized archives of the civil 
registry. 
www.graftombe.nl   website containing descriptions and photos of graves. 
www.cbg.nl    Central Bureau of Genealogy. 
www.delpher.nl 
www.familienbuch-euregio.eu/ 
nl.geneanet.org/fonds/individus/ 
CONSULTED BOOKS 
Citoyens en zielen in Kerkrade in 1796, by L. Augustus, H. Latten, L. Nijsten-Höfte, Kerkrade 
1996, part 3 of the “Reeks Fontes Rodenses”. 
 
Les actes du vicariat général de Liège au XVIIIe siècl. I Dispenses matrimoniales 1760-1769, 
item tome II 1770-1779, item tone III 1780-1794, by André Deblon, Liège 2001. 
 
“De inwoners van Simpelveld en Bocholtz in 1694” by A.S.M. Patelski, in Historische en 
heemkundige studies in en rond het Geuldal, Jaarboek 1994, Valkenburg aan de Geul, 1994, 
p.55-72. 
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Das Handbuch des Bardenberger Notars Paul Sevenich. Erste vollständige Ausgabe mit 
Einleitung und Erläuterungen herausgegeben von Karl Schlebusch, Aachen, 2000. 
 
Die Kölner Generalvikariatsprotokolle als Personengeschichtliche Quelle, Band I (in 2 
Halbbänden), Aus der Zeit vor 1700 by Hermann Deitmer S.J., Köln 1970; Item Band XII, 
Nichtkleriker in den Protokollen von 1786-1790, Johannes Ströber and Hans-Joachim Otten, 
Köln, 2008. 
 
Familienbuch der katholische Pfarrei Sankt Heinrich Horbach 1804-1899 by Käthe Wimmer, 
Köln, 2007. 
 
Familienbuch Sankt Laurentius Laurensberg [Stadt Aachen] by Willi Dovern, 3 banden, 
Frankfurt am Main, 2000. 
 
Das Pfarrarchiv St. Mariae Himmelfart Herzogenrath, by Louis Augustus, Grete Esser-Plum, 
Wolf D. Penning, Herzogenrath, 2008. 
 
Inventaris archief Kasteel Haag, Inleiding, Regesten, Zegels, Register, by Rien van den Brand, 
Stefan Frankewitz, Venray, 2008. Publication nr 20 of the Stichting Historie Peel-Maas-
Niersgebied. 
 
Inventaris van de archieven en de handschriften der abdij Kloosterrade by J.A.K. Haas, 
Maastricht, 1986, part 36 of the inventories of the Rijksarchief Limburg. 
 
Inventaris van de archieven van het klooster Hoog-Cruts te Noorbeek/Slenaken 1512-1798 
(1803) by R.M. de la Haye, Maastricht, 1987, part 39 of the inventories of the Rijksarchief 
Limburg. 
 
Inventaris van de archieven van de heerlijkheid en de schepenbank Wijlre 1464-1796 (1816) 
by R.M. de la Haye, Maastricht, 1993, part 49 of the inventories of the Rijksarchief Limburg. 
 
Cunegondes ontvoering. Een geschiedenis van religieuze strijd in de tijd van de verlichting 
(Original title: Cunegonde’s kidnapping. A story of religious conflict in the age of 
Enlightenment) by Benjamin J. Kaplan (translation by Roelof Posthuma), Amsterdam, 2014. 
 
Die Rimburg. Geschichte der Burg, der ehemaligen Herrschaft bezw. freien Reichsherrschaft 
und der Gemeinde Rimburg by H. Hanssen, Aachen, 1912. 
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“Het Land van Rode: zijn naam, zijn territorium en zijn gebieders” by Lei Heijenrath, in 
Facetten uit de geschiedenis van het Land van Rode, Heerlen, 2017, part 11 of the 
Historische Reeks Parkstad, p.11-39. 
 
“Van ‘s-Hertogenrade naar Limbourg sur Vesde: het tracé van de middeleeuwse Hertogsweg 
door Zuid-Limburg” by Lei Heijenrath, in Facetten uit de geschiedenis van het Land van 
Rode, Heerlen, 2017, part 11 of the Historische Reeks Parkstad, p.97-117. 
 
“De Staten van het Oostenrijkse Land van Rode in de 18e eeuw in vergadering bijeen” by Lei 
Heijenrath, in Facetten uit de geschiedenis van het Land van Rode, Heerlen, 2017, part 11 of 
the Historische Reeks Parkstad, p.160-212. 
 
“Macht en onmacht in de processen tegen de bokkenrijders, Brussel en de justitie in de 
(Oostenrijkse) Landen van ‘s-Hertogenrade en Valkenburg” by Mathieu Huijnen, Hub van 
Wersch, in Facetten uit de geschiedenis van het Land van Rode, Heerlen, 2017, part 11 of 
the Historische Reeks Parkstad, p.40-95. 
 
De abdij Kloosterrade – Rolduc (1104-1830), by Joep Offermans, Rotterdam, 2004. 
 
“Zes eeuwen personae, pastoors, kapelaans en rectors in de H. Laurentiusparochie te 
Voerendaal” by A.S.M. Patelski, in De goede herder, een geschiedenis van de parochie St. 
Laurentius te Voerendaal 1049-1999, Heerlen, 1999, part 1 of the Historische Reeks 
Parkstad Limburg.  
 
Licht op het zonneleen Gronsveld. Ontwikkeling en instellingen van het rijksonmiddellijke 
graafschap Gronsveld, elfde eeuw tot circa 1795, by Th.J. van Rensch, Maastricht, 2017. 
 
Handboek voor de geschiedenis van Limburg, by P.J.H. Ubachs, Hilversum, 2000. 
 
Eygelshoven gedurende acht eeuwen, 1131-1931. Gedenkboek uitgegeven door het 
gemeentebestuur bij de viering van het achthonderd jarig bestaan van Eygelshoven, by J.M. 
van de Venne, Eygelshoven, 1931. 
 
Wissenschaftliche Genealogie, Eine Einführung in die wichtigsten Grundprobleme, by Otto 
Forst de Battaglia, Bern, 1948. 
 
Limburgse voorouders. Handleiding voor genealogisch onderzoek in Limburg, by Régis de La 
Haye, Maastricht, 2005. 
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Herten in het Woud. Genealogie van de familie de La Haye, by Régis de La Haye, Jo Hoen, 
Geleen/Beek, 1996-2015, 15 parts. 
 
“De familie Kicken uit Wijle in de 17e en 18e eeuw” by A.S.M. Patelski in Historische en 
heemkundige studies in en rond het Geuldal, Jaarboek, 1992, p.7-64. 
 
“Merckelbach” in Nederland’s Patriciaat, Genealogieën van bekende geslachten, ‘s-
Gravenhage, 2014, p.201-224. 
 
“Genealogie van de familie Merckelbach uit het Land van Herle in de 17e en 18e eeuw” by 
A.S.M. Patelski in Zestig jaar vorsen in de geschiedenis van Parkstad Limburg, Heerlen, 2005, 
p.182-284. 
 
Limburgse verwantschappen. Bijzondere familierelaties gebaseerd op de kwartierstaat Van 
der Cruijs-Gilissen, by A.S.M. Patelski, Marie-Anne van der Cruijs, Gronsveld, Rotterdam, 
2012. 
 
“Limburgse nazaten van Karel de Grote”, by A.S.M. Patelski, in Limburgs Tijdschrift voor 
Genealogie 2014 (42):103-132. 
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AED Automated external defibrillator 
APD Action-potential duration 
AUC Area under the curve 
BrS Brugada syndrome 
CaMKII Ca2+/Calmodulin-kinase II 
CCD Cardiac conduction disease 
CHO Chinese hamster ovary 
CM Cardiomyocyte 
CPVT  Catecholaminergic polymorphic ventricular tachycardia 
DAD Delayed afterdepolarization 
EAD Early afterdepolarization 
ERS Early-repolarization syndrome 
EMW Electromechanical window 
FOXO1 Forkhead box O 1 
ICaL L-type calcium current 
ICl(Ca) Ca2+-activated Cl- current 
ICD Implantable cardioverter defibrillator 
IK1 Inward rectifier potassium current 
IKr Rapidly-activating delayed-rectifier potassium current 
IKs Slowly-activating delayed-rectifier potassium current 
INa Voltage-dependent cardiac sodium current 
INa-Ca Sodium-calcium exchanger current 
INa,L Late component of INa 
iPSC Induced pluripotent stem cells 
Iti Transient inward current 
Ito Transient outward current 
JLNS Jervell and Lange-Nielsen syndrome 
LSGS Left-stellate ganglion stimulation 
LTV Long-term variability 
LV   Left ventricle 
LVEF Left-ventricular ejection fraction 
LVP Left-ventricular pressure 
LQTS Long-QT syndrome 
LCSD Left cardiac sympathetic denervation 
MAP Monophasic action potential 
MEPPC Multifocal ectopic Purkinje-related premature contractions 
NaV1.5 Pore-forming alpha subunit of the cardiac sodium channel 
NF-κB Nuclear factor-κB 
nNOS Neural nitric oxide synthase 
NRI Net reclassification index 
NSVT Non-sustained VT 
PKA Protein-kinase A 
PVC Premature ventricular contraction 
QAoC Q-onset to aortic-valve closure 
ROC Receiver-operating characteristic 
RSGS Right-stellate ganglion stimulation 
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RV Right ventricle 
RVP Right-ventricular pressure 
RyR Ryanodine receptor 
SAC Stretch-activated channel 
SCD Sudden cardiac death 
SNP Single nucleotide polymorphism  
SR Sarcoplasmic reticulum 
SQTS Short-QT syndrome 
STV Short-term variability 
TBX5 T-box transcription factor 5 
TdP Torsades de pointes 
TDI Tissue-Doppler imaging 
TRPM4 Transient receptor potential M4 channel 
VF Ventricular fibrillation 
VT  Ventricular tachycardia 
VUS Variant of uncertain significance  
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Mijn allereerste dankbetuiging gaat uit naar : mijn copromotor, die tijdens mijn Paul Volders
proefschrift ‘promoveerde’ tot promotor. Het is als de dag van gisteren dat ik jouw kamer 
binnenliep met de intentie mij te bekwamen in wetenschappelijk onderzoek. De innovatieve 
mix van elektromechanische mechanismen van kameraritmieën in het erfelijk belaste hart 
sprak mij direct aan; enerzijds vanwege de translationele aspecten, anderzijds triggerde dit 
onderwerp een passioneel gevoel van mysterie. Tegelijkertijd lag de wetenschappelijke lat 
van het Volders lab hoog. Paul, je beschikt over de uitzonderlijke gave om mensen op 
subtiele wijze te inspireren en te motiveren. Jouw parate kennis over uiteenlopende 
onderwerpen aangaande de Klinische Cardiologie/Elektrofysiologie, de Cellulaire 
Elektrofysiologie maar ook computermodellen is zeer indrukwekkend. Beter en sneller dan 
elke online Pubmed zoekopdracht! Menig manuscript werd naar een hoger niveau getild 
door jouw scherpzinnige gebruik van de Engelse taal en gevoel voor tekstopbouw. Deze 
fijngevoeligheid ging, tot frustratie van velen, vaak gepaard met een niet te behoorlijke 
tijdsinvestering, maar, toegegeven, het eindresultaat was het wachten ruimschoots waard. 
Ik ben je zeer erkentelijk voor de visionaire rol die je vervulde tijdens mijn PhD- en 
carrièreplanning: “The sky is the limit!”. Je bent niet alleen een visionair maar ook een 
inspirator voor mij geweest. Ten slotte, denk ik graag terug aan de vele momenten, soms 
omlijst met een hapje en een drankje, waarop we vurig een veelvoud aan wetenschappelijke 
onderwerpen bediscussieerden die de basis vormden van de huidige manuscripten (Figuur 
PhD outline).  
 
Figure PhD outline. 
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 Natuurlijk ben ik veel dank verschuldigd aan het afdelingshoofd van de Cardiologie van 
het MUMC+, , die in mij geloofde en mij onderzoekstijd toekende in tijden van Harry Crijns
hoge klinische werkdruk. Zeker ook ben ik , de founding father van de Klinische Hein Wellens
Elektrofysiologie, zeer erkentelijk voor zijn voelbare steun, zijn visionaire inzichten en zijn 
mentorrol. Het is een enorme eer in zijn wetenschappelijke voetsporen te mogen treden 
door het onderwerp van kamerritmestoornissen/plotse hartsilstand verder uit te diepen. 
Einstein’s uitspraak is van grote toepassing hier: “If I have seen further, it is by standing on 
the shoulders of Giants.”  
 A special word of gratitude to all the highly esteemed members of the judgment 
committee: , , , , and  . Harry Crijns Hein Wellens Peter Schwartz Connie Bezzina Frits Prinzen
, thank you for the fruitfull and stimulating discussions on the long-QT Peter Schwartz
syndrome and the role of the autonomic nervous system in ventricular arrhythmogenesis. 
You are a genuin founding father of genetic cardiology. Your manuscripts are always a joy 
for the mind: a true language virtuoso! , I have profound respect for your Connie Bezzina
revolutionary scientific contributions to the field of Cardiogenetics. Your work on topics like 
SCN5A and sudden arrhythmic death are the basis of many scientific endeavors that come 
to our table. Thank you for being such an inspiring female role model. The judgment 
committee would not be complete without   with his impressive track record on Frits Prinzen
electromechanics of the heart and cardiac pacing. I am very fortunate that such esteemed 
scientists have judged my scientific work.  
 Gedegen wetenschappelijk onderzoek is geen individuele maar een teamsport, waarbij 
door gemeenschappelijke inzet een hoger niveau kan worden bereikt. In ieder team is er 
een onmisbare centrale middenvelder of spelverdeler: een zeer warm dank-je-wel voor Roel 
. Dé steun en toeverlaat van ieder patchclamp experiment: het lukte je zelfs om mij Spätjens
een natriumstroom te laten opnemen. Dé Eerste Hulp bij figuurreanimaties: van het 
opkuisen van ‘vervuilde’ ECG tracings tot de puntjes op de i bij figuuropmaak en -verfraaiing. 
Dit alles is omlijst door vriendelijkheid, bescheidenheid en een flinke dosis humor. Diech bis 
de onmisbare liem vaan ‘t team! Maar evenzeer ben ik  een welgemeend Sandrine Seyen
dankwoord verschuldigd. Natuurlijk was jouw inzet bij de experimenten van onschatbare 
waarde, maar nog meer heb ik onze privégesprekken altijd gekoesterd.  
 Being part an international research team has been a stimulating and unforgettable 
experience. To all present and previous members of the Volders’ lab, also known as the 
“work/vacation/vlaai” crew:  , , ,  Cristina Altrocchi Gudrun Antoons Beatrice Badone Mylène
,  ,  ,  ,  ,  , Champs  Michael Clerx Matthijs Cluitmans Miren David Jordi Heijman Daniel Johnson
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